

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022028 A2

- (51) International Patent Classification: Not classified
- (21) International Application Number: PCT/US02/28682
- (22) International Filing Date:
10 September 2002 (10.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/318,289 10 September 2001 (10.09.2001) US
60/318,293 10 September 2001 (10.09.2001) US
60/318,284 10 September 2001 (10.09.2001) US
60/363,498 11 March 2002 (11.03.2002) US
- (71) Applicant (for all designated States except US): MESO SCALE TECHNOLOGIES, LLC [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): KENTEN, John, H. [—/—]; 21021 Sugar Ridge Terrace, Boyds, MD 20841 (US). BIEBUYCK, Hans [—/—]; 1 Sterling Court, Rockville, MD 20850 (US). DAVYDOV, Ilya [—/—]; 13823 Grey Colt Drive, North Potomac, MD 20878 (US). PAMPORI, Nisar [—/—]; 11407 Ledbury Way, Germantown, MD 20876 (US). YAN CHENG, Steven [—/—]; 307 Treemont Way (US). NELSON, Stefani [—/—]; 2445 Lyttonsville Road, Apartment #902, Silver Spring, MD 20910 (US).
- (74) Agent: EVANS, Barry; Kramer Levin Naftalis & Frankel LLP, 919 Third Avenue, New York, NY 10022 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: METHODS, REAGENTS, KITS AND APPARATUS FOR PROTEIN FUNCTION ANALYSIS

(57) Abstract: Apparatus, systems, system components, methods, compositions, and reagents for determining the function and activity of peptides and proteins and for identifying and characterizing molecules that affect these functions and activities. More specifically, methods and reagents used to determine the various activities of peptides and proteins including their binding specificity, binding activity, their enzymatic activity and their ability to act as substrates for enzymes. The disclosed methods are especially suited for the analysis of peptide and protein function where large numbers of peptides and proteins need to be analyzed.



3048141
3048356
3048606
3445488
3446518
3449955
3451168
3453890
3454207
3454505
3459274
3460054



3460621
3461825
3462090
3462906
3463640
3853408
3857590
3859672
3877854
3886015
3886018
3886999



3901641
3906095
3907984
3908412
3910505
3912185
3912628 (RGS4)
3914731 (RGS4)
3920860 (RGS4)

30
-66
-97
32

WO 03/022028 A2



MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

Published:

— without international search report and to be republished
upon receipt of that report

(84) **Designated States (regional):** ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

**METHODS, REAGENTS, KITS AND APPARATUS FOR PROTEIN FUNCTION
ANALYSIS**

10 **1. CROSS REFERENCES TO RELATED APPLICATIONS**

This application claims priority to U.S. Provisional Application No. 60/318,284, filed September 10, 2001; U.S. Provisional Application Serial No. 60/318,293, filed September 10, 2001; U.S. Provisional Application Serial No. 60/318,289, filed September 10, 2001; U.S. Provisional Application No. 60/363,498, filed March 11, 2002; 15 and U.S. Provisional Application No. _____ [Attorney Ref. No. P16381US2], filed September 9, 2002, entitled: "Methods, Reagents, Kits and Apparatus for Protein Function", each of which are hereby incorporated by reference.

2. FIELD OF THE INVENTION

20 This invention provides apparatus, systems, system components, methods, compositions, and reagents for determining the function and activity of peptides and proteins and for identifying and characterizing molecules that affect these functions and activities. The methods and reagents of the invention are used to determine the various activities of peptides and proteins including their binding specificity, binding activity, 25 their enzymatic activity and their ability to act as substrates for enzymes. This invention is especially suited for the analysis of peptide and protein function where large numbers of peptides and proteins need to be analyzed.

5

3. BACKGROUND OF THE INVENTION

The steps involved in the transcription and translation (expression) of genes in cells are complex but the basic steps for protein to be produced from DNA are transcription and translation. The DNA is first transcribed into RNA, and then the RNA is translated by the interaction of various cellular components into protein. In prokaryotic cells transcription and translation are coupled, meaning that RNA is translated into protein during the time that it is being transcribed from the DNA. In eukaryotic cells the two activities are separate, making the overall process more complicated. DNA is transcribed into RNA inside the nucleus of the cell, but the RNA is further processed into mRNA and then transported outside the nucleus to the cytoplasm where it is translated into protein.

The ability of molecular biologists to isolate and clone genes has brought about the development of systems that can be used to express the proteins encoded by these genes or their corresponding mRNA messages. Methods for expressing proteins make it possible to manipulate genes and then study the effect of the manipulations on their function. The amount of protein to be produced, whether the gene is prokaryotic or eukaryotic and the relative merits of an *in vitro* cell-free or an *in vitro* whole-cell system, are some of the factors considered by researchers when selecting an expression system.

In vitro transcription systems using prokaryotic or eukaryotic cells are available; however, these systems are difficult to work with since intact cells are used. *In vitro* cell-free systems, on the other hand, are made from cell-free extracts produced from prokaryotic or eukaryotic cells that contain all the necessary components to translate

- 5 DNA or RNA into protein. Cell-free extracts can be prepared from prokaryotic cells such as *E. coli* and from eukaryotic cells such as rabbit reticulocytes and wheat germ. Cell-free systems are very popular because there are standard protocols available for their preparation and because they are commercially available from a number of sources. Although *in vitro* systems have many advantages to major draw back is that the amounts
- 10 of protein produced is generally low which makes the analysis of protein function and activity difficult. The problems with low levels of protein production have forced researchers to develop complex assay systems using gel based systems and radioactivity that limit the application of these *in vitro* methods for studies of protein function and activity.
- 15 *E. coli* S30 cell-free extracts were first described by Zubay, G. (1973 Ann. Rev. Genet. Vol 7, p. 267). These extracts can be used when the gene to be expressed has been cloned into a vector containing the appropriate prokaryotic regulatory sequences, such as a promoter and ribosome-binding site. Prokaryotic *E. coli* cell-free systems are considered coupled because transcription and translation occur simultaneously after the
- 20 addition of DNA to the extract.
- Rabbit reticulocyte lysate was described by Pelham, H. R. B. and Jackson, R. J. (1976, Eur. J. Biochem. Vol. 67, p. 247). This expression system is probably the most widely used cell-free system for *in vitro* translation, and is used in the identification of mRNA species, the characterization of their products and the investigation of
- 25 transcriptional and translational control.
- Wheat germ extract was described by Roberts, B. E. and Paterson, B. M. (1973, Proc. Natl. Acad. Sci. U.S.A., Vol. 70, P. 2330). Cell-free extracts of wheat germ support

5 the translation *in vitro* of a wide variety of viral and other prokaryotic RNAs, as well as eukaryotic mRNAs. (Anderson, C., et al. (1983) Meth. Enzymol. 101, 635). Generally, it is found necessary to include a ribonuclease inhibitor in the reaction mix of a wheat germ translation system, as ribonuclease activities in wheat germ extract are present.

Post-translational modifications that have been observed in rabbit reticulocyte
10 lysate or wheat germ extract include signal peptide cleavage, glycosylation, acetylation, isoprenylation, proteolysis myristoylation, protein folding and proteolytic processing (Glass, C. A. and Pollard, K. M. (1990). Promega Notes 26). Some modifications or processing events have required the introduction of additional biological machinery. For example, processing events, such as signal peptide cleavage and core glycosylation, are
15 examined by adding canine microsomal membranes (Walter, P. and Blobel, G. (1983) Meth. Enzymol. 96, 84) (Walter, P. and Blobel, G. (1983) Meth. Enzymol. 96, 84) or *Xenopus* egg extracts (Zhou, X, et al. U.S. Patent No. 6,103,489) to a standard translation reaction. The addition of membrane preps is valuable when investigating membrane bound proteins such as receptors. These *in vitro* systems have been used to express many
20 proteins, often in their native conformation and containing many of the normal and expected post-translational modifications.

RNA for translational studies can be obtained by either isolating mRNA or by making *in vitro* RNA transcripts from DNA that has been cloned into a vector containing an RNA polymerase promoter. The first method isolates mRNA directly from cells. The
25 second obtains RNA for *in vitro* translation by *in vitro* transcription. *In vitro* transcription of cloned DNA behind phage polymerase promoters was described by Krieg, P. and Melton, D (1984, Nucl. Acids Res., Vol. 12, p. 7057). This method has become a

5 standard method for obtaining RNA from cloned genes for use in *in vitro* translation reactions. The method uses DNA or a gene of interest that is cloned into a vector containing a promoter for an RNA polymerase. The vector is then purified and followed by an *in vitro* transcription reaction to make RNA transcripts. A number of vectors containing the SP6, T7 and T3 RNA polymerase promoters are commercially available
10 and are widely used for cloning DNA.

After rabbit reticulocyte lysate and wheat germ extract were developed as cell-free translation systems, coupling of transcription and translation was demonstrated. One system that was developed was a linked transcription and translation system (Roberts, B. E., et al. (1975), Proc. Natl. Acad. Sci. U.S.A., Vol 72, 1922-1926). This system involved
15 the use of wheat germ extract supplemented with E coli RNA polymerase and looked at transcription and translation of SV40 viral DNA. Another system was developed by Pelham, H. R. B, et al. (1978), Eur. J. Biochem., Vol. 82, 199-209, where coupled transcription and translation occurred after the introduction of vaccinia viral core particles into rabbit reticulocyte lysate.

20 Work has also been described using continuous cell-free *in vitro* translation systems with the emphasis on large-scale production of protein. Continuous translation involves a bioreactor (such as an Amicon 8MC ultrafiltration unit) in which large scale reactions are set up and protein is continually translated over extended periods of time. The reaction requires that a buffer be fed into the reaction as it progresses, and also
25 requires that the products of translation be removed from the reaction filter unit. This type of system works well with E. coli S30 extract and wheat germ extract when RNA template is introduced. See Spirin, et al. (1988) Science, Vol 242, 1162-1164. The system

5 also works using RNA templates in rabbit reticulocyte lysate. See Ryabova, et al. (1989) Nucl. Acid Res., Vol. 17, No. 11, 4412. The system is also known to work well with DNA templates in E. coli S30 extracts. See Baranov, et al. (1989) Gene, Vol 84, 463-466. PCT publication WO9102076 discloses continuous cell-free translation from DNA templates using eukaryotic lysates.

10 These methods of coupling transcription and translation have been further modified by coupling these *in vitro* transcription and *in vitro* translation steps in a single reaction mix from plasmid DNA containing RNA polymerase sites for the SP6, T7 or T3 RNA polymerases (Craig, D., et al (1992) Nucleic Acids Res. Vol 20, 4987-4995, US 5,665,563; US 5,324,637; US 5,492,817; EP566 714). These coupled reaction mixes are
15 available commercially from Promega both for the rabbit reticulocyte and wheat germ lysates.

The proteins from these translation or transcription translation reactions have been labeled using a variety of methods. This step is important given the fact that very small amounts of protein are produced in these translation reactions relative to the total amount
20 of protein (4-0.4 ug/ml relative to 50-60 mg/ml of endogenous proteins).

One labeling method is the genetic modification of the gene or genes of interest, which results in the translation of a protein containing amino acids, amino acid sequences or post-translational modifications not found in the normal translation product of the gene. These modifications provide for the use of various methods for detection and
25 purification of the translated proteins. These methods for the modification of the normal gene product are not always helpful as they can prevent the normal function of the protein due to the modification of the N terminal or C terminal portions of the protein.

5 Also these modifications can prove to be costly and time consuming when applied on large scale.

Another labeling method involves the use of radioactive amino acids in translation reaction resulting in the production of a labeled amino acid sequence that is encoded by the DNA or RNA used to drive the translation reaction. Radioactive labeled amino acid sequences produced this way have been valuable in the study, detection and
10 determination of these protein function and properties. The problems that are associated with the use of radioactivity are well known and make its use on a large scale problematic, unsafe and costly.

An alternative *in vitro* approach uses specific tRNAs linked to modified amino acids to produce amino acid sequences incorporating these modifications (Ohtsuka H, et
15 al., Nucleic Acids Symp Ser. 1997;(37):125-6. Hoeltke HJ, et al., Biotechniques. 1995;18(5):900-4, 906-7. Kurzchalia TV, et al. Eur J Biochem. 1988;172(3):663-8. McIntosh B, et al., Biochimie. 2000;82(2):167-74. Gite S, et al., Anal Biochem. 2000;279(2):218-25. Janiak F, et al., Biochemistry. 1990 8; 29(18):4268-77.). The best
20 example of this approach is with the use of a Lys tRNA that is modified to contain a biotin. The resulting biotinyl-Lys-tRNA is used in translation reactions resulting in the production of proteins labeled with Biotin at random within the protein sequence. This method has been used for the detection of proteins on gels and for the purification of proteins prior to gel based analysis. This method for labeling proteins in combination
25 with gel based detection methods has not provided a solution for rapid or simple assays for protein activity or function. Indeed some groups have found that this labeling method would not work when used in a solid phase assay due to endogenous biotinylase activity

5 and high levels of endogenous lysine which markedly inhibit the ability to incorporate significant amounts of biotinylated lysine into newly synthesized proteins (Gao, Z-H., (2000) Biochem Biophys Res Comm, 268, 562-566).

Thus these methods for producing proteins and labeling them to date do not allow for the facile analysis of protein function or activity.

10 In order to improve on this method for labeling proteins other derivatives of tRNA have been developed. One example is the lysine tRNA labeled with the fluorophore, BODIPY-FL (Promega, Madison WI (Promega Notes 77)). This has improved the detection methodologies but is still based on using gel electrophoresis and in gel detection systems that are expensive, slow and complex.

15 At this time, there are a number of commercially available instruments that utilize electrochemiluminescence (ECL) for analytical measurements including drug screening. Species that can be induced to emit ECL (ECL-active species) have been used as ECL labels. Examples of ECL labels include: i) organometallic compounds where the metal is from, for example, the noble metals of group VIII, including Ru-containing and Os-
20 containing organometallic compounds such as the tris-bipyridyl-ruthenium (RuBpy) moiety and ii) luminol and related compounds. Species that participate with the ECL label in the ECL process are referred to herein as ECL coreactants. Commonly used coreactants include tertiary amines (e.g., see U.S. Patent No. 5,846,485), oxalate, and persulfate for ECL from RuBpy and hydrogen peroxide for ECL from luminol (see, e.g.,
25 U.S. Patent No. 5,240,863. The light generated by ECL labels can be used as a reporter signal in diagnostic procedures (Bard et al., U.S. Patent No. 5,238,808). For instance, an ECL label can be covalently coupled to a binding agent such as an antibody, nucleic acid

5 probe, receptor or ligand; the participation of the binding reagent in a binding interaction can be monitored by measuring ECL emitted from the ECL label. Alternatively, the ECL signal from an ECL-active compound may be indicative of the chemical environment (see, e.g., U.S. Patent No. 5,641,623 which describes ECL assays that monitor the formation or destruction of ECL coreactants). For more background on ECL, ECL
10 labels, ECL assays and instrumentation for conducting ECL assays see U.S. Patents Nos. 5,093,268; 5,147,806; 5,324,457; 5,591,581; 5,597,910; 5,641,623; 5,643,713; 5,679,519; 5,705,402; 5,846,485; 5,866,434; 5,786,141; 5,731,147; 6,066,448; 6,136,268; 5,776,672; 5,308,754; 5,240,863; 6,207,369 and 5,589,136 and Published PCT Nos. WO99/63347; WO00/03233; WO99/58962; WO99/32662; WO99/14599; WO98/12539; WO97/36931
15 and WO98/57154.

Commercially available ECL instruments have demonstrated exceptional performance. They have become widely used for reasons including their excellent sensitivity, dynamic range, precision, and tolerance of complex sample matrices. The commercially available instrumentation uses flow cell-based designs with permanent
20 reusable flow cells. Recently, ECL instrumentation has been disclosed that uses reagents immobilized on the electrode used to induce ECL (see, e.g., U.S. Patent No. 6,207,369 and Published PCT Application No. WO98/12539). Multi-well plates having integrated electrodes suitable for such ECL measurements have also been recently disclosed (see, e.g., copending Provisional Application No. 60/301,932 entitled "Assay Plates, Reader
25 Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001, and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby incorporated by reference, each hereby incorporated by reference.

5 The use of multi-well assay plates allows for the parallel processing and analysis
of multiple samples distributed in multiple wells of a plate. Typically, samples and
reagents are stored, processed and/or analyzed in multi-well assay plates (also known as
microplates or microtiter plates). Multi-well assay plates can take a variety of forms,
sizes and shapes. For convenience, some standards have appeared for some
10 instrumentation used to process samples for high throughput assays. Assays carried out
in standardized plate formats can take advantage of readily available equipment for
storing and moving these plates as well as readily available equipment for rapidly
dispensing liquids in and out of the plates. Some well established multi-well plate formats
include those found on 96-well plates (12 x 8 array of wells), 384-well plates (24 x 16
15 array of wells) and 1536-well plate (48 x 32 array of well). The Society for Biomolecular
Screening has published recommended microplate specifications for a variety of plate
formats (see, <http://www.sbsonline.org>), the recommended specifications hereby
incorporated by reference.

20

4. SUMMARY OF THE INVENTION

This invention provides apparatus, systems, system components, methods,
compositions, and reagents for determining the function and activity of peptides and
proteins and for identifying and characterizing molecules that affect these functions and
25 activities. The methods and reagents of the invention are used to determine the various
activities of peptides and proteins including their binding specificity, binding activity,
their enzymatic activity and their ability to act as substrates for enzymes. This invention

5 is especially suited for the analysis of peptide and protein function where large numbers of peptides and proteins need to be analyzed.

One embodiment of the invention comprises a multiwell plate with a plurality of wells, preferably with at least 20 wells containing the *in vitro* transcription and translation products of at least one, and preferably plurality of, unique nucleic acid construct. The multiwell plate may advantageously have at least 40 wells or most advantageously at least 84 wells. The multi-well assay plates may have any number of wells of any size or shape, arranged in any pattern or configuration, and can be composed of a variety of different materials. Preferred embodiments of the invention use industry standard formats for the number, size, shape and configuration of the plate and wells. Examples of standard formats include 96-, 384-, 1536-, and 9600-well plates, with the wells configured in two-dimensional arrays. Other formats may include single well plates (preferably having a plurality of assay domains), 2 well plates, 6 well plates, 24 well plates, and 6144 well plates. Furthermore, the number of unique nucleic acid constructs advantageously is at least 2, more preferably at least 6, even more preferably at least 24, even more preferably at least 40, even more preferably at least 84 and most advantageously at least 300. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials which may be used as solid phases in solid phase assays. The wells of the multiwell plate may include integrated electrodes which may also be used as solid phases in solid phase assays, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. Advantageously the *in vitro* transcription and translation is carried out in the presence of a tRNA precharged with a modified amino acid. In a preferred embodiment of the invention each well contains

- 5 multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids to be individually contacted to one of the multiple zones or spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.
- 10 The invention also comprises a multiwell plate with at least 20 wells containing the *in vitro* transcription and translation products of at least one unique nucleic acid construct and coated with the products of the *in vitro* transcription translation reaction. The multiwell plate may advantageously have at least 40 wells or most advantageously at least 84 wells. The multi-well assay plates may have any number of wells of any size or
- 15 shape, arranged in any pattern or configuration, and can be composed of a variety of different materials. Preferred embodiments of the invention use industry standard formats for the number, size, shape and configuration of the plate and wells. Examples of standard formats include 96-, 384-, 1536-, and 9600-well plates, with the wells configured in two-dimensional arrays. Other formats may include single well plates
- 20 (preferably having a plurality of assay domains), 2 well plates, 6 well plates, 24 well plates, and 6144 well plates. Furthermore, the number of unique nucleic acid constructs advantageously is at least 2, more preferably at least 6, even more preferably at least 24, even more preferably at least 40, even more preferably at least 84 and most advantageously at least 300. Also the wells of the multiwell plate can comprise carbon or
- 25 a carbon composite materials which may be used as solid phases in solid phase assays. The wells of the multiwell plate may include integrated electrodes which may also be used as solid phases in solid phase assays, preferably these are configured so that the

5 multiwell plate is able to support electrochemiluminescence. Advantageously the *in vitro* transcription and translation is carried out in the presence of a tRNA precharged with a modified amino acid. In a preferred embodiment of the multiwell plate each well contains multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or
10 spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.

The invention comprises a multiwell plate containing beads with each well containing the *in vitro* transcription and translation products of at least one unique nucleic
15 acid construct. The multiwell plate may advantageously have magnetic beads. Preferably, the *in vitro* transcription and translation is carried out in the presence of a tRNA precharged with a modified amino acid.

The invention also comprises a multiwell plate with at least 20 wells coated with a specific binding species that is used to bind the *in vitro* transcription and translation
20 products of at least one unique nucleic acid construct. The invention also comprises these plates, wherein the well surfaces provide a solid phase which coated with the products of the *in vitro* transcription translation reaction, preferably via binding to the specific binding species. The multiwell plate may advantageously have at least 40 wells or most advantageously at least 84 wells. Also the number of unique nucleic acid
25 constructs advantageously is at least 40 and most advantageously at least 84. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials which may be used as solid phases in solid phase assays and/or to support the immobilized

5 amino acid sequences. The wells of the multiwell plate may include integrated electrodes which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. Preferably, the *in vitro* translation is carried out in the presence of a tRNA precharged with a modified amino acid. In a preferred embodiment of the multiwell plate each well contains multiple zones (sometimes referred to herein as assay domains or spots) which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence. In a preferred embodiment the specific binding species is selected from the nucleic acid, peptides or proteins

The invention also comprises a multiwell plate with at least 20 wells coated with an amino acid sequence containing a modified amino acid that is produced as follows. Initially a nucleic acid construct is obtained and transcribed to generate RNA. This RNA is then translated in a cell-free translation system (preferably a cell lysate) containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing the modified amino acid. These transcription and translation steps can also be combined in a single *in vitro* reaction. This amino acid sequence is then contacted with a well of a multiwell plate with at least 20 wells, where by a well surface coated with an amino acid sequence containing a modified amino acid is produced. The multiwell plate can contain at least 40 wells most advantageously the multiwell plate has at least 84 wells. Also the wells of the multiwell plate can comprise carbon or a carbon composite

- 5 materials which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences. The wells of the multiwell plate may include integrated electrodes which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. In a preferred
- 10 embodiment of the multiwell plate each well contains multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.
- 15 The invention also comprises a method of producing a multiwell plate with at least 20 wells coated with an amino acid sequence containing a modified amino acid. This is, preferably, produced by obtaining a nucleic acid construct and transcribing it to generate RNA. This RNA is then translated in a cell-free translation system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence
- 20 containing a modified amino acid. These transcription and translation steps can also be combined in a single *in vitro* reaction. Amino acid sequences prepared in this way are then introduced into wells of a multiwell plate with at least 20 wells, where by a multiwell plate having wells coated with these amino acid sequences is produced. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials
- 25 which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences. The wells of the multiwell plate may include integrated electrodes which may be used as solid phases in solid phase assays and/or to

5 support the immobilized amino acid sequences, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. In a preferred embodiment of the multiwell plate each well contains multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell
10 plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.

The invention also comprises a method of producing a multiwell plate with at least 20 wells coated with an amino acid sequence containing a modified amino acid and post-translational modifications. This is, preferably, produced by obtaining one or a series
15 of nucleic acid constructs followed by transcribing these to generate RNA. These RNA are then translated in a cell-free system (preferably a cell lysate) containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid and post translational modifications. These amino acid sequences are then introduced into wells of a multiwell plate with at least 20 wells, where
20 by a multiwell plate coated with an amino acid sequence containing a modified amino acid and post-translational modifications is produced. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences. The wells of the multiwell plate may include integrated electrodes which may be used as
25 solid phase supports in solid phase assays and/or to support the immobilized amino acid sequences, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. In a preferred embodiment of the multiwell plate each well

5 contains multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.

10 The invention also comprises a method of producing a multiwell plate with at least 20 wells coated with an amino acid sequence containing a modified amino acid and post-translational modifications. This is, preferably, produced by obtaining one or a series of nucleic acid constructs followed by transcribing these to generate RNA. These RNAs are then translated in a cell-free system (preferably a cell lysate) containing a tRNA
15 precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid. These amino acid sequences are then introduced into wells of a multiwell plate with at least 40 wells, to coat said wells with amino acid sequences containing a modified amino acid. These coated multiwell plates are then contacted with an enzyme, where by a multiwell plate with at least 40 wells coated with an amino acid
20 sequence containing a modified amino acid and a post-translational modification is produced. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials which may be used as solid phases in solid phase assays. The wells of the multiwell plate may include integrated electrodes, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. In a preferred
25 embodiment of the multiwell plate each well contains multiple zones or spots which allow multiple amino acid sequences containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell

5 plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.

The invention also comprises a method of producing a multiwell plate with at least 20 wells coated with an amino acid sequence containing a modified amino acid and post-translational modifications. This is, preferably, produced by obtaining one or a series
10 of nucleic acid constructs and transcribing these nucleic acids to generate RNA. The RNA is then translated in a cell-free translation system (preferably a cell lysate) containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid. These amino acid sequences are then introduced into the wells of a multiwell plate with at least 20 wells, to coat said multiwell
15 plate with an amino acid sequence containing a modified amino acid. These coated multiwell plates are then contacted with an enzyme effective at removing a post-translational modification. Following this treatment with this enzyme to remove the post-translational modifications the multiwell plate is contacted with a second enzyme, where by a multiwell plate with at least 20 wells coated with an amino acid sequence containing
20 a modified amino acid and a post-translational modification is produced. Also the wells of the multiwell plate can comprise carbon or a carbon composite materials which may be used as solid phases in solid phase assays and/or to support the immobilized amino acid sequences. The wells of the multiwell plate may include integrated electrodes which may be used as solid phase supports in solid phase assays and/or to support the immobilized
25 amino acid sequences, preferably these are configured so that the multiwell plate is able to support electrochemiluminescence. In a preferred embodiment of the multiwell plate each well contains multiple zones or spots which allow multiple amino acid sequences

5 containing the modified amino acids each individually to be contacted to one of the multiple zones or spots in a well of a multiwell plate. Alternatively, amino acid sequences may be contacted with multiple zones in a well, e.g., to measure multiple different characteristics of an amino acid sequence.

The invention also comprises a method for screening nucleic acid constructs for
10 those encoding amino acid sequences subject to post-translational modifications. This is, preferably, achieved as follows. A nucleic acid construct is obtained and transcribed to generate RNA. This RNA is then translated in a cell-free translation system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid. This amino acid sequence is then subjected to the
15 detection of its post-translational modifications using, preferably, a solid phase assay. In one example, the amino acid sequence is captured onto a solid phase using a binding species specific for the post-translational modification. Following this the captured amino acid sequences is detected on the solid phase using the modified amino acid. In another example, the amino acid sequence is captured onto a solid phase via a binding species
20 specific for said modified amino acid. This captured amino acid sequence is then subject to detection using, e.g., a binding species specific for the post-translational modification. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence.

The invention also comprises a method for screening nucleic acid constructs for
25 those encoding amino acid sequences subject to post-translational modifications. This is, preferably, achieved as follows. A nucleic acid construct is obtained and transcribed to generate RNA. This RNA is then translated in a cell-free translation system containing a

5 tRNA precharged with a modified amino acid and a substrate for a post-translational modification, to produce an amino acid sequence containing said modified amino acid and said post-translational modification. The detection of the post-translational modifications of the amino acid sequence is achieved using, preferably, a solid phase assay. In one example, the amino acid sequence is captured onto a solid phase via a
10 binding species specific for said modified amino acid and detecting using a binding species specific for a post-translational modification. In another example, the amino acid sequence is captured onto a solid phase using a binding species specific for the post-translational modification. This is followed by detecting the captured amino acid sequences on the solid phase using, e.g., a binding species specific for the modified
15 amino acid. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence.

The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences subject to post-translational modifications. This is, preferably, achieved as follows. A nucleic acid construct is obtained and transcribed to
20 generate RNA. The RNA is translated in a cell-free translation system containing a tRNA precharged with a modified amino acid and a substrate for a post-translational modification modified with a label, to produce an amino acid sequence containing the modified amino acid and the post-translational modification. The post-translational modifications of the amino acid sequence are, preferably, detected using a solid phase
25 assay. In one example, the amino acid sequence is captured onto a solid phase via a binding species specific for said modified amino acid and detected using the label on the post-translational modification. In another example, the amino acid sequence is captured

- 5 onto a solid phase via a binding species for the label on the post-translational modification and detected using the modified amino acid. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence. Examples of binding species specific for post-translational modifications include antibodies, antibodies to ubiquitin and antibodies to phosphotyrosine.
- 10 The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences with enzymatic activity, preferably, comprising the following steps. A nucleic acid construct is obtained and transcribed to generate RNA. The RNA is translated in a cell-free system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing the modified amino
- 15 acid. The enzymatic activity of the amino acid sequence is preferably detected using a solid phase assay. In one example, the amino acid sequence is captured onto a solid phase via a binding species specific for the modified amino acid, enzyme reaction buffer is added and the product of the enzyme activity is detected. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence.
- 20 The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences that are substrates of enzymatic activity comprising, preferably, the following steps. A nucleic acid construct is obtained and transcribed to generate RNA. The RNA is translated in a cell-free system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence
- 25 containing the modified amino acid. The amino acid sequences which are substrates of an enzyme activity are detected using, preferably, a solid phase assay. In one example, the amino acid sequences are captured onto a solid phase via a binding species specific

5 for the modified amino acid, an enzyme is added and the product of the enzyme activity is detected. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence. Preferably, the amino acid sequences are pre-treated prior to contact with the enzyme activity to add or remove a post-translational modification.

The invention also comprises a method for screening nucleic acid constructs for
10 those encoding amino acid sequences with binding activity comprising, preferably, the following steps. A nucleic acid construct is obtained and transcribed to generate RNA. The RNA is translated in a cell-free system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing the modified amino acid. The binding activity towards a binding partner is, preferably, detected in a solid
15 phase assay. In one example, the assay comprises capturing the amino acid sequence onto a solid phase by binding it to a binding partner immobilized on the solid phase and detecting the captured amino acid sequence using the modified amino acid. In another example, the assay comprises capturing the amino acid sequence on a solid phase via a binding reagent specific for the modified amino acid and detecting the binding partner on
20 the solid phase. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence.

The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences with binding activity comprising, preferably, the following steps. A nucleic acid construct is obtained and transcribed to generate RNA.
25 The RNA is translated in a cell-free system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing the modified amino acid. The binding activity of the amino acid sequence for a binding partner is measured,

5 preferably, using a solid phase assay. In one example, the assay comprises contacting the amino acid sequence with a solid phase coated with a binding species specific for the modified amino acid, contacting the amino acid sequence with the binding partner, and detecting complexes having the binding partner on the solid phases. The immobilizing step may occur before, during or after, the contacting step. Alternatively, binding partner
10 is captured on the solid phase and the modified amino acid is detected. Amino acid sequences having the desired activity may be identified from their nucleic acid sequence.

The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences with binding activity comprising, preferably, the following steps. A first nucleic acid and second nucleic acid construct are obtained and
15 transcribed to generate a first and second RNA. The first RNA is translated in a cell-free system containing a tRNA precharged with a modified amino acid comprising a first binding species, to produce a first amino acid sequence containing said first binding species. The second RNA is translated in a cell lysate containing a tRNA precharged with a modified amino acid containing a detectable species, to produce a second amino
20 acid sequence containing the detectable species. The binding of the two amino acid sequences is detected using, preferably, a solid phase assay. In one example, the assay comprises contacting a sample of the first amino acid sequence with the second amino acid sequence and capturing the binding species on a solid phase via a second binding species and detecting the detectable species bound to the solid phase. Amino acid
25 sequences having the desired activity may be identified from their nucleic acid sequence.

The invention also comprises a method for screening nucleic acid constructs for those encoding amino acid sequences with nascent binding activity comprising,

5 preferably, the following steps. A nucleic acid construct is obtained and transcribed to generate RNA. The RNA is translated in a cell lysate containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid. The amino acid sequence is captured onto a solid phase via a binding species specific for the modified amino acid and contacting with an enzyme to covalently modify
10 the amino acid sequence. The binding of the modified amino acid sequence to a binding partner is detected, preferably, by a solid phase assay. In one example, the assay comprises contacting the amino acid sequence with a second binding species labeled with a detectable species and detecting the binding of the second binding species to the covalently modified solid phase. The second binding species may be labeled with a
15 detectable label made using a method comprising the following steps: obtaining a nucleic acid construct, and transcribing the construct to generate RNA and translating said RNA in a cell lysate containing a tRNA precharged with a second modified amino acid, to produce an amino acid sequence containing the second modified amino acid.

This invention provides the identification of kinase activity for proteins that had
20 not previously been demonstrated to have in vitro kinase activity. It also comprises methods for the determination of kinase activity. These kinases that can be used for the screening of compound libraries for inhibitors or activators of these kinases. This invention also provides for assays that allow the investigation of the activity of these kinase isolated from cells and or tissue samples for both studies into disease and
25 diagnostic applications.

The invention also comprises a method for screening for antigens that bind antibodies comprising, preferably, the following steps. A nucleic acid construct is

5 obtained and transcribed to generate RNA. The RNA is translated in a cell-free system to
produce an amino acid sequence. The binding of the amino acid sequence to an antibody
is, preferably, measured using a solid phase assay. In one example, the amino acid
sequence is immobilized on a solid phase and contacted with an antibody. Binding of the
antibody to the solid phase is detected by measuring the amount of antibody on the solid
10 phase. Alternatively, the antibody may be immobilized and the assay may involve
measuring the amount of the amino acid sequence on the solid phase. Amino acid
sequences having the desired activity may be identified from their nucleic acid sequence.

5. BRIEF DESCRIPTION OF THE FIGURES

15

Figure 1 is a gel electrophoresis analysis of a transcription and translation reaction with a
series of EST clones, each lane is identified with its IMAGE ID #.

Figure 2 shows the results electrochemiluminescence assay for identifying ubiquitilated
proteins. The plot shows ECL signal (vertical axis) as a function of the specific clone
20 number (horizontal axis).

Figure 3 shows the results electrochemiluminescence assay for identifying protein having
Tyrosine Kinase activity. The plot shows ECL signal (vertical axis) as a function of the
specific clone number (horizontal axis).

25

5 **6. DETAILED DESCRIPTION OF THE INVENTION**

 The present invention relates to methods for producing proteins and identifying protein function, structure and/or activity. The invention also provides for compositions, systems and apparatuses for accomplishing these methods. Advantageously, preferred methods of the invention employ proteins produced by *in vitro* cell-free transcription and
10 translation systems and are tolerant of high levels of impurities in the protein preparations. By simplifying the processing of expressed proteins, the methods of the invention are especially conducive to the rapid, parallel, processing and/or screening of large numbers of proteins.

 Through the use of the methods of the invention, large numbers of proteins
15 (preferably greater than 80, more preferably greater than 1000, more preferably greater than 10,000 and most preferably greater than 20,000) may be screened, preferably in parallel, for specific functional or structural attributes of interest. These attributes include, but are not limited to, the group consisting of: i) binding activity (i.e., the ability to participate in a binding interaction with a binding partner); ii) enzymatic activity; iii)
20 chemical reactivity; iv) substrate activity (i.e., the ability to act as a substrate an enzyme or other catalyst); v) post-translational modification; and vi) regulatory activity (e.g., the ability to alter the regulation of a cell or other complex biological or biochemical system).

 Advantageously, the same methods used to screen for protein activity are also
25 suitable for screening for molecules that modulate that activity by carrying out the measurement of activity in the presence of potential modulators and measuring the change in activity. Accordingly, one embodiment of the invention comprises expressing

5 a library of proteins (preferably, in a multi-well plate format) by *in vitro* expression of a library of nucleic acid constructs encoding the proteins; screening the library of proteins for proteins with an activity of interest and screening one or more proteins having the desired activity against a library of substances to identify modulators of the activity of these proteins.

10 In preferred embodiments, the proteins are produced by *in vitro* cell-free translation methods, preferably by coupled transcription/translation methods. Applicants have demonstrated that these techniques are amenable to the parallel synthesis of large numbers of proteins in multi-well plates. Surprisingly, the proteins produced from these cell-free systems may be analyzed without purification, although in some applications it
15 may be advantageous to purify the proteins prior to analysis, e.g., to remove interfering activities from the cell-free protein synthesis reagent. In especially preferred embodiments, the protein synthesis methods are designed to produce proteins that share a common chemical moiety (e.g., a detectable label) that allow the proteins to be purified, immobilized or detected using a uniform set of conditions.

20 The proteins can be screened for a variety of attributes of interest using conventional detection techniques for measuring protein attributes (e.g., techniques based on measurements of fluorescence, electrochemiluminescence, chemiluminescence, radioactivity, refractive index, magnetic fields, light scattering, etc.), preferably, using detection techniques that are carried out in a high-throughput and/or highly parallel
25 fashion. Activities of interest may be measured, e.g., via the measurement of the quantity of an analyte; the measurement of a property of a sample (e.g., temperature, luminescence, electrochemical activity, color, turbidity, etc.); the measurement of a

5 chemical, biochemical and/or biological activity (e.g., an enzymatic activity); the measurement of a kinetic or thermodynamic parameter (e.g., the rate or equilibrium constant for a reaction), etc. The assay techniques may be involve the detection of labels or, alternatively may not require labels (e.g., refractive index based techniques such as surface plasmon resonance). The assay techniques may involve the detection of reactions
10 of species in solution (homogenous assays) or may involve at least some species on a solid phase (solid phase or heterogeneous assays). Preferably, the screening assays are carried out in a parallel fashion in multi-well plates (e.g., 24, 96, 384, or 1536 well plates). Even more preferably, the assays are carried out using solid phase assay formats (e.g., assays that presence of the attribute of interest to the attachment or release of an
15 assay component from a solid phase support). Most preferably, the assays are solid phase assays employing ECL detection. In certain preferred embodiments, a plurality of attributes of a protein are measured in one well of a multi-well plate, e.g., by using a patterned array of assay domains on a surface of the well, the different domains designed for measuring different attributes.

20 The association or dissociation of labels from a surface (e.g., as occurs in a solid phase binding assay) can be measured in a washed format or, if the detection technique is surface-selective, in an unwashed format. The surface (e.g., the working electrode surface of a well in an ECL multi-well plate) can be washed prior to contacting a solution (e.g., with a solution containing an ECL coreactant, such as TPA that provides an
25 appropriate environment for the induction of ECL from ECL labels) so as to remove unbound labeled reagents ("washed" assay format). Alternatively, the wash step may be omitted and, if appropriate, reagents such as ECL coreactants are added without first

5 removing unbound labeled reagents ("unwashed" assay format). The surface selectivity of ECL measurements, especially in measurements involving the use of electrodes as solid phase assay supports, allows ECL measurements to be carried out in washed or unwashed formats. Alternatively, unwashed heterogeneous assays may be carried out using other surface selective techniques such as surface proximity assay. In washed ECL
10 assays, it is preferred that the ECL measurement be conducted within a short time period after the addition of the coreactant solution to avoid loss of signal due to dissociation of the reagent in a binding interaction. In the unwashed assay, the timing is less important because free ligand remains in solution and the effect of the addition of the ECL coreactant on the binding equilibrium is small. In this case, the ECL measurements may
15 be conducted as long as 1 hr after addition of the ECL coreactant solution with only small changes in signal.

Preferably, the proteins to be analyzed are produced in a labeled form using an *in vitro* translation, e.g., by including tRNAs charged with labeled amino acids in the translation reaction. These proteins may be used either directly or after affinity
20 purification using the attached label. These proteins are then either immobilized via the label or are detected via the label.

In one embodiment, the labeled protein is contacted with a capture reagent that is immobilized on a solid phase, the capture reagent binding to the label so as to immobilize the labeled protein on the solid phase. Attributes of the protein may then be measured by
25 solid phase assay. For example, the proteins can be analyzed for specific structural features or post-translational modifications by contacting them with binding reagents (e.g., antibodies) that are specific for those structural features or post-translational

- 5 modifications and measuring the formation of binding complexes (preferably, via the detection of a second label attached to the binding reagent). Alternatively binding activity is measured by contacting the proteins with potential binding partners (e.g., specific proteins, peptides, lipids, drugs, nucleic acids, sugars and oligosaccharides, etc.) and measuring the formation of binding complexes (preferably, via the detection of a
- 10 second label attached to the potential binding partner). In another alternate embodiment, the proteins are analyzed for substrate activity by contacting them with an enzyme or other chemical modification reagent and measuring the modification of the protein, e.g., via a, preferably labeled, binding reagent specific for the modified or unmodified form (or, alternatively, by measuring the cleavage from or attachment to the protein of a
- 15 labeled assay component. In another alternate embodiment, the enzymatic activity (e.g., kinase, phosphatase, protease, cyclase, lipase, nuclease, ligase, polymerase or glycosidase activity) of the protein is measured by contacting the immobilized protein with a enzymatic substrate and measuring the consumption of substrate or production of enzymatic product.
- 20 Analogous methods exist for analyzing proteins that are not directly immobilized via the label. In these cases, the binding partner or binding reagent, as described above, are preferably immobilized on a solid phase. The binding of the labeled test protein to the immobilized reagent is, preferably, detected via the detection of the label.
- Post-translational modification, as used herein refers to structural modifications of
- 25 proteins after they have been translated. These can be in the form of covalent modifications or non-covalent.

5 Examples of covalent post-translational modifications that can be detected according to the invention include signal peptide cleavage, phosphorylation, acetylation, adenylation, proteolysis, amino peptidase clipping, arginylation, disulphide bond formation and cleavage, amidation, glycosylation, isoprenylation, myristoylation, ubiquitination, SUMOlation, and covalent addition of proteins including Agp12 and
10 Nedd8.

 Examples of non-covalent post-translational modifications that can be detected according to the invention include changes in the structure or folding state of a given protein (e.g., denaturation) or its non-covalent interactions with other proteins, nucleic acid, carbohydrate, drugs, compounds or lipids. For example the alteration of prions
15 structure from PrPc to PrPsc resulting in resistance to protease activity. Other examples include the binding of a protein as a homo or hetero polymer, insertion in to a lipid membrane, or binding to a glycosyl group, or binding to a drug or compound. Examples of drug or compound binding include for example the interaction of steroid receptors with a steroid.

20 *In vitro* translation systems may introduce post-translational modifications into translated proteins. Often, these post-translational modifications (especially as introduced using eukaryotic translation systems, in particular, the reticulocyte systems) may indicative of post-translational modifications that are observed *in vivo*. Advantageously, the methods of the invention may be used to identify proteins that receive specific types of
25 post-translational modifications.

 In other applications, e.g., in assays for substrate activity, the post-translational modifications may be the same as the modifications which are introduced by, e.g., an

5 enzyme of interest and may therefore interfere with the assay. In these applications, it may be advantageous to contact the protein with a demodifying activity that removes the interfering modification. Preferably, the protein is immobilized to simplify removal of the demodifying activity (e.g., via wash steps) prior to conduct of the assay. In other applications, it may be desirable to contact the protein with a modifying reagent to
10 introduce post-translational modifications prior to conducting an assay. Some proteins may only show an activity after post-translational modification. Thus, an assay of the invention for a characteristic of protein (e.g., binding activity, substrate activity, enzymatic activity, etc.) may comprise the step of treating the protein with a modifying activity (this treatment is most preferably applied after immobilization of the protein on a
15 solid phase) to uncover a nascent activity of the protein. Especially preferred treatments are protease treatment, phosphorylation and dephosphorylation. This technique enables the screening of proteins in different modification states and analysis of the effect of modifications on activity. Preferably, the protein is immobilized to simplify removal of the modification activity (e.g., via wash steps) prior to conduct of the assay. Optionally,
20 the protein is first treated with demodifying activities then treated with modifying activities in order to ensure that the protein is in a defined, reproducible modification state.

The invention relates, in part, to the production and analysis of proteins formed by the *in vitro* transcription and translation of nucleic acid constructs. These nucleic acid
25 constructs are characterized by their ability to direct an RNA polymerase to produce an RNA transcript that, in turn, is able to direct the synthesis of a protein or polypeptide sequence. The nucleic acid construct may comprise DNA and/or RNA (preferably,

- 5 DNA) and may include regions that are single stranded, double stranded (through base pair binding to its complementary sequence), or partially double stranded. The nucleic acid constructs, preferably, contain an RNA polymerase promoter sequence that directs the activity of a RNA polymerase to copy at least a portion of the nucleic acid construct to produce an RNA transcript. This transcript, preferably, either encodes a protein or
- 10 polypeptide or a portion of a protein or polypeptide. The proteins or polypeptides may correspond to amino acid sequences that are found in nature or may be man-made sequences (i.e., sequences not found in nature). The nucleic acid constructs may include synthetic nucleic acid analogs or derivatives that are capable of being copied by transcriptional machinery.
- 15 Preferred nucleic acid constructs include plasmid based cloning vectors containing a cloned DNA sequence of a protein or amino acid sequence (natural or man-made). These plasmid based vectors are, preferably, produced by growing the plasmids in E.coli cultures and purifying the plasmid DNA to obtain the DNA in a form that can be used. Alternate preferred nucleic acid constructs include DNA sequences that have been
- 20 generated using PCR or other amplification protocols. Advantageously, the production of nucleic acid constructs by nucleic acid amplification avoids the use of cloning vectors and cloning protocols that involve transfer and amplification of the DNA in a host organism. In one embodiment, DNA and or RNA from an organism is amplified and engineered during the PCR to generate a nucleic acid construct of the invention that is
- 25 able to direct the production of a RNA sequence under direction of a RNA polymerase. This RNA sequence is then able to produce the protein or proteins of interest via the translation of the RNA sequence.

5 Preferred cloning vectors used in the nucleic acid constructs of this invention include those that contain RNA polymerase sites positioned such that they will allow the production of an RNA strand from the cloned DNA. Suitable cloning vectors containing RNA polymerase sites are available from a number of commercial suppliers including Promega (Madison, WI) Invitrogen (Carlsbad, CA) Novagen (Madison, WI) Clontech
10 (Palo Alto CA). Examples of the RNA polymerases are SP6, T7 and T3. Examples of cloning vectors that contain promoters for these polymerases include pSP72 (Promega, Madison WI), pCITE-2 and -4 (Novagen, Madison, WI). The methods for cloning in to these vectors are well known in the art and reagents and kits are commercially available (Invitrogen, Carlsbad, CA. Clontech, Palo Alto, CA). Many clones are available in
15 suitable vectors; especially preferred nucleic acid constructs include clones distributed by the I.M.A.G.E. Consortium (Lawrence Livermore National Lab, Livermore, CA).

Preferably, gene sequences of interest in vectors are correctly orientated relative to the RNA polymerase sites and within a reasonable distance such as from 0 to 2000 bases, ideally 0 to 500, most ideally 0 to 200. The methods for directionally cloning are
20 well known in the art and are typically part of most cloning methods for mRNA. Alternatively the DNA sequences are cloned without directionality which results in a mixture of clones with the DNA sequence in both of the possible orientations relative to the RNA polymerase site.

Other suitable vectors for use with the invention are vectors that contain
25 additional sequences to the previously described vectors which allow the cloning of the gene of interest in such a way that these additional sequences are incorporated into the transcribed RNA and thus into the translation products of these RNA's. This approach

5 has been used for the cloning of many genes to allow the production of translation products that are fused to other sequences of amino acids that allows the translations products to be detected and or purified. These additional sequences of amino acids are typically referred to as affinity tags, epitope tags, or purification tags. Examples of such vectors include pGADT7, pGBKT7 (Clontech, Palo Alto CA) pcDNA5/FRT/V5-His-
10 TOPO, pSecTag/FRT/V5-His-TOPO (Invitrogen, Carlsbad, CA). Examples of these affinity, epitope or purification tags include, V5, myc, His, FLAG, GST, and MBP.

Nucleic acid constructs can be replicated using standard nucleic acid replication methods including growth in culture (e.g., using standard methods for replicating plasmid DNA) and *in vitro* amplification methods such as PCR, NASBA (Romano JW, et
15 al., Immunol Invest. 1997;26:15-28), rolling circle replication (Zhang DY, et al., Mol Diagn. 2001, 6:141-50). These steps are, preferably, followed by purification of the constructs. Methods for the isolation of plasmid DNA are well known in the art; examples of commercially available kits are available from Promega (Madison WI) and Qiagen (Los Angeles, CA).

20 An alternative route to the nucleic acid constructs of the invention obviates the cloning steps and makes use of *in vitro* methods throughout. With these methods the sequences of interest are amplified using standard nucleic acid amplification methods such as RTPCR, PCR, NASBA and rolling circle amplification. Preferably, oligonucleotide primers (e.g., primers in a PCR amplification) are selected such that the
25 amplification product includes the gene sequence of interest as well as other additional features such as an RNA polymerase recognition site, In more preferred embodiments, other additional features are engineered into the amplification product such as an ATG

5 initiation codon (preferably, modified to match the Kozak sequence such as
CCACCATGG to improve translation, see, e.g., Kozak, M., J. Mol Biol. (1987) 196,
947), a termination of translation site, a 3' UTR and/or a poly A sequence. Optionally a
5' internal ribosome entry site (IRES) may also be introduced. These features may be
introduced into the amplification product by incorporating them (or their complement)
10 within the primers that are used for amplification.

These primers are then used in an *in vitro* reaction with a sample containing the
sequence of interest; examples of samples include mRNA, genomic DNA, cDNA, total
RNA or cloned DNA. These sources of the sequences of interest may be purified or
unpurified. In the case of purified DNA this typically would consist of a mixture of
15 sequences that have been purified from the tissue or cell sample. In the case of unpurified
material this could take the form of whole cells, tissue samples, cell lysates and tissue
homogenates. Examples of methods suitable for use in the *in vitro* production of nucleic
acid constructs of the invention are illustrated in the following publications (Bateman, JF.
et al, Human Mutation, (1999) 13, 311. Kirshgesser, M. et al, (1998) 36, 567. Rao, VR., et
20 al, (1999) J. Biol.Chem. 274, 37893).

Alternatively the nucleic acid constructs of the invention may be RNA generated
using *in vitro* methods or via the use of viral RNA replication as found in Picornaviruses,
Myxovirus, Reovirus and RNA bacteriophage R17, Qb, MS2 and f2; using RNA
dependent RNA polymerases. These RNA viruses can be used to clone and isolate
25 specific genes using standard recombinant methods. Alternatively these RNA dependent
RNA polymerases may direct the *in vitro* production of RNA for translation from an
existing RNA template. The RNA template may be produced from a DNA clone or DNA

- 5 sequence or from an in vitro constructed RNA template. This may be achieved for example with mRNA; initially the RNA is treated with calf intestinal phosphatase, to remove the 5' phosphate from partial transcripts, these treated RNAs are then treated with tobacco acid pyrophosphatase to remove the 5' mRNA cap, exposing the 5' phosphate. Following this step the modified mRNA is then ligated to a sequence effective in
- 10 directing the activity of a RNA dependent RNA polymerase. These ligated and modified mRNA sequences are then hybridized to an RNA oligonucleotide that hybridizes to the 3' poly A and introduces a site for RNA dependent RNA polymerase. These RNA sequences are then made double stranded using a RNA dependent RNA polymerase followed by the synthesis of RNA for translation using a RNA dependent RNA
- 15 polymerase that is activated by the sequence attached at the 5' end of the mRNA. Optionally the addition of the 5' sequence for the RNA dependent RNA polymerase may be carried out with out the use of the calf intestinal phosphatase and tobacco acid pyrophosphatase steps that ensure that only full-length RNA sequences are subjected to the production of RNA for translation using the RNA dependent RNA polymerase.
- 20 In certain preferred embodiments of the invention, translation and, optionally, transcription of nucleic acid constructs to produce proteins is carried out in an assay plate used for carrying out an assay for an activity of interest (e.g., plates as described elsewhere in this specification having assay domains coated with i) a substrate of an activity, ii) a binding reagent specific for a substrate of an activity, iii) a binding reagent
- 25 specific for a product of an activity, iv) a binding reagent specific for a post-translational modification of the translation products, v) a binding reagent suitable for immobilizing the translation products, etc.). The assays of the invention are then carried out in this

5 same plate. Alternatively, in other preferred embodiments, the translation reaction is carried out in one container, preferably, the well of a multi-well plate and the translation products transferred to an assay plate for analysis. This embodiment may be advantageous when only small amounts of translation products are used in an assay.

The assays of the invention may detect or utilize binding interactions of binding
10 species. Binding species, as used herein, is used to describe a molecular species that is able to bind to another molecular species, its binding partner. These binding interactions are characterized in that they are non covalent, or covalent having dissociation constants which are, preferably, lower than 1 mM, more preferably lower than 100 μ M, more preferably lower than 10 μ M and most preferably higher than 1 μ M. Examples of binding
15 species and binding partners include biotin, antibodies, streptavidin, avidin, EDTA, chelates (e.g., EDTA, NTA, IDA, etc.), antigens, fluorescein, haptens (e.g., fluorescein, digoxigenin, etc.), proteins, peptides, drugs, nucleic acids, nucleic acid analogues, lipids, carbohydrates, protein A, protein G, protein L, receptors, ligands, inhibitors, lectins, enzymes, substrates, transition state analogues, mechanism based inhibitors, epitopes,
20 affinity tags (e.g., epitope tags such as his(6), glutathione, Myc, S-tag, T7-Tag), etc..

The assays of the invention may utilize labels. Label or detectable label is used herein is used to describe a substance used to detect (directly or indirectly) a molecular species. The label may be the molecular species itself or it may be linked to the molecular species. In certain embodiments of the invention, labels are used in order to follow or
25 track a given molecular species, for example, to determine its distribution and concentration (as, for example, a radio-labeled drug molecule is used to determine its pharmacological properties when introduced into an animal or patient). In alternative

5 embodiments, a label is introduced into a binding species so as to allow the binding
species to be used to track and/or determine the presence and/or amount of a binding
partner of the binding species. For example, immunoassays using labeled antibodies (e.g.,
antibodies labeled with ECL labels) can be used to detect and determine binding partners
(analytes) bound by the antibody. Examples of this approach are exemplified by the ECL-
10 based clinical immunoassays sold by Roche Diagnostics (Indianapolis, IN) under the
Elecsys tradename.

 In some embodiments of the invention, labels are used which may be detected
directly, e.g., on the basis of a physical or chemical property of the label (e.g., optical
absorbance, fluorescence, phosphorescence, chemiluminescence,
15 electrochemiluminescence, refractive index, light scattering, radioactivity, magnetism,
catalytic activity, chemical reactivity, etc.). Examples of directly detectable labels
include, radioactive labels, fluorescent labels, luminescent labels, enzyme labels,
chemiluminescent labels, electrochemiluminescent labels, phosphorescent labels, light
scattering or adsorbing particles (e.g., metal particles, gold colloids, silver colloids),
20 magnetic labels, etc.

 In other embodiments of the invention, labels are used which may be detected
indirectly via interactions with species comprising directly detectable labels. These
indirectly detectable labels are, preferably, binding species; these binding species readily
allow the binding to a binding partner that is labeled with a directly detectable label.
25 Examples of indirectly detectable labels include binding species as described above, e.g.,
antibodies, antigens, haptens, avidin, biotin, streptavidin, fluorescein, nucleic acid

- 5 sequences, nucleic acid analogue sequences, epitope tags (such as myc, FLAG, GST, MBP, V5), digoxigenin, etc.

Homologous when used herein is used to describe a molecular species' relationship with another molecular species. Two molecular species are homologous when they share a set of molecular properties such as composition, function or structure.

- 10 In the case of nucleic acids and proteins, the extent of homology can be described in terms of the degree of sequence similarity. For example, two proteins or nucleic acids may be considered homologous when they have greater than 20% sequence in common, ideally greater than 30%, or preferentially more than 40% sequence in common.
- Homology can also be described for protein and nucleic acid sequences based on the data
- 15 from a BLAST search of the sequences in the NIH genebank database (<http://www.ncbi.nlm.nih.gov/BLAST>). In BLAST 2.0, for example, an E value of 1 assigned to a hit from a homology search can be interpreted as meaning that in a database of the current size one might expect to see 1 match with a similar score simply by chance. Thus any E value less than 1 would not be expected to happen by chance and would
- 20 indicate that the two sequences are homologous. This approach to description of homology can also be formally applied to other molecular characteristics such as structure as quantified using VAST or a similar protein structure searching algorithm (<http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.shtml>). The VAST p-value is a measure of the significance of the comparison, expressed as a probability. For example, if
- 25 the p-value is 0.001 then the odds are 1000 to 1 against seeing a match of this quality by pure chance. Thus a VAST p-value of less than 0.001 demonstrates a significant degree of homology.

5 The invention relates, in part, to the production of proteins in cell free systems and the analysis of these proteins. Protein synthesis is, preferably, accomplished using cell lysates or extracts (crude or partially purified) that contain the machinery necessary for protein synthesis. This machinery is found in most living cells, however, certain cell types are preferred because of their high protein synthesis activity. Three preferred
10 translation systems for producing proteins are the bacterial (more preferably E coli extract, most preferably E coli S30 cell free extract), plant germ (most preferably, wheat germ) and reticulocyte (most preferably, rabbit reticulocyte) lysate translation systems. Optionally, the cell lysates are supplemented with additional components such as ATP, tRNA, amino acids, RNA polymerases, microsomes, protease inhibitors, proteosome
15 inhibitors, etc. that enhance the functioning of the translation machinery, provide a missing component of the machinery, inhibit protein degradation or provide an additional activity such as transcription or post-translational modification. In an alternate embodiment of the invention the cell-free system is reconstituted from individual purified or partially purified components (e.g., a reconstituted E coli translation system using
20 recombinant components as described in Shimizu et al. (2001) Nature Biotechnology 19, 751-755). In another alternate embodiment, a cell-based translation system is used.

 The E.coli systems are advantageous when a gene has been cloned into a vector with prokaryotic regulatory sequences, such as the promoter and ribosome binding site. These systems are coupled in that transcription and translation can occur simultaneously.
25 The E.coli extract systems have been the subject of much optimization and allow the production of mg amounts of protein using large scale (1ml) reactions fed with reagents through semi-permeable membranes.

- 5 Wheat germ and the rabbit reticulocyte based cell free systems are suitable for the translation of mRNA into proteins. Preferably, these lysates are supplemented with RNA polymerases so that they carry out both transcription, to generate the mRNA, and translation to produce protein thus producing what is called a coupled system as seen in E.coli. The lysates based on the wheat germ and the rabbit reticulocyte may also be
- 10 supplemented with other components in order to introduce additional activities to these lysates. In one embodiment, a lysate is supplemented with microsomes (preferably, dog pancreatic microsome preparations) or xenopus oocyte extract to allow for certain post-translation modifications as well as the processing of proteins which are secreted, inserted or associated with membranes.
- 15 In especially preferred embodiment, proteins are produced using a cell free translation system that is supplemented with tRNAs that are charged with labeled or amino acids so that the proteins incorporate the label. It is preferable to use a tRNA that corresponds to an amino acid with a hydrophilic or charged side chain (most preferably tRNA_{Lys}) so as to make it more likely that the label will be found on the exterior of the
- 20 protein. A variety of suitable charged tRNAs are commercially available including tRNA_{Lys} charged with lysines that are labeled on their side chains with fluorophores (such as fluorescein and BODIPY) or binding species (such as biotin). Most preferably, only a fraction of a specific tRNA (e.g., tRNA_{Lys}) in a translation reaction (preferably, less than 50 %, more preferably, < 10 %) is charged with a label so as to ensure that the number of
- 25 incorporated labels in a protein molecule is low and that the labeling does not significantly influence the structure or functional properties of the protein.

5 In preferred embodiments of the invention, solid phase supports are used for purifying, immobilizing, or for carrying out solid phase activity assays for analyzing the activity of one or more expressed proteins. Examples of solid phases suitable for carrying out the methods of the invention include beads, particles, colloids, single surfaces, tubes, multiwell plates, microtitre plates, slides, membranes, gels and
10 electrodes. When the solid phase is a particulate material it is, preferably, distributed in the wells of multi-well plates to allow for parallel processing of the solid phase supports. Proteins of interest or other assay reagents may be immobilized on the solid phase supports, e.g., by non-specific adsorption, covalent attachment or specific capture using an immobilized capture reagent that binds, preferably specifically, the protein or assay
15 reagent of interest. Immobilization may be accomplished by using proteins or assay reagents that are labeled with binding species that form binding pairs with immobilized capture reagents. Optionally, a protein is immobilized on a solid phase, the solid phase is washed and the protein is analyzed; the wash step allows for the rapid purification of the protein from other, potentially interfering, components of the translation reaction.
20 Optionally, a protein is treated, prior to analysis, to add or remove post-translational modifications.

 Especially preferred solid phase supports are electrode surfaces integrated into the wells of multi-well plates. Such devices allow ECL measurements to be carried out in a high-throughput, highly parallel, fashion. Exemplary multi-well plates are disclosed in
25 copending Provisional Application No. 60/301,932 entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001 (particularly in the description of Plate Type B, Type C, type D, and Type E in Example

5 6.1) and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002,
each hereby incorporated by reference. The electrodes in such plates, preferably,
comprise a carbon composite electrode material such a carbon ink.

The multi-well assay plate can incorporate the electrode in one or more wells of
the plate. The assay region (e.g., a given well of a multi-well plate) may also comprise
10 additional electrodes. Preferably at least one electrode in an assay region (a well of a
multi-well plate) is suitable for use as a working electrode in an electrode induced
luminescence assay, at least one electrode is suitable for use as counter electrode in an
electrode induced luminescence assay. Optionally, there is at least one electrode that is
suitable for use as a reference electrode (e.g., in a three electrode electrochemical
15 system). The surface of the working electrode in an electrode induced luminescence
assay can be used for immobilization of one or more assay components. Electrodes used
in the multi-well assay plates of the invention are typically non-porous, however, in some
applications it is advantageous to use porous electrodes (e.g., mats of carbon fibers or
fibrils, sintered metals, and metals films deposited on filtration membranes, papers or
20 other porous substrates. These applications include those that employ filtration of
solutions through the electrode so as to: i) increase mass transport to the electrode surface
(e.g., to increase the kinetics of binding of molecules in solution to molecules on the
electrode surface); ii) capture particles on the electrode surface; and/or iii) remove liquid
from the well.

25 The wells of multiwell plate can further comprise a plurality (e.g., 2 or more, 4 or
more, 7 or more, 25 or more, 64 or more, 100 or more, etc.) of discrete assay domains.
Multi-domain multiwell plates which are adapted to allow assay measurements to be

5 conducted using electrode induced luminescence measurements (most preferably, electrochemiluminescence measurements) are described in copending Provisional Application No. 60/318,293 entitled "Methods and Apparatus for Conducting Multiple Measurements on a Sample", filed on September 10, 2001, and U.S. Application Serial No. _____ (Attorney Ref. No. 100405-06410), entitled "Methods and Apparatus for

10 Conducting Multiple Measurements on a Sample", filed on September 10, 2002, each hereby incorporated by reference. Multiple assay domains patterned on a surface of a well (e.g., on an electrode in a well adapted for conducting electrode induced luminescence measurements) may be defined by physical boundaries which can include ledges or depressions in the surface, patterned materials deposited or printed on the

15 surface, and or interfaces between regions of the surface that vary in a physical property (e.g., wettability). Such physical boundaries simplify the patterning of reagents on surfaces of a well by confining and preventing the spreading of small drops of reagents applied to an assay domain. By providing two levels of multiplexing (multiple wells per plate and multiple domains per well), Multi-domain multi-well (MDMW) Plates provide

20 a variety of advantages over conventional multi-well plates that only have one assay domain per well. For example, a MDMW Plate having N wells and M assay domains per well allows a panel of M assays to be run on a plurality of N samples. Conducting the same series of assays on conventional N-well plates would require M plates, M times more sample and reagents, and considerably more pipetting and plate handling steps to

25 achieve the same performance. Conducting the same series of assays on conventional array "chips" would involve the handling and movement of N chips and would likely not be compatible with standard plate handling equipment designed for use with multi-well

5 plates. Conducting the same series of assays on a single ultra-high density multi-well plate with M x N wells would generally lead to reduced assay sensitivity (sample volume and, therefore, number of analyte molecules, tends to scale inversely with the density of wells on a plate) as well as to other problems associated with ultra-high density plate formats (e.g., expensive and complicated fluid dispensing equipment, lack of mixing, 10 evaporative losses, trapping of air bubbles, inability to carry out wash steps, etc.).

Multi-well and Multi-domain Multi-well plates can be used in a plurality of diverse assays. In one assay format, the same analyte is measured at different assay domains within a well, the different assay domains being designed to measure a different property or activity of the analyte. Alternatively, an enzyme with multiple different 15 activities is measured in a well comprising different assay domains that differ in their selectivity for each enzymatic activity of the enzyme (e.g., assay domains that comprise substrates for selected enzymatic activities and/or assay domains that are capable of capturing and measuring the substrates or products of selected enzymatic activity), that are designed to measure binding activities of the enzyme (e.g., assay domains comprising 20 potential binding partners of the enzyme or that are designed to capture the enzyme so as to allow the measurement of interaction with potential binding partners in solution) and/or assay domains designed to measure the ability of the enzyme to act as a substrate for a second enzyme (e.g., a binding domains designed to allow for a specific binding assay of the product of the action of the second enzyme on the first enzyme). In another 25 assay format, a well comprises a domain for measuring the amount of an enzyme (e.g., via a binding assay such as an immunoassay) and one or more other domains for measuring one or more activities associated with the enzyme; this allows the measured

5 activity to be referenced to the amount of enzyme. The inclusion of assay domains capable of capturing an enzyme of interest has the added advantage of allowing the purification of the enzyme from a crude sample within the assay well and/or the pre-treatment of the enzyme with a modifying activity that exposes a nascent activity of the enzyme. A well may also comprise an assay domain capable of capturing an enzyme of
10 interest and one or more additional assay domains for measuring an activity of the enzyme of interest. Methods using such a well may include a wash step for purifying the enzyme from impurities in a crude enzyme preparation.

In an embodiment of the invention, a series of nucleic acid constructs is obtained with the genes of interest located within the construct such that the gene of interest can be
15 transcribed into RNA that can direct the synthesis of the protein encoded by the genes of interest. The nucleic acid from these is then subjected to an in vitro transcription reaction and followed by an in vitro translation reaction. These two reactions can also be combined in a single in vitro reaction. During the translation reaction the protein produced in the transcription and translation reaction is also labeled using a modified
20 tRNA that directs the incorporation of a modified amino acid during this step.

Following the transcription and translation reaction the proteins produced in the mix may be captured on to a solid phase. Examples of solid phases suitable for carrying out the methods of the invention include beads, particles, colloids, single surfaces, tubes, multiwell plates, microtitre plates, slides, membranes, gels and electrodes. The capture of
25 the proteins is achieved using a binding partner specific for the modification introduced by the modified tRNA during the translation reaction. A good example of how this is achieved is by the use of the biotin-lys-tRNA that results in a protein containing lysine

- 5 residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using an avidin or streptavidin coated solid phase.
- Alternative methods for capture of the proteins produced include non-specific or passive adsorption, and via the binding to specific binding partners other than those for the modified amino acids introduced by the addition of modified tRNA (e.g., binding
- 10 partners of affinity tags present in the expressed protein). Alternatively the proteins produced may be generated without the use of the modified tRNA and captured using alternative methods for capture, including non-specific or passive adsorption, and via the binding to specific binding partners for the produced proteins (e.g., binding partners of affinity tags present in the expressed proteins).
- 15 In this embodiment of the invention solid phase bound protein products of an in vitro transcription and translation reaction are produced. In the preferred embodiment these step are all carried out in a multiwell plate with 20 wells or more, or ideally 40 wells or more, or most ideally 84 wells or more that allows for the rapid and efficient analysis of the immobilized proteins. For example, a plurality of proteins (preferably
- 20 greater than 80, more preferably greater than 1000, more preferably greater than 10,000 and most preferably greater than 20,000) are produced in parallel and immobilized in separate wells of one or more multi-well plates (e.g., 24, 96, 384 or 1536 well plates). In a most preferred embodiment of the invention the protein products of the in vitro transcription and translation reaction are immobilized on to one of the following in a
- 25 multi-well format: carbon containing surfaces or magnetic beads. In an alternative preferred embodiment of the invention the protein products of the in vitro transcription and translation reaction are immobilized on to one of the plates described in more detail

5 in copending Provisional Application No. 60/301,932 (entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001, and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby incorporated by reference, and particularly in the description of Plate Type B, Type C, Type D, and Type E in Example 6.1. Immobilization in these multi-well plates
10 may be advantageous, even in applications that do not involve ECL measurements, do to the excellent adsorption properties and high binding capacity of the carbon-containing electrode surfaces.

In certain embodiments of the invention, a protein expressed by the expression methods of the invention is characterized by its ability to bind to a potential binding
15 partner (e.g., a biologically relevant binding partner or a binding reagent that specifically binds a structural characteristic such as an epitope or post-translational modification). In one embodiment, the binding event is measured using technique that does not require a detectable label (e.g., surface plasmon resonance, agglutination). In another embodiment, the binding event is measured using a technique the measures a change in a property of
20 labels linked to the protein and/or potential binding partner (e.g., techniques that measure changes in fluorescence polarization, lifetime or energy transfer). In a preferred embodiment, one of the protein or potential binding partner is immobilized on a solid phase support so that the binding event may be measured by measuring the accumulation of the other member of the binding pair on the solid phase. Most preferably, this
25 measurement is accomplished via a detectable label attached to the other member of the binding pair. In such assay methods, the number of binding interactions is correlated to the accumulation of labels on the solid phase; this accumulation of labels being

5 measurable by a variety of techniques (e.g., fluorescence for fluorescence labels, enzyme activity for enzyme labels, ECL for ECL labels, etc.). Most preferably, the solid phase is an electrode material, the labels are ECL labels and the accumulation of labels is measured via an ECL measurement.

In certain other embodiments of the invention, a protein expressed by the expression methods of the invention is characterized by its catalytic activity or its ability to act as a substrate in the presence of a catalytic activity or other chemical activity. Where such activity is characterized as a joining (i.e., an activity that joins two or more species, e.g., nucleic acid ligase activity, nucleic acid polymerase activity, protein translation activity, ubiquitin ligase activity, etc.) and/or cleaving activity (i.e., an activity that results in the cleaving of a species into two or more components, e.g., protease activity, nuclease activity, glycosidase activity, etc.), the activity can be measured using techniques analogous to those described for binding reactions. By way of example, an activity that joins a first substrate having a first label with a second substrate is measured by immobilizing the second substrate on a solid phase support (e.g., by passive adsorption or by capture via the specific binding of the second substrate or a second label on the second substrate to a binding reagent on the solid phase support) and measuring the amount of the first label on the solid phase. In another example, a cleaving activity is measured by using a substrate having a first label that is immobilized on a solid phase support (e.g., by passive adsorption or by capture via the specific binding of a second label on the substrate to a binding reagent on the solid phase support) and measuring the loss of labels from the solid phase in the presence of the activity.

5 In certain other embodiments of the invention, an activity is measured by using a substrate that exhibits a detectable change in a chemical or physical property when acted on by the activity of interest (e.g., luminescence, color, ability to act as an ELC coreactant, etc.).

10 Assays for post-translational modifications

 In one embodiment of the invention, a nucleic acid construct is preferably obtained with the genes of interest located within the construct such that the gene of interest can be transcribed into RNA that can direct the synthesis of the protein encoded by the genes of interest. The nucleic acid construct is then subjected to an *in vitro* transcription reaction and followed by an *in vitro* translation reaction. These two
15 reactions can also be combined in a single *in vitro* reaction.

 The protein product (or, alternatively, protein obtained by any other method) is then analyzed for the presence of post-translational modifications of interest. Preferably, a plurality of constructs comprising different genes are prepared and the protein products
20 of these genes produced and analyzed, most preferably in parallel in the wells of multi-well plates.

 Preferably, during the translation reaction the protein produced is also labeled, most preferably by using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this protein expression step the reaction
25 mix is then subjected to assays for protein function, and or activity and or structure. For example the protein in the mix is captured on to a solid phase using a binding protein specific for the label introduced during the translation reaction. A good example of how

5 this is achieved is by the use of the biotin-lys-tRNA that results in a protein containing lysine residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using an avidin coated solid phase. Examples of the solid phase include beads, particles, colloids, single surfaces, tubes, multiwell plates, microtitre plates, slides, membranes, gels and electrodes, The preferred plates are
10 described in more detail in copending Provisional Application No. 60/301,932 (entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001, hereby incorporated by reference) and particularly in the description of Plate Type B, Type C, Type D, and Type E in Example 6.1 and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby
15 incorporated by reference.

With these proteins immobilized on to a solid phase the proteins are then available for an assay to determine if they have been subject to any structural modifications or post-translational modifications. These post-translational modifications are then detected using a labeled binding species specific for the post-translational
20 modification that binds to the immobilized proteins containing these post-translational modifications. An example of how this is achieved is illustrated by phosphorylation of tyrosines. This post-translational modification is carried out by protein kinases and this is readily detected using antibodies specific to phosphotyrosine. In this example the antibody would be labeled with a detectable label and the bound signal detected to
25 determine the amount phosphorylation for a given protein form the translation reaction. An example of such a reagent is Abzyme (IGEN International, Inc., Gaithersburg MD) that is an antibody to phosphotyrosine labeled with an electrochemiluminescent (ECL)

5 label. In the case of other post-translational modifications, examples of post-translational modifications that can be detected with antibodies include ubiquitinylation, SUMO, other phosphorylated sequences, acetylation, prenylation, farnesylation, and geranylation.

In a further embodiment of the invention based on the example above a labeled substrate for a given post-translation modification is included in the translation reaction.

10 Examples of such substrates include ubiquitin, SUMO-1, Nedd8 or Agp12 or homologous substrates. Examples of labels that could be used include, metal chelates, biotin, binding species, digoxigenin, enzymes, fluorophores, luminescent species and ECL labels. In a preferred embodiment of a labeled substrate, ubiquitin is labeled with an ECL label.

15 The result of the inclusion of a labeled substrate for a given post-translational reaction is that those proteins that are subjected to this post-translational modification are produced with the post-translational modification including the label. This results in the production of a labeled protein. Proteins that are labeled in this way through the action of a post-translational modification and are also labeled as described using modified tRNA
20 contain two, preferably different, labels. Thus these proteins are readily detected by immobilization through one of the labels and detected with the other. In a preferred embodiment the protein is modified with a biotin during translation with biotin-Lys-tRNA and subjected to post-translational modification using ECL labeled ubiquitin.

In an alternative embodiment the invention involves either obtaining clones or the
25 production of clones in a desired cloning vector or nucleic acid construct. The DNA from these is then subjected to an in vitro transcription reaction and followed by an in vitro translation reaction. These two reactions can also be combined in a single in vitro

- 5 reaction. During the translation reaction the protein produced is also labeled using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this protein expression step the reaction mix is then subjected to assays for post-translational modification. The protein in the mix is then captured on to a solid phase using a binding protein specific for the post-translational modification. A good
- 10 example of how this is achieved is by the use of an antibody specific for a post-translational modification for example an antibody to ubiquitin immobilized on to a solid phase. This allows the capture of proteins that have been ubiquitinated on to the solid phase. Examples of the solid phase include beads, particles, colloids, single surfaces, tubes, multiwell plates, microtitre plates, slides, membranes, gels and electrodes.
- 15 With these proteins immobilized on to a solid phase the proteins are then available for an assay to determine if they have been captured and thus subject to any structural modifications or post-translational modifications. These proteins are then detected using a binding species specific for the modified amino acid that has an attached label. A good example of how this is achieved is by the use of the biotin-lys-tRNA in the translation
- 20 reaction resulting in a protein containing lysine residues modified with biotin. The biotinylated proteins that result and are then captured through the post-translational modification binding species and are subsequently detected using streptavidin (also including avidin or anti-biotin antibodies) labeled with a detectable label.
- In the case of other post-translational modifications antibodies are available to
- 25 ubiquitinylation, SUMO, other phosphorylated sequences, acetylation, which would readily allow the capture of the proteins produced in an in vitro translation reaction that are subjected to these post-translational modifications.

5

Assays for enzyme activity.

In another embodiment of the invention clones are either preferably produced or obtained in the desired vectors or nucleic acid constructs. The constructs are then subjected to an *in vitro* transcription reaction and followed by an *in vitro* translation reaction. These two reactions can also be combined in a single *in vitro* reaction. The protein product, or alternatively a protein obtained by other means, is then incubated under conditions conducive to the activity of interest (pH, temp, presence of cofactors, substrates, energy sources, etc.) analyzed for the presence of the activity. Preferably, a plurality of constructs comprising different genes are prepared and the protein products of these genes produced and analyzed, most preferably in parallel in the wells of multi-well plates. Such screens can be used, for example, to identify proteins with a specific category of activity (e.g., all tyrosine kinases) or to elucidate biochemical pathways by identifying the enzyme responsible for a reaction of a known substrate. In one example, a panel of proteins is screened against a panel of substrates (the substrates, preferably, being immobilized as an array) to identify previously unknown enzyme/substrate pairs. Most preferably, the substrate array is immobilized within the wells of a multi-well plate so that a large number of proteins can be quickly screened in parallel.

Preferably, during the translation reaction the protein produced is also labeled, preferably by using a modified tRNA that directs the incorporation of a modified amino acid during this step. In one case for example the protein in the mix is captured on to a solid phase using a binding protein specific for the label introduced during the translation reaction. A good example of how this is achieved is by the use of the biotin-lys-tRNA

5 that results in a protein containing lysine residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using a streptavidin coated solid phase. It is also possible to use other binding species specific for biotin including avidin and anti-biotin antibodies.

The immobilized proteins are, optionally purified of other components of the translation system (e.g., by washing the solid phase) and are then analyzed for their enzyme activity. This is typically determined by the addition of the desired substrate for the activity of interest. The substrate is then acted on by the immobilized enzyme activity produced by the transcription and translation reactions to produce the product of the enzyme activity of interest. The activity of the enzyme is then determined by the detection and or quantitation of the product of the reaction. Optionally the loss of the substrate may also be determined. The measurements are, preferably, carried out as described above by i) measuring a detectable change in a property of a substrate on reaction of the substrate to form product; ii) measuring the binding activity of a substrate or product for binding reagents specific for one of the product and substrate or iii) through a measurement of joining or cleaving activity.

Optionally, the protein is treated with a post-translational modification activity prior to conducting the enzymatic assay so as to uncover a nascent activity/.

Examples of preferred enzyme activities that may be detected include kinases, hydrolases, protease, polymerases, glycosidases, and phosphatases. Other preferred enzyme activities that can be measured include the activities of enzymes that catalyze the post-translational modification of proteins, e.g., signal peptide cleavage, phosphorylation, acetylation, adenylation, proteolysis, amino peptidase clipping, arginylation, disulphide

- 5 bond formation and cleavage, amidation, glycosylation, isoprenylation, myristoylation, ubiquitination, SUMOlation, Agp12 ligation, Nedd8 ligation and covalent addition of proteins. Examples of enzyme activities which may be measured include cleaving or joining enzymes such as amidases, proteases, peptidases, glycosidases, saccharases, glycopeptidases, nucleases (including ribonucleases and deoxyribonucleases),
- 10 endonucleases (including restriction endonucleases), exonucleases, ribosomes, ribosomal RNA, ribozymes, self-splicing molecules such as introns or inteins, esterases, phosphodiesterases, phosphorylases, AP endonucleases, polymerases (e.g., DNA or RNA polymerases), nucleic acid repair proteins, amino peptidases, carboxy peptidases, aminoacyl-tRNA synthetases, ADP-ribosyl transferases, proteases of the complement
- 15 pathway, proteases of the thrombolytic pathways, transferases, endoglycosidases, exoglycosidases, lipases, endoproteinases, glutathione S-transferases, polysaccharide or oligosaccharide synthases (e.g. glycosyl transferases or glycogen synthases), ligases, ubiquitin-protein ligases, trans-glutaminases, integrases, and DNA glycosylases (e.g., uracil-DNA glycosylases), helicases, etc.
- 20 Examples of substrates that may be used for kinases include, poly (Glu-Tyr), peptides, proteins, and proteins produced by a process of transcription and translation. In a preferred example, the substrate is a generic substrate that is broadly targeted acted on by a genus of enzymes (by way of example, applicants have found that poly (Glu-Tyr) can be used as a generic substrate in screens for tyrosine kinases. The product of the
- 25 action of a tyrosine kinase on the poly (Glu-Tyr) is to generate poly (glu-Tyr) containing phosphorylated tyrosines which is readily detected in a sandwich binding assay format using an antibody to phosphotyrosine immobilized on to a solid phase and labeled anti

5 phospho-tyrosine antibody such as Abzyme (IGEN International, Inc., Gaithersburg MD). In a further embodiment the proteins produced in the translation reaction may also be subjected to the action of a post-translational modification prior to determination of its enzyme activity. Examples of this include the phosphorylation of a protein from the translation reaction prior to its assay for kinase activity. Thus, the methods of the
10 invention may be used for identifying post-translational modifications that regulate enzymatic activity.

According to one preferred embodiment, the invention is directed to the identification of proteins with self-modifying activities. A protein expressed according to the methods of the invention (and, preferably, immobilized as described above) is
15 incubated under conditions conducive to the activity of interest. The same protein is then assayed for the presence of a self-modification of interest (e.g., via its binding activity for a binding reagent specific for the modification of interest or via the cleavage or joining of a labeled component from or to the protein. Most preferably, the protein is immobilized on a solid phase (as described above) and the extent of modification assays measured
20 according to the solid phase assay techniques described above.

According to one preferred embodiment, the invention is directed to efficient methods for screening proteins for their ability to modify both themselves and other species. Both these activities may be biologically relevant (particularly for receptor kinases) and also provide complementary indicators of a proteins function. By way of
25 example, one embodiment of this class of methods will be illustrated through assays for the identification of the *in vitro* kinase activity and autophosphorylation activity of proteins.

5 According to this embodiment of the proteins are immobilized onto a surface of a solid phase such as the surfaces in wells of multi-well plates (according, e.g., to the immobilization methods described above). The proteins are incubated under conditions appropriate for a modifying activity of interest (e.g., kinase activity) in the presence of a substrate for the activity of interest (preferably, a generic substrate such as poly(glu,tyr) 10 in the case of tyrosine kinase activity). The presence of self-modified proteins on the solid phase is measured using the solid phase assay techniques of the invention (e.g., via the use of labeled anti-phosphotyrosine antibodies for measuring auto-phosphorylation). The presence of modified substrate is also measured via the assay techniques of the invention (e.g., by carrying out a sandwich immunoassay for phosphorylated poly(glu, 15 tyr).

 The measurement of the modified substrate can be carried out in a separate assay compartment (e.g., by transferring the kinase reaction supernatants to another multi-well plate. Alternatively, both measurements can be carried out in the same well by including in the well two discreet assay domains: an assay domain for immobilizing the test 20 protein (e.g. an assay domain having an immobilized capture reagent, such as avidin, for capturing a test protein comprising a binding species such as biotin) and a discreet assay domain having appropriate reagents for measuring the modified substrate (e.g., an assay domain comprising an antibody specific for the modified substrate such as an anti-phosphotyrosine antibody. The invention also provides for an *in vitro* assay to screen for 25 candidate substances, e.g., small molecules, proteins, nucleic acids, lipids, etc. that are effective at inhibiting or activating the kinase activity (against self and/or other substrates) of the identified kinases.

5 The invention includes *in vitro* assays for the auto-phosphorylating activity and/or substrate phosphorylating activity for potential kinases selected from the list of kinases below. Preferably, the auto-phosphorylation assays are conducted using kinases that are expressed and immobilized as described above. Preferably, the substrate phosphorylation assays employ poly(glu,tyr) as a generic substrate.

10 The list of potential kinases includes the kinases listed below. Preferred kinases for use with the assays of the invention are Ephb3, Ephb4 and Fgfr4.

	<u>IMAGE#</u>	<u>Locus</u>	<u>Kinase</u>
	2644960	Kit	kit oncogene
	2654352	Fgfr2	fibroblast growth factor receptor 2
15	3482498	Tek	endothelial-specific receptor tyrosine kinase
	3601246	FRK	B-cell src-homology tyrosine kinase
	3673003	Ephb3	Eph receptor B3
	3866791	JAK1	Janus kinase 1 (a protein tyrosine kinase)
	3896359	FGFR1	fibroblast growth factor receptor 1 (fms-related TK2)
20	3921724	FGR	FYN oncogene related to SRC
	3978518	Hck	hemopoietic cell kinase
	3982920	Clk4	CDC like kinase 4
	3989782	Yes	Yamaguchi sarcoma viral (v-yes) oncogene homolog
	3995512	CLK2	CDC-like kinase 2
25	4013934	Ephb4	Eph receptor B4
	4036253	CLK3	CDC-like kinase 3
	4037899	FGFR1	fibroblast growth factor receptor 1
	4238984	Kdr	kinase insert domain protein receptor
	4239139	Fgfr4	fibroblast growth factor receptor 4
30	4343428	PTK2B	protein tyrosine kinase 2 beta
	4384416	BTK	Bruton agammaglobulinemia tyrosine kinase
	4387232	CLK1	CDC-like kinase 1
	4419700	LCK	lymphocyte-specific protein tyrosine kinase
	4419973	FGR	GR feline sarcoma viral (v-fgr) oncogene homolog
35	4471986	ALK	anaplastic lymphoma kinase (Ki-1)
	4485050	Fert2	fer (fms/fps related) protein kinase
	4498209	EPHB1	EphB1
	4515877	Frk	fyn-related kinase
	4537393	TTK	TTK protein kinase
40	3673003	Ephb3	Eph receptor B3
	4013934	Ephb4	Eph receptor B4
	4239139	Fgfr4	fibroblast growth factor receptor 4

5 Assays for substrate activity.

 In an alternative embodiment of the invention clones are preferably either produced or obtained in the desired vectors or nucleic acid constructs. The DNA from these is then subjected to an in vitro transcription reaction and followed by an in vitro translation reaction. These two reactions can also be combined in a single in vitro
10 reaction. The protein product, or alternatively a protein obtained by other means, is then incubated in the presence of a modifying activity, e.g., an enzymatic activity, under conditions conducive to the activity (pH, temp, presence of cofactors, substrates, energy sources, etc.) and analyzed for the presence of modifications derived from the activity. Preferably, a plurality of constructs comprising different genes are prepared and the
15 protein products of these genes produced and analyzed, most preferably in parallel in the wells of multi-well plates. In one embodiment, each protein is immobilized in a separate well of a multi-well plate. In an alternative embodiment, a plurality of proteins are immobilized in an array in a well of a multi-well plate (or on a protein "chip") so that a panel of activities (preferably, one per well or chip) can be screened in parallel against a
20 panel of potential substrates (preferably, a plurality per well or chip).

 Preferably, during the translation reaction the protein produced is also labeled, preferably by using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this protein expression step the reaction mix is then subjected to assays to determine if it is a substrate for an enzyme. In one
25 embodiment the protein in the mix is captured on to a solid phase using a binding protein specific for the label introduced during the translation reaction. A good example of how this is achieved is by the use of the biotin-lys-tRNA that results in a protein containing

- 5 lysine residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using an avidin coated solid phase.

The immobilized are, optionally, purified of other components of the translation system (e.g., by washing the solid phase) and then analyzed for their substrate activity. In order to determine if a specific protein is substrate for a given enzyme activity the

10 immobilized proteins are contacted with an enzyme followed by an assay to detect the modifications of the immobilized proteins by the enzyme activity (e.g., by contacting the protein with a, preferably labeled, binding reagent that is specific for the modification or, in the case of a joining activity, via the use of a labeled co-substrate that is joined to the protein as a result of the activity). In one example, an assay for protease substrates

15 involves the use of specific binding reagents or antibodies that recognize the protein as altered by the protease. This readily allows the detection of the action of the enzyme and determination of a substrate for the enzyme. In another example, a protein kinase is contacted with the immobilized proteins from the translation reaction and the resulting phosphorylation detected using a specific antibody for said phosphorylation as described

20 above for post-translational modifications. In a further example a ubiquitination enzyme, or enzyme mixture is contacted with the immobilized proteins from the translation reaction and the resulting ubiquitination detected using a specific antibody for said ubiquitination. In the case of ubiquitination an alternative approach would be to make use of ubiquitin labeled with a detectable species such as an ECL label.

25 In a further extension of this methodology, the proteins that are produced in the translation reaction may be assayed for substrate activity prior to immobilization and detection.

- 5 Optionally, the proteins produced in the translation reaction may be subjected, prior to exposure to the test activity, to a pretreatment step that removes post-translational modifications introduced in the translation step (in particular, modifications of the type introduced by the test activity). By way of example, phosphates on a test protein that were introduced during protein translation may interfere with an assay for kinase activity.
- 10 Examples of such a pretreatment steps include phosphatase treatment, deubiquitination, de-farnesylation, de-geranylation, de-glycosylation.

- In a further embodiment the proteins produced in the translation reaction may also be subjected, prior to the determination of its substrate activity, to the action of a post-translational modification activity. This embodiment enables the screening of specific
- 15 modifications on substrate activity. Examples of this approach include the phosphorylation of a protein from the translation reaction prior to its assay for ubiquitination.

Assays for binding activities of proteins.

- 20 In an alternative embodiment of the invention clones are preferably either obtained or produced in a desired cloning vector or nucleic acid construct. The DNA from these is then subjected to an *in vitro* transcription reaction and followed by an *in vitro* translation reaction. These two reactions can also be combined in a single *in vitro* reaction. The protein product, or alternatively a protein obtained by other means, is then
- 25 incubated in the presence of a potential binding partner and analyzed for formation of a binding complex. Preferably, a plurality of constructs comprising different genes are prepared and the protein products of these genes produced and analyzed, most preferably

5 in parallel in the wells of multi-well plates. In one embodiment, each protein is immobilized in a separate well of a multi-well plate. In an alternative embodiment, the potential binding partner may be immobilized and the test protein is introduced in solution. In another embodiment, a plurality of proteins are immobilized in an array in a well of a multi-well plate (or on a protein "chip") so that a panel of potential binding
10 partners (preferably, one per well or chip) can be screened in parallel against a panel of proteins (preferably, a plurality per well or chip). Alternatively, the potential binding partners are the species immobilized in the array and the test proteins are introduced into individual wells.

Preferably, during the translation reaction the protein produced is also labeled,
15 preferably by using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this protein expression step the reaction mix is then subjected to assays for protein binding activity. In one case, for example the protein in the mix is captured on to a solid phase using a binding protein specific for the label introduced during the translation reaction. A good example of how this is achieved is by
20 the use of the biotin-lys-tRNA that results in a biotinylated protein containing lysine residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using an avidin, or streptavidin coated solid phase. Optionally, the proteins may be treated with a post-translational modifying activity prior to analysis so as to uncover a nascent binding activity.

25 With these proteins immobilized on to a solid phase, the proteins are then available for an assay to determine the protein's binding activities. These binding activities are determined by measuring the binding of the protein to a binding partner that

5 is, preferably, labeled. Preferably, the binding partner is added to the proteins captured on to the solid phase and incubated to allow binding. Following this step the degree of binding is determined based on a determination of the amount of binding partner captured on to the solid phase, e.g. via measurement of a label on the binding partner.

In an alternative embodiment, the potential binding partner is immobilized on a
10 solid phase support and the potential binding partner is contacted with a labeled test protein generated from a translation reaction. The formation of binding complexes is determined by measuring the amount of labeled test protein on the solid phase.

Preferred potential binding partners include proteins, peptides (e.g., recognition sequences from a protein), lipids, phosphoinositides, nucleic acids, hormones (including
15 steroids), drugs, etc. In a preferred embodiment, the potential binding partner is a peptide that has a modification that is the same as a post-translational modification. By way of example, a potential binding partner may be a short phosphorylated peptide, preferably a putative recognition sequence from a known protein, e.g., the following recognition site from I κ B α (H2N-LKKERLLDDRHD(p)SGLD(p)SMKDEEYC-COOH) [SEQ ID No. 1].
20 The binding assays of the invention may be used to identify proteins that bind to this recognition sequence.

Potential binding partners for use in the binding assays of the invention are, preferably, labeled with a detectable label. The label may be used to detect the occurrence of a binding interaction, in particular, when the translated test protein is
25 immobilized on a solid phase. Alternatively, when the potential binding partner is immobilized on a solid phase, the label may be used to capture the potential binding partner on a solid phase via the interaction of the label with a capture reagent that binds

- 5 the label. Peptidic potential binding partners are, preferably, labeled at a Cys residue, e.g., the I κ B α peptide [SEQ ID No. 1] described above is preferably labeled at the C-terminal Cys residue with a label such as the ECL label ORI-TAG maleimide.

- Other methods for immobilizing a potential binding partner onto a solid phase include conventional immobilization methods such as passive adsorption, covalent
- 10 linkage to a chemically activated surface including NHS ester, epoxide, maleimide chemistries and cross-linking reagents. Useful cross-linking reagents include cross-linking reagents that comprise one or more functional groups capable of reacting with components of a lipid/protein layer or an electrode surface (e.g., imidoesters, active esters such as NHS esters, maleimides, α -halocarbonyls, disulfides such as pyridyldithiols,
- 15 carbodiimides, arylazides, amines, thiols, carboxylates, hydrazides, aldehydes or ketones, active carbamates, glyoxals, etc.). In some applications it may be advantageous to use photo-reactive cross-linkers (such as arylazides) so as to better control the cross-linking process. Exemplary cross-linking agents include homo- and hetero-bifunctional cross-linking agents such as those sold by Pierce Chemical Co. and/or described in the 1994
- 20 Pierce Catalog and Handbook (Pierce Chemical Co., Rockford, IL, 1994), the chapters relating to cross-linking agents hereby incorporated by reference.

- In the case of small molecules or peptides these can be directly immobilized using the chemically activated surfaces as described previously. In an alternative method the small molecules are first coupled using typical chemistries such as NHS ester, epoxide,
- 25 cross-linking chemistries (see above), maleimide to a carrier typically a large molecule such as a protein that can then be immobilized using a simple passive adsorption methods: An example of this is the coupling of Cys or SH containing peptides to

5 maleimide activated BSA. These Peptide:BSA conjugates can then be immobilized readily using passive adsorption methods. In another alternative the small molecules are first coupled to a another binding species such as biotin or fluorescein, these conjugates are then immobilized using a binding species:binding partner interaction such as biotin:streptavidin, biotin:avidin, biotin:antibiotin, fluorescein:anti-fluorescein. Examples
10 of such small molecule conjugates include thyroxine-biotin and triiodothyronine-biotin (Roche Diagnostics, Indianapolis, IN), biotinylated-phosphoinositides (Rao, VR., J. Biol Chem. 1999, 274, 37893).

Assays for protein:protein binding interactions.

15 In another embodiment of the invention clones are preferably either obtained or produced in a desired cloning vector or nucleic acid construct. The DNA from these is then subjected to an *in vitro* transcription reaction followed by an *in vitro* translation reaction to produce a first library of translated proteins. The transcription and translation reactions can be combined.

20 Preferably, proteins are labeled with a first label during the translation reaction, preferably by introducing a modified tRNA that directs the incorporation of a modified amino acid. The process is repeated to produce a second library of translated proteins comprising a second label, e.g., by using a different modified tRNA species having a different modified tRNA. For example, biotin-lys-tRNA is used for one translation and
25 BODIPY®FL-lys-tRNA for the other. Proteins from the first library are mixed with proteins from the second library and the formation of binding complexes is measured to identify pairs of proteins that have binding affinity for each other. The translation

5 reactions and/or binding assays are preferably carried out in parallel in a multi-well plate format.

Preferably, protein:protein interactions are detected in the following way. Two translation products from the two different libraries are mixed together to form a mixture of the two differently labeled translation products. These are allowed to bind and the
10 resulting mixture is then captured on to a solid phase using a binding species specific for one of the labels in the products of the translation (alternatively, one of the translation products is first captured and is then contacted with the other translation product). Following this (or sequentially) a labeled or detectable binding species is added which recognizes the label not used to immobilize the product of the translation reaction
15 (alternatively, this label is a directly detectable label and is detected directly). In this way the interaction between the proteins produced in the two translation reactions is detected. An example of this is where a gene is transcribed and translated in the presence of BODIPY®FL-lys-tRNA and a gene is transcribed and translated in the presence of biotin-lys-tRNA. These reactions result in the production of proteins that are labeled with
20 BODIPY®FL and biotin respectively. These two-labeled proteins in the translation mix are mixed and allowed to interact. These proteins are then captured on to a solid phase using for example streptavidin followed by detection of the BODIPY®FL to allow the determination of protein:protein binding. Another example of this is where a gene is transcribed and translated in the presence of $\text{Ru}(\text{bpy})_3^{2+}$ -lys-tRNA and a gene is
25 transcribed and translated in the presence of biotin-lys-tRNA. These reactions result in the production of proteins that are labeled with $\text{Ru}(\text{bpy})_3^{2+}$ and biotin respectively. These two labeled proteins in the translation mix are mixed and allowed to interact. These

- 5 proteins are then captured on to a solid phase using for example streptavidin followed by detection of the $\text{Ru}(\text{bpy})_3^{2+}$ to allow the determination of protein:protein binding.

Assays for nucleic acid sequence binding activity.

- In an one embodiment of the invention clones are preferably either obtained or
10 produced in a desired cloning vector or nucleic acid construct. The DNA from these is then subjected to an *in vitro* transcription reaction and followed by an *in vitro* translation reaction. These two reactions can also be combined in a single *in vitro* reaction. During the translation reaction, the protein produced is also labeled using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this
15 protein expression step the reaction mix, or alternatively a reaction mix obtained by other means, is then subjected to assays for nucleic acid sequence binding activity. In one case for example the protein in the mix is captured on to a solid phase using a binding protein specific for the modification introduced by the modified tRNA during the translation reaction. A good example of how this is achieved is by the use of the biotin-lys-tRNA
20 that results in a biotinylated protein containing lysine residues modified with biotin. The biotinylated proteins produced in this way are then captured on to a solid phase using an avidin coated solid phase.

- With these proteins immobilized on to a solid phase the proteins are then available for an assay to determine the proteins nucleic acid sequence binding activities.
25 These nucleic acid sequence binding activities are determined using various methods including using a labeled nucleic acid sequence. Typically the nucleic acid sequence is added to the proteins captured on to the solid phase and incubated to allow binding.

5 Following this step the degree of binding is determined based on a determination of the amount of label captured on to the solid phase. In a preferred embodiment the nucleic acid sequence is a DNA sequence that has been labeled with an ECL label during synthesis using ORI-TAG® labelled phosphoramidite (IGEN International, Inc., Gaithersburg, MD). In an alternative protocol the labeled nucleic acid is added to the translation reaction prior to immobilization of the translation product on to a solid phase.

10 In an alternative embodiment of the invention clones are either obtained or produced in a desired cloning vector or nucleic acid construct. The DNA from these is then subjected to an in vitro transcription reaction and followed by an in vitro translation reaction. These two reactions can also be combined in a single in vitro reaction. During the translation reaction the protein produced is also labeled using a modified tRNA that directs the incorporation of a modified amino acid during this step. On completion of this protein expression step the reaction mix is then subjected to assays for nucleic acid sequence binding activity. In this embodiment the binding activity of the protein from the transcription translation system is analyzed by determining its binding to an immobilized nucleic acid sequence. For example a potential nucleic acid sequence is immobilized on to a solid phase using methods known in the art such as passive adsorption, covalent linkage to a chemically activate surface including NHS ester, epoxide, cross-linking reagents (see above), maleimide chemistries. In an alternative method the nucleic acid sequence are first coupled using typical chemistries such as NHS ester, epoxide, maleimide to a carrier typically a large molecule that can then be immobilized using a simple passive adsorption methods. This method also allows for the construction of arrays of multiple nucleic acid sequences within a single container. Also the labeling of

5 the nucleic acid either during synthesis or post synthesis with a small molecule binding species such as biotin, fluorescein, digoxigenin also allows for the immobilization of the nucleic acid on to a solid phase in specific arrays using an immobilized binding partner. With the nucleic acid sequence immobilized on to the solid phase the labeled proteins that have been produced in the transcription and translation reaction are contacted with
10 this coated solid phase. The binding activity of the proteins from the transcription and translation reactions is determined based on the detection of the modified amino acid incorporated during the translation reaction. Typically this is achieved using labeled; avidin, streptavidin or an antibody specific for the modification on the modified amino acid.

15

Assay for antigens.

An alternative embodiment of the invention is directed to the discovery of antigens recognized by antibodies. These antibodies may be monoclonal or polyclonal or patient samples, i.e., serum or plasma. These patients may be animal or human and may
20 or may not have been diagnosed with a disease or medical condition. Examples of patient who have been diagnosed with a disease or medical condition include autoimmune disease, immunological disorders, asthma, heart disease, MS, atherosclerosis and cancer. Screens for antigens have been made typically using bacterial expression methods; this invention includes novel methods for screening for antigens using proteins
25 (preferably, labeled) produced in a transcription and translation reaction. The proteins are contacted with the antibodies and the formation of binding complexes is measured. Preferably, the binding measurements are carried out in a solid phase format and involve

- 5 the capture of the translated proteins and detection of the antibody or, alternatively, capture of the antibody and detection of the translated proteins. The antibodies and/or proteins are, preferably, labeled and captured and/or detected via these labels. Alternatively, the antibodies are captured or detected using antibody-specific binding reagents such as Proteins A, G or L or secondary antibodies. In one example, translated
- 10 proteins are immobilized on to a solid phase followed by detection of those binding to the added antibodies using either directly labeled antibodies or via a labeled binding species specific for the added antibody. In the preferred embodiment the proteins produced in the transcription and translation reaction (nucleic acid constructs such as a cDNA library or a collection of clones expected to contain the antigens specific for the antibodies of
- 15 interest) are immobilized on to a solid phase in a multiwell plate as described above. The proteins are contacted with the antibodies and the formation of binding complexes is detected. Each protein may be analyzed in individual wells of a multi-well plate. Alternatively, an array of proteins is produced in a well of a multi-well plate or on a protein chip and a plurality of binding assays are carried out in one reaction volume. In
- 20 the most preferred embodiment the proteins produced in the translation are labeled using a modified precharged tRNA such as biotin-lys-tRNA as described earlier. These labeled proteins are then immobilized by binding to avidin or streptavidin immobilized on to a carbon containing surface or magnetic beads. These immobilized proteins are thus available for binding to the antibodies to allow the detection and determination of the
- 25 genes and proteins of the antigens recognized by the antibodies. The antibodies bound to the immobilized antigen are detected using for example ECL labeled anti antibodies (IGEN International, Inc., Gaithersburg, MD).

5

Recruitment Assays.

As described above, certain embodiments of the invention preferably involve expression of a protein using a cell-free translation system, immobilization of the protein (preferably, via a label introduced into the protein during the translation reaction) and assaying the immobilized protein for an activity (e.g., a catalytic activity, a substrate activity, a binding activity, etc.). Surprisingly, applicants have found occasional translated proteins that appear unlikely to have an activity of interest (on the basis, e.g., of sequence, structure or historical data) but that test strongly positive for the activity. Applicants have discovered that, in many cases, this apparent contradiction is due to the recruitment of active components of the translation reaction mixture to the solid phase via binding of the active component to the translated protein.

By way of the example, applicants have screened immobilized proteins for kinase activity and found proteins that test positive but do not appear to have inherent kinase activity. In one specific example, a biotin-labeled protein was produced by transcription/translation in a rabbit reticulocyte system that was supplemented with tRNA that was charged with biotin-lys, the protein was immobilized on a streptavidin-coated surface and the immobilized protein was assayed for kinase activity by measuring its ability to phosphorylate poly(Glu,Tyr). The mechanism of this effect has been shown to be the recruitment of endogenous kinases in rabbit reticulocyte lysate through binding to the biotin-labeled protein; the observed activity can be significantly reduced or eliminated through the use of high stringency washes designed to dissociate the binding interaction responsible for the recruitment.

5 In one embodiment of the invention, a translated protein, or alternatively a protein obtained by other means, is immobilized, the protein is not washed or washed with a low stringency wash, and the protein is assayed for an activity of interest or for its ability to recruit a species having an activity of interest. In another embodiment, a translated protein is immobilized, the protein is washed with a high stringency wash, and the protein
10 is assayed for an activity of interest in the absence of recruited species. By comparison of the results of these two experiments, positive results can be categorized as resulting from inherent activity or recruitment. In another embodiment of the invention, a translated protein is i) immobilized, ii) the protein is not washed or washed with a low stringency wash, iii) the protein is assayed for an activity of interest or its ability to
15 recruit a species having an activity of interest (e.g., by introduction of a substrate for an enzymatic activity), iv) the protein is washed in a high stringency wash and v) the protein is assayed for the activity of interest in the absence of recruited species. Thus, it is possible to analyze both conditions using one set of immobilized proteins.

 Preferably, the high stringency wash is a high salt buffer, preferably, having an
20 salt concentration of greater than or equal 750 mM, or more preferably 1 M. Alternatively, high stringency may be accomplished through non-physiological pH (preferably > 8.5 or < 6) or the introduction of denaturing detergents or chaotropic agents. The label used in the translation reaction is preferably chosen for its ability to participate in binding reaction that is relatively insensitive to high stringency conditions
25 (e.g., biotin-avidin or biotin-streptavidin).

5 The identity of recruited species may be identified through a variety of analytical techniques including sequencing, mass spectrometry, capillary electrophoresis, HPLC, electrophoresis, western blotting, antibody arrays, or a combination thereof.

Alternative approaches.

10 In a further embodiment of the invention the *in vitro* transcription and translation reaction can be carried out in the presence of a membrane preparation (e.g., microsomes) that allows for the signal peptide processing, insertion into membranes and glycosylation of the proteins produced by the *in vitro* translation reaction. Examples of membrane preparations that can be used include canine microsomal membranes (Walter, P. and
15 Blobel, G. (1983) Meth. Enzymol. 96, 84), *Xenopus* egg extracts (Zhou, X, et al (200) In Vitro Cell. Dev.Biol. –Animal 36, 293-298; US 6,103,489). This alternative can be applied to all the various examples outlined above where an interest in the membrane bound proteins is a primary consideration. This approach can be especially valuable when screening for a receptor for a given ligand. Such ligands may be drugs, proteins, lipids,
20 phospholipids etc., where the receptor is thought to be a membrane bound protein. The proteins may be immobilized and/or analyzed according to the methods of the invention while membrane bound. Alternatively, they are released from the membranes prior to processing or analysis. To release the translocated proteins or to fully expose the receptors after translation the microsomal membranes are, preferably, lysed using
25 detergents such as 1% Triton X-100. This step allows the binding, enzyme, and/or substrate activity of the proteins to be fully accessed. This lysis step may be carried out either before or after immobilization (using, e.g., the methods based on the modified

- 5 amino acids precharged on tRNA, or affinity tags included in the expressed protein, or directly immobilized by passive adsorption.

In another alternative embodiment of the invention the proteins produced in the transcription translation reaction are produced with epitope tags or affinity tags that are incorporated into the coding sequence of the various genes of interest. This can be used in
10 place of the modified tRNA to label the products of the translation reaction. These epitope tags can thus be used to bind to solid phases and for detection via the use of specific binding partners to these epitope tags. The specific binding partners are typically antibodies but may include other classes of binding partners. Examples of useful affinity tag/binding partner pairs include GST:glutathione, Peptide:avidin, MBP:maltose, DNA
15 binding protein:DNA, His₆:Ni-NTA.

In another alternative embodiment of the invention the proteins produced in the transcription and translation reaction are immobilized directly to the solid phase via various methods such as passive adsorption, or coupling to chemically activated surfaces using various chemistries such as NHS ester, epoxide and maleimide. Proteins
20 immobilized in this way are thus available for detection of specific interactions or reactions.

In another alternate embodiment of the invention, the translation step is omitted from methods of the invention that employ transcription and translation. In this embodiment, mRNA coding for an amino acid sequence of interest, preferably purified
25 mRNA, is added directly to a translation system (preferably a cell-free translation system).

5 In another alternate embodiment of the invention, the assays of the invention are conducted on proteins that are not generated by *in vitro* translation, preferably labeled proteins. These may be proteins that are purified from natural sources or expressed in living cells.

 In a preferred embodiment of the subject invention these various materials and
10 methods are all handled in multiwell plates. Typically these plates have 20 or more wells, 40 or more wells, 84 or more wells, 96 or more wells, 384 or more wells or 1536 or more wells.


7. EXAMPLES

15 The examples provided below provide demonstrate certain aspects of the invention. In some examples, an assay technique is used to measure a known activity of a protein. It is understood that the same technique will be applicable for identifying other proteins that have these or similar activities, in particular, proteins in which these activities have not been previously identified.

20 **Materials and Methods.**

 Compound 1 pictured below (Sulfo-TAG™ label- NHS Ester, Meso Scale Diagnostics) is the NHS ester of an electrochemiluminescent label used to label biomolecules for electrochemiluminescence measurements. Labeling of biomolecules was carried out by adding Sulfo-TAG NHS Ester to a solution of the biomolecule in
25 phosphate buffered saline, pH 8.0. The labeled biomolecules were typically purified from unbound label by size exclusion chromatography (using, e.g., Superdex Peptide Gel or Sephadex G50, Pharmacia Biosciences) or reverse phase HPLC. For labeled proteins,

- 5 the ratio of labels per protein was calculated from the concentration of labels (calculated from the extinction coefficient of Sulfo-TAG label at 455 nm, $\epsilon_{455} \sim 13,700 \text{ M}^{-1}\text{cm}^{-1}$) and the concentration of protein (determined using the BCA Protein Assay, Pierce Chemicals).



- Electrochemiluminescence measurements were carried out using screen-printed carbon ink electrodes patterned on the bottom of specially designed 96-well multi-well or multi-domain multi-well plates. The multi-well plates are described in more detail in
- 15 copending Application No. 60/301,932 (entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001) and particularly in the description of Plate Type B in Example 6.1 (IPR plate) and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby incorporated by reference. The multi-domain multi-well plates are described in more detail in copending
- 20 Application No. _____ (entitled "Methods and Apparatus for Conducting Multiple Measurements on a Sample", filed on September 10, 2001) and U.S. Application Serial

5 No. _____ (Attorney Ref. No. 100405-06410), entitled "Methods and Apparatus for Conducting Multiple Measurements on a Sample", filed on September 10, 2002, each of which is hereby incorporated by reference. Analogous plates are now commercially available (MSD Multi-Array Plates and Multi-Spot Plates, Meso Scale Discovery). Each well of the plate has a patterned working electrode comprising 1, 4, 7, or 10 assay domains (roughly in the center of the well) that are exposed regions of electrode surface that are defined by a patterned dielectric layer on the electrode surface. The dielectric layer could be used to confine small volumes of liquid to specific assay domains (e.g., to allow for confinement of an immobilization reagent to the working electrode surface). Each well also has two counter electrodes surfaces (roughly at two edges of the well). In some examples, the carbon ink electrodes were treated with an oxygen plasma to increase the surface area of exposed carbon particles and to improve the wettability of the surface (plasma treatment was not required for carrying out the assays, however, in some applications plasma treatment was found to improve the ratio of signal to background as well as assay precision).

20 The plates were coated with proteins, such as streptavidin, avidin, or an antibody by depositing an aliquot of a protein stock solution (preferably 0.1-0.5 mg/ml in PBS, pH7.4, 0.01% Triton-X100) onto the working electrode surface of each well of 96-well IPR plate and air-drying for 5 hours. Following the coating, the plate was blocked overnight with a blocking solution (containing BSA in a PBS buffer with stabilizers) at 4°C followed by three washes with PBS. Alternatively, following the adsorption step the plates were washed 3 times with 300 µl of a solution containing 2 % Sucrose, 0.1% Tween, 0.2% Kathon, 2.3 % Ammonium Dihydrogen Phosphate, dried in a vacuum

25

5 chamber for 3.5 minutes, placed in foil pouches containing desiccant, vacuum sealed and stored at 4C. Just prior to use, these plates were blocked with 300 µl of the BSA-containing blocking solution overnight at 37°C followed by three washes with water.

Unless indicated otherwise, electrochemiluminescence from ECL labels on the surface of the carbon electrodes was induced and measured using an imaging plate reader
10 as described in Examples 6.1 and 6.3 of copending Provisional Application No. 60/301,932 (entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001, hereby incorporated by reference) and U.S. Application Serial Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby incorporated by reference. Analogous plate readers are now commercially available
15 (Sector HTS™ instrument, Meso Scale Discovery).

Binding Buffer 1 (BB1) refers to PBS, pH7.4 containing 0.1%BSA, 0.1% bovine IgG, 0.2% tween-20, and protease inhibitors (protease inhibitor cocktail, EDTA free, Roche Applied Science). Binding Buffer 2 (BB2) refers to 25 mM Tris-HCl buffer pH 7.4 containing 100 mM NaCl, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT and
20 protease inhibitors (protease inhibitor cocktail, EDTA free, Roche Applied Science). Proteins were produced by coupled transcription/translation using TnT reaction mixes (Promega Corp, WI). The TNT Quick coupled transcription-translation system (Promega) contains rabbit reticulocyte lysate pre-mixed with most of the reaction components necessary to carry out transcription and translation *in vitro* (TNT mix),
25 including all the amino acids except methionine. Unless otherwise noted, biotin-labeled *in vitro* translated proteins were produced in reaction mixtures that contained 8-30 µg/ml of a selected plasmid encoding protein of interest, 5 µl of TNT T7 Quick reticulocyte

5 lysate mix (Promega Corp, WI) or TnT SP6 Quick Coupled Transcription / Translation System (Promega Corp, WI), 20 μ M methionine, 50 μ M MG-132 (Calbiochem, proteasome inhibitor to inhibit degradation of ubiquitylated proteins by proteasome) and 20 μ g/ml biotinylated Lys-tRNA (transcend tRNA, Promega). The reactions were allowed to proceed for 20-90 min at 30°C. The reactions were stopped by the addition of
10 BB1 supplemented with 20 mM AMP-PNP (Sigma, a non-hydrolyzable ATP analog), 20 mM N-ethylmaleimide (Sigma, an irreversible inhibitor of deubiquitylating enzymes) or, alternatively, by the addition of BB2. BB1 was used in screens involving the ubiquitination pathway. BB2 was used for other assay formats. The produced proteins were used in the assays of interest with or without further purification.

15

EXAMPLE 1. ECL Assay For Ubiquitylation Of RGS4 In Reticulocyte Lysates Using Sulfo TAG™-Labeled Ub

The example demonstrates the detection of ubiquitylated proteins produced by *in vitro* translation by adding labeled ubiquitin in the translation reaction.

20 The following experiment describes detection and measurement of ubiquitylation of RGS4 (Regulator of G-protein signaling 4), a previously described substrate of a subset of the ubiquitin-proteasome system, called the N-end rule pathway (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941).

RGS4 was produced by transcription/translation of 30 μ g/ml plasmid pcDNA3-
25 RGS4 (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941) under the conditions described in Materials and Methods except for the addition of 1 μ M Ub aldehyde (Calbiochem, to inhibit deubiquitylating enzymes) and 5 μ M Sulfo-Tag-labeled

- 5 Ub (having an average of 4.1 labels per Ub molecule). Then 3 μ l of the reaction was mixed with 50 μ l of BB1 in a 96-well streptavidin-coated non-plasma treated IPR (NPT IPR) plate. The plate was left on a tabletop shaker for 1 hour to allow for binding of biotinylated proteins to the surface. Thereafter the plate was washed three times with PBS followed by the addition of 100 μ l of ORIGEN® Assay Buffer (IGEN International, 10 Inc., Gaithersburg, MD) into each well, and ECL signals were measured using an imaging plate reader (IPR).

- In a typical experiment the presence of RGS4-encoding plasmid produced a 5-15 fold higher ECL signal compared to the empty vector (Table 1). We also used this assay to compare ubiquitylation of RGS4 and RGS4_{C2V} mutant, which was previously shown to 15 be a much poorer substrate of the ubiquitin-proteasome pathway in the reticulocyte lysate system (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941). In our assay RGS4 produced 3-4 fold higher ECL signal compared to RGS4_{C2V}, when the same amounts of the corresponding plasmids were added to the reaction mixtures (Table 1)

- 20 **Table 1.** IPR readings obtained in the ORIGEN assay using Sulfo-TAG-labeled Ub

Reticulocyte lysate	Plasmid	Experiment 1	Experiment 2
-	None	539	528
+	Empty vector	1974	1857
+	RGS4	29294	27303
+	RGS4-C2V	7744	7614

5 **EXAMPLE 2. ECL assay for ubiquitylation of RGS4 using Sulfo-TAG labeled streptavidin and IPR plate coated with FK2 antibody**

The example demonstrates detection of ubiquitylated proteins produced by in vitro translation, using immobilized antibodies able to bind the ubiquitin post-translational modification.

10 Transcription-translation reaction mixtures were prepared as described in the Example 1 except that no labeled ubiquitin was added. Some reactions also contained 1mM dipeptide inhibitor of the N-end rule pathway (either Arg- β -Ala, or Trp-Ala) together with 50 μ M bestatin as indicated (Table 2). The reaction was allowed to proceed for 20 min at 30°C. Then 1 μ l of the reaction was mixed with 50 μ l of BB1
15 supplemented with 20 mM AMP-PNP, 20 mM N-ethylmaleimide, and 2 μ g/ml Sulfo-TAG-labeled streptavidin in a well of an IPR plate coated with an anti-ubiquitin antibody (FK2 antibody, Affiniti). The plate was left on a tabletop shaker for 1 hour to allow for ubiquitylated proteins to bind to the surface of the plate and for the Sulfo- TAG-labeled streptavidin to bind to biotinylated proteins. Thereafter the plate was washed three times
20 with PBS followed by addition of 100 μ l of ORIGEN Assay Buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals were measured using an imaging plate reader.

In a typical assay the presence of RGS4-encoding plasmid produced a 30-100 fold higher ECL signal compared to the empty vector (Fig. 2, Table 2). This signal was reduced 3-4
25 fold in the presence of Arg- β -Ala (a type 1 inhibitor of the N-end rule pathway), but not in the presence of Trp-Ala (a type 2 inhibitor of the N-end rule pathway) in agreement with the previous report that RGS4 is a type 1 N-end rule substrate in reticulocyte lysates

- 5 (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941). In the same assay RGS4 produced 3-5 fold higher ECL signal compared to RGS4_{C2V}, when the same amounts of the corresponding plasmids were added to the reaction mixtures (Table 2).

Table 2. IPR readings obtained in the ORIGEN ubiquitylation assay using Sulfo-TAG-
10 labeled streptavidin and IPR plate coated with FK2 antibody

Plasmid	Dipeptide inhibitor	Experiment 1	Experiment 2
Empty vector	-	376	355
RGS4	-	23441	23137
RGS4	Arg- β -Ala	6224	6184
RGS4	Trp-Ala	19196	19268
RGS4-C2V	-	5567	5362

**EXAMPLE 3. ECL Assay For Ubiquitylation Of RGS4 Using Sulfo-TAG-
Labeled FK2 Antibodies And Streptavidin-Coated IPR Plate**

- The example demonstrates detection of ubiquitylated proteins produced by *in*
15 *vitro* translation, using labeled antibodies specific to the Ub post-translational modification.

- The protein was prepared as described Example 2 and mixed with 60 μ g/ml Sulfo-TAG-labeled FK2 antibody (Affiniti) having 5.6 labels per antibody, in a streptavidin-coated NPT IPR plate. The plate was left on a tabletop shaker for 1 hour to
20 allow for biotinylated proteins to bind to the surface of the plate and for the antibody to bind to ubiquitylated proteins. Thereafter the plate was washed three times with PBS followed by the addition of 100 μ l of ORIGEN assay buffer (IGEN International, Inc., Gaithersburg MD) into each well, and ECL signals were measured using an imaging plate (See, Example 1).

- 5 In a typical assay the presence of RGS4-encoding plasmid produced a 15-30 fold higher ECL signal compared to the empty vector (Table 3).

Table 3. IPR readings obtained in the ORIGEN ubiquitylation assay using Sulfo-TAG-labeled FK2 antibody and IPR plate coated with streptavidin

Reticulocyte lysate	Plasmid	IPR readings
-	None	2230
+	Empty vector	4023
+	RGS4	85993

10

EXAMPLE 4. Detection Of Ubiquitinated Proteins Produced In A Transcription And Translation Reaction By Capture With An Anti-Ubiquitin Antibody Immobilized On To A Multiwell Plate.

A. Preparation of plasmid DNA

- 15 The following EST clones in bacteria were obtained: IMAGE ID #, 3446518, 3446518, 3446518, 3914731 (RGS4), 3914731 (RGS4), 3914731 (RGS4) (Incyte, Palo Alto). Bacteria containing EST clones were grown in 2 ml LB with 50 µg/ml Amp, and DNA was isolated using QIAprep Spin Miniprep Kit (Qiagen). DNA yield was 5-20 µg.

B. ECL ubiquitylation assay

- 20 Proteins were prepared from the EST clones in transcription-translation reaction mixtures (total volume 12.5 µL) as described in the Materials and Methods except for the addition of 1 µM Ub aldehyde (Calbiochem). Then 1 µl of the reaction product was mixed with 50 µl of BB1 supplemented with 20 mM AMP-PNP, 20 mM N-ethylmaleimide and 2µg/ml Sulfo-TAG-labeled streptavidin in to each well of an IPR
25 plate coated with FK2 antibody. The plate was left on a tabletop shaker for 1 hour to

5 allow for ubiquitylated proteins to bind to the surface of the plate and for the Sulfo-TAG-labeled streptavidin to bind to biotinylated proteins. Thereafter the plate was washed three times with PBS followed by addition of 100 μ l of ORIGEN Assay Buffer (IGEN, International, Inc., Gaithersburg MD) into each well, ECL signals were measured using an imaging plate reader.

10 All the three RGS4-encoding IMAGE clones (3912628, 3914731 and 3920860) produced strong specific signal in this assay. Analysis of additional 30 random IMAGE clones identified one strong and few weak substrates of ubiquitylation. Clone 3446518 identified as a strong positive encodes uncharacterized protein CGI-147 of approx 19 kDa (Figure 1).

15 As previously reported, RGS4 is a substrate of the N-end rule-dependent ubiquitylation in reticulocyte lysates (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941). To determine if the protein produced from clone 3446518 was similarly ubiquitylated through the N-end rule pathway, the ECL ubiquitylation assay was performed in the presence of dipeptide inhibitors Arg- β -Ala (type 1 inhibitor of the
20 N-end rule pathway), or Trp-Ala (type 2 inhibitor of the same pathway). As was shown on Figure 2, the RGS4 signal was reduced 3-4 fold in the presence of Arg- β -Ala (a type 1 inhibitor of the N-end rule pathway), but not in the presence of Trp-Ala (a type 2 inhibitor of the N-end rule pathway) in agreement with the previous report that RGS4 is a type 1 N-end rule substrate in reticulocyte lysates (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941). In contrast, the dipeptides had little effect on the assay
25 signal from clone 3446518 (Fig. 2). Thus, a different pathway of the ubiquitin system mediates ubiquitylation of the protein produced from clone 3446518.

5

Table 4. ECL readings obtained in the ECL based ubiquitylation assay using Sulfo-TAG-labeled streptavidin and IPR plate coated with FK2 antibody

IMAGE ID	Dipeptide inhibitor	Experiment 1	Experiment 2	Experiment 3
3446518	-	11767	11551	11660
3446518	Arg- β -Ala	10484	10829	9665
3446518	Trp-Ala	11249	11550	11464
3914731 (RGS4)	-	41670	43729	41806
3914731 (RGS4)	Arg- β -Ala	15074	15016	14555
3914731 (RGS4)	Trp-Ala	41229	40401	38552
mock	-	358	348	316

10 C. ³⁵S-labeling of proteins and SDS-gel electrophoresis

The same clones, which were assayed in ECL ubiquitylation assay, were used to produce ³⁵S-labeled proteins. Transcription-translation reaction mixtures contained components described in Materials and Methods and 400 μ Ci/ml ³⁵S-methionine (AmershamPharmaciaBiotech), 1 μ M Ub aldehyde (Calbiochem) in a total volume of

15 12.5 μ l. The reaction was allowed to proceed for 45 min and was stopped by addition of 4-fold excess of SDS-gel loading buffer (Invitrogen) with 5% β -mercaptoethanol. The samples were heated for 5 min at 95°C prior to loading, and SDS-gel electrophoresis was performed on 10-20% Tris-glycine gels (Novex) followed by autoradiography. As can be seen in Figure 1, the vast majority of the tested clones produced protein.

20

5 **EXAMPLE 5. Detection Of Ubiquitylation Of RGS4 Using Sulfo-TAG**

Labeled Ub In M-8 Analyzer

The Example describes detection of ubiquitinated proteins produced in a transcription and translation reaction via capture onto magnetic beads in a multiwell plate format.

10 For M-8 ubiquitylation assays we assembled reaction mixtures which contain 30 µg/ml plasmid pcDNA3-RGS4 or pcDNA3-RGS4-C2V (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941) as indicated in Table 5, and carried out the TnT reactions in the presence of labeled ubiquitin as described in the Example 1. Then 10 µl of the reaction product was mixed with 50 µl of BB1 supplemented with 20 mM AMP-
15 PNP, 20 mM N-ethylmaleimide, and 20 µg streptavidin coated magnetic beads (Streptavidin Dyna-Beads, Dynal) in a 96-well plate. The plate was left on a tabletop shaker for 1 hour to allow for binding of biotinylated proteins to Dynal beads. Thereafter the volume in each well was adjusted to 200 µl with binding buffer, and ECL signals were measured in M-8 Analyzer (IGEN International, Inc., Gaithersburg, MD).

20

Table 5. M-8 readings obtained in the ORIGEN assay using Sulfo-TAG labeled Ub

Reticulocyte lysate	Plasmid	Experiment 1	Experiment 2
-	None	3798	5226
+	Empty vector	8575	9004
+	RGS4	87339	71463
+	RGS4-C2V	30201	26712

5 **EXAMPLE 6. Detection Of Ubiquitylation Of RGS4 Using Sulfo-TAG**
Labeled FK2 Antibody In M-8 Analyzer

The example shows detection of ubiquitinated proteins produced in a transcription and translation reaction via capture on to magnetic beads in a multiwell plate format. In this example, ubiquitination is detected using labeled antibody.

10 Transcription-translation reaction mixtures containing pcDNA3-RGS4 or pcDNA3-RGS4-C2V plasmids(Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941) were prepared and used as described in the Example 2. The reaction products were mixed with 3 µg Sulfo-TAG labeled FK2 antibody in a 96-well plate in a binding buffer. Sulfo-TAG labeled FK2 antibody had 5.6 Sulfo-TAG labels per antibody

15 molecule. The plate was left on a tabletop shaker for 1 hour to allow for binding of the antibody to ubiquitylated proteins. Then 30 µl of BB1 supplemented with 20 mM AMP-PNP, 20 mM N-ethylmaleimide and containing 20 µg dynal beads streptavidin (Dynal) were added to each well, and the plate was left on the shaker at room temperature for another hour to allow for binding of biotinylated proteins to dynal beads. Thereafter the

20 volume in each well was adjusted to 200 µl with BB1, and ECL signals were measured in M-8 Analyzer (IGEN International, Inc., Gaithersburg MD).

Table 6. M-8 readings obtained in the ORIGEN assay using Sulfo-TAG labeled FK2 antibody

25

Reticulocyte lysate	Plasmid	M-8 readings
-	None	6330
+	Empty vector	6414
+	RGS4	187328

+	RGS4-C2V	14689
---	----------	-------

5

EXAMPLE 7. Assay To Screen For Tyrosine Kinase Activity.

The example demonstrates an ORIGEN based HTS assay for tyrosine kinase activity of fer (fms/fps related) protein tyrosine kinase, testis specific 2 (Fert2) expressed in reticulocyte lysate. The assay format developed for this purpose utilizes following steps:

Proteins were produced in an *in vitro* transcription and translation reaction. The reaction mix consisted of the following: 1-150 ng of plasmid DNA (Mock Luciferase, Promega, or Fert2 (IMAGE ID# 4485050, Incyte Genomics, CA), and components described in Materials and Methods in a final volume of 6.25 μ l. This resulted in the transcription and translation of the various proteins with incorporated biotin groups randomly at the positions of the various lysine residues determined by the coding sequence for the gene. The reaction was stopped by mixing with BB2. Biotinylated proteins from 50 μ l of the mixture (representing 0.5 μ l to 1 μ l of TnT reaction) were immobilized onto SA or avidin coated NPT-IPR plates by shaking at room temperature for 45 min. The unbound components of the reaction containing endogenous kinases were removed by three washes with TT- buffer [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton], two five minutes washings with high-salt wash buffer [25 mM Tris-HCl buffer pH 7.4, 0.004% Triton, 1M NaCl and 5 mM DTT] and 3 more washes with TT- buffer. To these immobilized and purified proteins a tyrosine kinase substrate, 5 nM pEY (poly Glu-Tyr, Sigma, MO), was added in a 50 μ l reaction solution containing 5 mM MgCl₂, 5 mM MnCl₂, 100 μ M ATP, 25 mM Tris-HCl buffer pH 7.4, 0.05 mM Na₃VO₄,

5 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche Molecular Biochemicals). This mixture was incubated with shaking at room temperature overnight to allow phosphorylation of the pEY substrate by the immobilized kinases. Following this incubation, 45 μ l of this mixture was transferred to a streptavidin or avidin-coated NPT IPR plate coated with biotinylated anti-phosphotyrosine antibody (PY20, Zymed

10 labs, CA) followed by incubation for 30 minutes at room temperature to allow the binding of the phosphorylated pEY substrate to the PY20 coated NPT plate. Following this binding step, 50 ng Sulfo-TAG labeled anti-phosphotyrosine in buffer containing 25 mM Tris-HCl buffer pH 7.4, 5 mM MgCl₂, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT and 0.05% IgG was added followed by incubation at room temperature for 30

15 min. The unbound reagents were removed by one time washing with water, and the TAG label was detected in presence of 150 μ l IPR assay buffer (0.4 mM Gly-Gly buffer, pH 7.8, 1 mM EDTA, 0.1 M TPA). The ECL signals were measured using an imaging plate reader.

The ECL signal produced by kinase activity of Fert2, expressed in 0.5 to 1 μ l of

20 TnT reaction, was about 1000 to 1100 fold higher than the background noise produced by Mock (Luciferase) (see Table 7).

Table 7

	ECL signal
Fert2	1,608,671
Mock	1,478

- 5 The kinase activity from Fert2 demonstrated by this assay format was specific, as the signal decreased significantly in the absence of Fert2 DNA, biotinylated Lysine tRNA or the substrate pEY (see Table 8).

Table 8

Plasmid	Reagents	ECL signal
+	no tRNA	1,752
-		1,445
+	no pEY	1,309
+		1,608,671

10

The phosphorylation of the substrate was further demonstrated to be the result of kinase activity as the signal was abolished in the absence of ions or in the presence of EDTA (see Table 9).

15 Table 9

	Mock	Fert2
Control	1,320	1,637,307
no Mg, no Mn	1,027	2,851
+ EDTA	911	1,287

- 20 A concentration dependent expression of Fert2 activity was seen when increasing amounts of cDNA was expressed and assayed by this format, however, a maximum activity was registered at the DNA concentration of 100 ng of DNA per 5 µl of TnT reaction. A background level of signal seen at all the DNA concentrations of Mock was considerably lower than the signal seen from the kinase (see Table 10).

Table 10

DNA $\mu\text{g}/5 \mu\text{l}$	Mock	Fert2
0.00	1,027	1,027
0.001	3,232	4,432
0.003	2,648	129,797
0.010	2,155	1,440,103
0.020	2,299	1,463,489
0.040	2,880	1,523,121
0.060	2,774	1,553,370
0.080	1,478	1,608,671
0.100	1,413	1,687,039
0.125	1,133	1,626,868
0.150	1,639	1,599,024

5

EXAMPLE 8. Assay To Screen for Autophosphorylation Activity.

The example demonstrates an ORIGEN based HTS assay for autophosphorylation activity of Spleen Tyrosine kinase and Eph receptor-A7 expressed in reticulocyte lysate.

- 10 Using in vitro expression screening strategy, we have demonstrated the autophosphorylation activity from full-length clones Spleen Tyrosine Kinase (SYK) and Eph receptor-A7 (EphA7). The assay format developed for this purpose utilizes following steps:

- Proteins were produced from DNA plasmids of Mock Luciferase, Promega,
- 15 tyrosine kinase clone Spleen Tyrosine kinase (SYK, IMAGE ID# 3870426) and Eph receptor-A7 (EphA7, IMAGE ID# 3991628) (Incyte Genomics, CA) and immobilized on streptavidin or avidin coated NPT-IPR plates as described in the Example 7. To promote autophosphorylation in these immobilized and purified proteins, Mn^{++} ions were added in a 50 μl reaction containing 5 mM MgCl_2 , 5 mM MnCl_2 , 100 μM ATP, 25 mM Tris-
- 20 HCl buffer pH 7.4, 0.05 mM Na_3VO_4 , 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche Molecular Biochemicals). This mixture was incubated with

5 shaking at room temperature overnight to allow autophosphorylation. Following this incubation, wells were washed 2 times with TT-buffer and 2 times with water. Following this step, 50 ng Sulfo-TAG labeled anti-phosphotyrosine in buffer containing 25 mM Tris-HCl buffer pH 7.4, 5 mM MgCl₂, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT and 0.05% IgG in a final volume of 50 µl was added followed by incubation at
10 room temperature for 45 min. The unbound reagents were removed by one time washing with water, and the TAG label was detected in presence of 150 µl IPR assay buffer (0.4 mM Gly-Gly buffer, pH 7.8, 1 mM EDTA, 0.1 M TPA). The ECL signals were measured using an imaging plate reader.

The ECL signal produced by autophosphorylation activity of tyrosine kinases
15 expressed in 0.5 µl of TnT reaction, was about 25 fold (in SYK) or 47 fold (in EphA7) higher than the background noise produced by Mock (Luciferase) (see Table 11).

Table 11

	ECL signal
SYK	21,495
EphA7	39,967
Mock	847
Water	763

20

EXAMPLE 9. Screening For Tyrosine Kinase Substrates.

The example demonstrates an ORIGIN based HTS assay for SRC phosphorylation of SKAP-HOM in reticulocyte lysate using Sulfo-TAG labeled anti-phosphotyrosine. Tyrosine kinases may phosphorylate protein substrates with high
25 specificity. However, the map of such substrates for each of the known kinase is far from

5 being complete. We have developed a screening method to detect specific phosphorylations of in vitro expressed cDNAs. The assay format developed for this purpose utilizes following steps:

Proteins were produced in an *in vitro* transcription and translation reaction and immobilized on streptavidin or avidin coated NPT-IPR plates as described in the

10 Example 7. DNA plasmids used in this example were Mock Luciferase, Promega, SKAP-HOM (IMAGE ID# 3893964, Incyte Genomics) or tyrosine kinase clone Spleen Tyrosine kinase (SYK, IMAGE ID# 3870426, Incyte Genomics, CA). Additionally, NPT-IPR plates were washed 3 times with water following protein immobilization. The Immobilized and purified proteins were de-phosphorylated by adding two units of

15 Shrimp alkaline phosphatase (SAP, Roche Molecular Biochemicals) in 50 μ l reaction containing 50 mM Tris-HCl buffer pH 8.5 and 5 mM $MgCl_2$ for 2 hours at 37C. The de-phosphorylated proteins were washed 3 times with water and specifically re-phosphorylated in the presence of known kinase (0.1 mU SRC/ μ l) in a buffer containing

20 25 mM Tris-HCl buffer pH 7.4, 5 mM $MgCl_2$, 0.05 mM Na_3VO_4 , 0.004% TritonX-100 and 2 mM DTT. The specifically phosphorylated proteins were washed one time with water and detected in presence of 50 ng Sulfo-TAG labeled anti-phosphotyrosine in buffer containing 25 mM Tris-HCl buffer pH 7.4, 5 mM $MgCl_2$, 0.05 mM Na_3VO_4 , 0.004% TritonX-100, 2 mM DTT and 0.05% IgG in a total volume of 50 μ l at room temperature for 45 min. The unbound reagents were removed by washing three times

25 with water, and the TAG label was detected in presence of 150 μ l IPR assay buffer (0.4 mM Gly-Gly buffer, pH 7.8, 1 mM EDTA, 0.1 M TPA). The ECL signals were measured using an imaging plate reader.

- 5 We have demonstrated that SRC specifically phosphorylates SKAP-HOM, a protein that was predicted to be a potential substrate based on its homology to known SRC substrates (Curtis DJ, et al (2000) Exp Hematol, 28, 1250-9; Marie-Cardine A, et al (1998) FEBS Lett, 435, 55-60). The control proteins SYK or Luciferase (Mock) did not show significant levels of phosphorylation by SRC. The non-specific tyrosine
- 10 phosphorylation of Mock, SYK or endogenous substrates of the TnT system were of considerable lower magnitude, about 17 fold lower to that of the SKAP-HOM (Table 12).

Table 12

Reticulocyte lysate		-	+	+	+	+
Plasmid		none	SYK	SKAP-HOM	Mock	none
no SRC	no SAP	338	1,003	496	370	374
no SRC	+ SAP	197	271	307	265	270
+ SRC	+ SAP	1,014	1652	32,028	1147	1,033

15 EXAMPLE 10. Screens For Phosphopeptide Binding Proteins

Example of ECL based assays for phosphopeptide and protein interaction. The model assay measures the interaction between β TRCP and phosphorylated I κ Ba peptide captured on a solid phase.

- A phosphopeptide derived from the I κ Ba degradation motif [SEQ ID No. 1] and a
- 20 phosphopeptide derived from c-Myc [SEQ ID No. 4] were chemically synthesized (New England Peptide, Fitchburg MA) with the following sequences respectively:

H2N-LKKERLLDDRHD(p)SGLD(p)SMKDEEYC-COOH.
H2N-CPSEDIWKKFELLP(p)TPPL(p)SPSRRSGL-COOH

25

5 The cystine residues at the C- or N-terminuses were added to the sequences to allow for covalent coupling of the peptide to a carrier protein. The IkBa peptide [SEQ ID No. 1] contains the six-residue motif with "DSGXKS" consensus sequence that confers the binding to the β TRCP, an F-box/WD40 repeat containing protein. The binding of the peptide to β TRCP is absolutely dependent on the presence of the two phosphoserine
10 residues. Singly phosphorylated peptide or phosphothreonine substitution abolish interaction. The c-Myc derived phosphopeptide [SEQ ID No. 4] was used as a control.

A maleimide pre-activated BSA (Pierce, Pittsburgh PA), which contains estimated 17 active maleimide groups on the protein surface, was used as the protein carrier, and was supplied as a lyophilized preparation. Coupling of the IkBa peptide
15 [SEQ ID No. 1] to the pre-activated BSA was carried out with 2 mg BSA (30 nmol) and 17 equivalents of the 25 residue phosphopeptide in 400 μ l PBS. The reaction was terminated with 2 mM L-cystine after incubation at room temperature for 30 minutes. The peptide:BSA conjugate was then purified on PD-10 gel filtration column to remove uncoupled peptide and analyzed with SDS PAGE to monitor the coupling reaction. Since
20 the molecular weight of phosphorylated IkBa peptide [SEQ ID No. 1] is 3055, a BSA carrier with all 17 maleimide groups conjugated to this peptide would have a molecular weight of 119 kD, which is in agreement with the apparent molecular weight observed on the denaturing SDS gel. After coupling and purification, the column fractions containing the peptide:BSA conjugates were pooled and the protein concentration of the pooled
25 samples was determined by BCA assay (Pierce, Pittsburgh PA). NaN_3 , (0.02%) was added to the final peptide:BSA conjugate sample for long term storage at 4 °C.

5 To prepare IPR plates for use in the assay, approximately 2.4 pmol BSA, 1.2 pmole IkB α -24pp peptide-BSA conjugate or 1.2 pmole of Myc-p58Tp62S peptide-BSA conjugate in 2.5 μ l were deposited on the carbon working electrode surface in a single well of a 96-well plate. At this stage, the plates were dried then used or stored under desiccated condition. A few hours prior to usage, the plates were rehydrated and blocked
10 with 3% BSA, in PBS.

 Two β TRCP genes, β TRCP1 and β TRCP2, are present in the human genome on chromosome 5 and 10, respectively. The coding sequence of these two genes shares over 90% identity and several full-length cDNAs of which are available as EST clones from Incyte (Palo Alto, CA) IMAGE #3491843 and 4237375. Also included were three other
15 non specific EST clones as controls (Incyte, Palo alto, CA). Plasmid DNAs from these EST clones and other clones were prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs were used to produce the β TRCP protein and proteins encoded by the other DNAs as described in the Example 7. Proteins were transferred into wells of the peptide-coated and BSA-blocked IPR plates. Sulfo-TAG labeled streptavidin
20 (50 to 100 ng/well) was added to each well as the detection agent. The binding reaction can be carried out in cold room for over two hours or at room temperature for 1 hour without significant difference. After binding, the IPR plates were washed twice with PBS and 100 μ l of ORIGEN assay buffer (IGEN International, Inc., Gaithersburg, MD) was added to each well before reading the ECL signal. The ECL signals were measured
25 using an imaging plate reader (IPR).

A typical result of this assay is given in Table 13, which shows the ECL signals obtained when 3 random, negative cDNAs and 2 positive cDNAs are translated and subjected to

- 5 the phosphopeptide binding assay. The protein products from these two positive clones bound specifically to the phosphorylated I κ B α 25pp peptide but not to the control peptide derived from oncogene c-Myc despite of the fact that the c-Myc peptide contains a similarly diphosphorylated motif: P(p)TPPL(p)S. These results demonstrate the sensitivity and specificity of this assay for binding activities encoded by the DNA clones.

10

Table 13

Clones name or IMAGE#	Average ECL signal		
	I κ B α peptide [SEQ ID No. 1]	c-Myc peptide [SEQ ID No. 4]	BSA control
No DNA	379	344	337
3491843 (β TRCP1)	40879	2118	1719
4237375 (β TRCP2)	21501	896	672
3872466	371	351	352
4419252	341	316	342
39907115	368	341	342

EXAMPLE 11. Assay For Interaction Among Multiple Proteins And Their Cognate Recognition Phosphopeptides Arrayed On Multiple Spots In A Single Well.

- 15 Four phosphopeptides and their cognate binding proteins (Table 14) were selected for an integrated assay of multiple peptide-protein interaction in 4-spot Multi-Array plates. The I κ B α -24pp peptide and its binding protein, β TRCP, are described in Example 10. The remaining peptides are derived from the carboxyl terminus of the EGF receptor. These phosphotyrosine containing peptides are recognized by different adaptor
- 20 or effector proteins of the receptor tyrosine kinase signaling pathway.

Table 14

Peptide name	Binding protein	Sequence
--------------	-----------------	----------

#1	EGFR-pY992 [SEQ ID No. 5]	PLC γ	DADE(p)YLIPQQGFFSPSTSC
#2	EGFR-pY1068 [SEQ ID No. 7]	Grb2, PLC γ	LPVPE(p)YINQSVKRPAGSVC
#3	EGFR-pY1148 [SEQ ID No. 9]	Shc	KGSHQISLDNPD(p)YQQDFFPKEAKPNC
#4	I κ Ba -24pp [SEQ ID No. 1]	β TRCP	LKKERLLDDRHD(p)SGLD(p)SMKDEEYC

5

These four peptides were coupled to BSA carrier protein through cysteine residue. After purification on PD-10 gel filtration columns, the peptide-BSA conjugates were then deposited on the assay domains of a 4-spot multi-array IPR plate (i.e., in one of the four exposed regions of working electrode defined by the dielectric layer) with an automated

10 micro-dispensing system (Bio-Dot Dispenser, Bio-Dot, Irvine CA). Typically about 120 fmole of peptide:BSA conjugate in 0.25 μ l was deposited on each spot of a 4-spot multi-array IPR plate. These plates are dried then used or stored under desiccated conditions. A few hours prior to usage the plates were rehydrated and blocked with 3% BSA in PBS. EST clones encoding β TRCP1 (3491843), β TRCP2 (4237375), mCBP (3872466) Grb2

15 (4398016) and PLC γ (4419252) (Incyte, Palo Alto, CA), were isolated using a QIA-prep column (QIAGEN, Los Angeles, CA) and used to program protein expression in a Quick coupled SP6 TnT reaction supplemented with Transcend biotin-tRNA label following the manufactures protocol (Promega, Madison WI). The in vitro translated and biotin-

20 labeled proteins were then assayed in the 4-spot multi-array IPR plates under conditions described in Example 10. As shown in Table 15, ECL signals imaged from spot 1(I κ Ba - 24pp-BSA conjugate) were 100-fold higher in wells containing β TRCP1 and β TRCP2 than in wells derived from TnT reaction mixtures containing no exogenous DNA. By contrast spots 2-4 in the same wells gave low ECL signals. Thus, in this assay format,

5 each peptide not only serves as the capture agent for assaying specific interaction with its binding protein, but also at the same time serves as a control for other peptide-protein interaction to be determined in the same well. The same principle was illustrated once again by the binding of Grb2 and PLC γ proteins with EGFR carboxyl terminus phosphotyrosine peptides. These proteins also were found to bind specifically to the

10 correct peptide sequences. An expected cross binding reactivity was seen between PLC γ protein and EGFR-pY992 [SEQ ID No. 5] and pY1068 [SEQ ID No. 7] peptides.

These results demonstrated the potential of the use of multiple binding domains (4 spots) in a single well to increase both the speed and specificity of screens for binding interactions. This method also provides for significant savings of reagents in a screen

15 with 4 differing binding species.

Table 15 Single-well assay for multiple peptide-protein interactions

		3491843	4237375	3872466	4398016	4419252	No DNA
Spot	Peptide-BSA	β TRCP1	β TRCP2	mCBP	Grb2	PLC γ	control
1	IkB α -24pp [SEQ ID No. 1]	2466	5040	446	22	26	14
2	EGFR-pY1148 [SEQ ID No. 9]	36	35	278	20	110	13
3	EGFR-pY1068 [SEQ ID No. 7]	24	24	126	441	1485	10
4	EGFR-pY992 [SEQ ID No. 5]	54	60	498	44	1404	31

20 EXAMPLE 12. ECL Based Assays For Phosphopeptide And Protein Interaction.

This example demonstrates a multi-plexed approach for screening for proteins that bind phosphopeptides. The assay used an array of multiple phosphopeptides for identifying

- 5 multiple protein-peptide interactions in a single well and used a coded multiplex approach.

The following peptides were chemically synthesized (New England Peptide, Fitchburg MA). The peptides were coupled to pre-activated maleimide BSA according to the procedure described in Example 11.

- | | | | |
|----|---------------|-----------------|-----------------------------------|
| 10 | EGFR-pTyr992 | [SEQ ID No. 5] | DADE(p)YLIPQQGFFSSPSTSC |
| | EGFR-pTyr1068 | [SEQ ID No. 7] | LPVPE(p)YINQSVPKRPAGSVC |
| | EGFR-pTyr1148 | [SEQ ID No. 9] | KGSHQISLDNPD(p)YQQDFFPKEAKPNC |
| | IkBa-24ppC | [SEQ ID No. 1] | LKKERLLDDRHD(p)SGLD(p)SMKDDEEYC |
| | Myc-p58Tp62S | [SEQ ID No. 4] | CPSEDIWKKFELLP(p)TPPL(p)SPSRRLSGL |
| 15 | Smad3C | [SEQ ID No. 11] | CGPLQWLDKVLTMGSPHNPIS(p)SV(p)S |

- The peptides EGFR-pTyr992 [SEQ ID No. 5], EGFR-pTyr1068 [SEQ ID No. 7] and EGFR-pTyr1148 [SEQ ID No. 9] were derived from the phosphorylation sites in EGF receptor. Peptide IkBa-24ppC [SEQ ID No. 1] is described in Example 10. The
- 20 peptides Myc-p58Tp62S [SEQ ID No. 4] and Smad3C [SEQ ID No. 11] are derived from c-Myc and SMAD3. In the case of the EGFR and IkBa peptides, certain binding partners are known (Table 16).

Table 16

Peptide	SEQ ID NOs	Binding Partner
EGFR-pTyr992	[SEQ ID No. 5]	Phospholipase C gamma 1 (PLC γ)
EGFR-pTyr1068	[SEQ ID No. 7]	Grb 2
EGFR-pTyr1148	[SEQ ID No. 9]	Shc 1
IkBa-24ppC	[SEQ ID No. 1]	β TRCP1 and β TRCP2

25

To prepare the Multi-Spot IPR plates, in this example we made use of pools of the peptide:BSA conjugates to coat each of 4 spots per well in a 96 well plate. To achieve this we made the following pools;

5 Pool A; EGFR-pTyr1148, IkBa-24ppC, Myc-p58Tp62S.

Pool B; EGFR-pTyr992, EGFR-pTyr1148, Smad3C.

Pool C; EGFR-pTyr1068, IkBa-24ppC, Smad3C.

Pool D; EGFR-pTyr992, EGFR-pTyr1068, Myc-p58Tp62S.

This combination of the various peptides results in any single peptide being present in
 10 two pools. Each of these four pools is then spotted on to a unique spot in a 4 spot array.
 In this way any single binding protein with specificity for only one of the peptides would
 bind to two spots; the identity of the two spots would allow the identification of the
 peptide involved in the binding reaction. The coding resulting from the pools described
 above are presented in Table 17.

15

Table 17

Peptide	SEQ ID NOs	Pool Code
EGFR-pTyr992	[SEQ ID No. 5]	B, D
EGFR-pTyr1068	[SEQ ID No. 7]	C, D
EGFR-pTyr1148	[SEQ ID No. 9]	A, B
IkBa-24ppC	[SEQ ID No. 1]	A, C
Myc-p58Tp62S	[SEQ ID No. 4]	A, D
Smad3C	[SEQ ID No. 11]	B, C

Typically approximately 120 fmole of peptide:BSA conjugate in 0.25 μ l was
 deposited on each spot of a 4-spot multi-array IPR plates using a BioDot Dispenser (Bio-
 20 Dot Inc., Irvine CA). At this stage, the plates were dried then used or stored under
 desiccated condition. A few hours prior to usage, the plates were rehydrated and blocked
 with 3% BSA, in PBS.

To test the system the following EST clones IMAGE # 3491843, 4237375, 4398016,
 4419252, 3872466, 3907115 were obtained. These clones express the following genes

- 5 β TRCP1, β TRCP2, Grb2, PLC γ , CBP and Shc1, respectively. Plasmid DNAs from these various clones were prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs were used to produce proteins as described in the Materials and Methods. Proteins were transferred to a well of the 4 spot peptide-coated and BSA blocked ECL plates. The binding assay (using Sulfo-TAG labeled streptavidin as a detection agent)
- 10 was carried out according to the procedures described in Example 11.

The ECL signals for each pooled peptide spot (A-D) are presented in Table 18.

Table 18 also lists the code (i.e., pattern of positive spots) obtained with each protein.

The identity of the binding peptide as determined by the code is presented in Table 19.

15 **Table 18.**

Spot		3491843	4237375	4398016	4419252	3872466	3907115
	Blank	β TRCP1	β TRCP2	Grb2	PLC γ	CBP	Shc1
A	22	9536	7791	36	239	19	260
B	54	208	105	38	2783	30	318
C	28	11184	8615	509	1550	22	24
D	20	171	74	386	3388	15	26
Code	Neg.	A, C	A, C	C, D	B, C, D	Neg.	A, B

Table 19.

Clone	Peptide determined from code	Match with expected result
No DNA	Negative	Expected
3491843	I κ B α -24ppC	Expected
4237375	I κ B α -24ppC	Expected
4398016	EGFR-pTyr1068	Expected
4419252	EGFR-pTyr992 & EGFR-pTyr1068	Expected
3872466	Negative	Expected
3907115	EGFR-pTyr1148	Expected

5 The expected two spot matches were observed in all cases except for clone
4419252 (a PLC γ clone). This clone gave a three spot code that was indicative of the
protein binding two different peptides. This result was expected and also observed in
Example 11.

These results demonstrate the potential of this method of pooling peptides or binding
10 species in combination with multiple spots to improve the screening of large numbers of
binding species immobilized on to a solid phase.

EXAMPLE 13. Direct Coating Of Proteins Onto Solid Phase.

EST clones IMAGE #'s 3886018, 3910505 and 3915089 were obtained from
15 Incyte (Palo Alto, CA). Plasmid DNA was prepared from these EST clones using
QIAprep96 Turbo Miniprep (cat#27191, QIAgen, Los Angeles, CA), according to
manufacturer's instructions. cDNA was eluted using 150 μ l buffer EB (QIAgen).

The proteins were produced in the transcription translation (TnT) reaction as
described in the Materials and Methods.

20

For binding of the proteins from the TnT reaction to the solid phase we used the
following protocol. 30 μ l PBS pH 7.4 was added to each well of an NPT IPR plate. 2 μ l of
the TnT reaction was added to each well, the plate was covered with sealing film and
incubated for 1h at ambient temperature with shaking. After incubation, the plate was
25 washed 3X with PBS. 50ng Sulfo-TAG labeled streptavidin (see Materials and Methods)
was added to each well in a 50 μ l volume using IPR assay buffer (25mM Tris pH7.4,
0.005% Triton, 2mM DTT, 1% BSA, protease inhibitors) and the IPR plate was

- 5 incubated for 1h at RT with shaking. After incubation, the plate was washed 3X with PBS, 100µl ORIGEN assay buffer (IGEN International, Inc., Gaithersburg, MD) added to each well and the ECL signals measured.. The results in Table 20 demonstrate the binding of proteins directly to a solid phase from the TnT reactions and show that this procedure can be used to measure the amount of the translated protein. This procedure
- 10 provides a useful control for correcting biases in screening data resulting from variation in the concentrations of translated proteins.

Table 20,

Clone ID	3886018	3910505	3915089	No DNA
ECL signal	6198	4835	7669	1192

- 15 **EXAMPLE 14.** Assay To Detect Binding Species Produced By In Vitro Translation Using A Magnetic Bead Based Assay System (Prophetic).

Detection of the binding of β TRCP to a phosphopeptide derived from I κ B α .

- In order to demonstrate the detection of binding species produced by an in vitro translation system using bead based systems, we use the well known binding interaction
- 20 between a phosphopeptide of I κ B α , H2N-LKKERLLDDRHDS(p)GLDS(p)MKDEEYE [SEQ ID No. 1] and the protein β TRCP.

The following peptides are synthesized.

I κ B20-bio, H2N-LKKERLLDDRHDSGLDSMKDEEYEC-biotin (biotinylated [SEQ ID No. 2])

- 25 I κ B20-p-bio, H2N-LKKERLLDDRHDS(p)GLDS(p)MKDEEYEC-biotin (biotinylated [SEQ ID No. 1]).

5 These peptides are immobilized on to Dynal M280 beads coated with streptavidin making use of the well known streptavidin biotin interaction. The peptide is dissolved in PBS, 0.1% NP40 and incubated with the beads for 1 hour followed by 4 washes into binding buffer (50mM Tris-HCL pH7.5, 300mM NaCl, 2mM EDTA, 0.1% NP40 and protease inhibitor cocktail (Roche)).

10 The TnT reaction are carried out following the manufactures protocol. The reaction is was as follows, 25µl of lysate (coupled TnT, Promega, Madison WI), 0.5µg of plasmid DNA. The plasmid DNA contains the βTRCP gene fused in frame with the Flag epitope and contains a RNA polymerase site. A plasmid vector directing transcription of flag-βTRCP gene fusion is constructed using synthetic PCR primers to the EST clone
15 IMAGE # 3491843. The primers
TATGTCGACATGGATTATAAGGATGACGATGACAAAGACCCGGCAGAGGCG
GTGCTG [SEQ ID No. 13] and TATGCGGCCGCTTATCTGGAGATGTAGGTGTA
[SEQ ID No. 14] are used to generate the flag-βTRCP gene fragment of about 1750
bases. This PCR DNA product is then subject to restriction digestion with Sal1 and Not1
20 following the manufactures protocol (New England Biolabs, Beverly, MA). The cut PCR
DNA product is gel purified and ligated into Sal1 and Not1 cut pCMV-SPORT6
(Invitrogen, Carlsbad, CA). The ligation is transformed into E.coli and the clones
screened for the correct insert.

 One of the resulting clones is used in the TnT reaction to produce the fusion
25 protein Flag-βTRCP. Protein expression in the TnT reaction is confirmed using
radioactive Met following the manufactures protocol (Promega, Madison, WI).

5 To determine if we can detect the binding of flag- β TRCP to the phosphopeptide we incubate the products of the TnT reaction specific for the flag- β TRCP with beads coated with the consensus phosphopeptide or the control peptide. These beads are washed and ORI-TAG® (IGEN International, Inc., Gaithersburg, MD) labeled anti Flag antibody is added in binding buffer and then incubated followed by analysis in an ORIGIN M8
10 (IGEN International, Inc., Gaithersburg, MD). The results of this study demonstrate a strong signal from the flag- β TRCP binding to the phosphopeptide but not to the control no phosphorylated sequence produced in the TnT system. This strong signal is reflected in a high signal to noise ratio (as calculated using the signals obtained from translation mixtures having no exogenous DNA, unrelated clones or control peptide).

15

EXAMPLE 15. Assay For DNA Binding Proteins Produced In A Tnt Reaction (Prophetic).

In this assay cDNA clones are subjected to a TnT reaction followed by the detection of those proteins that are able to bind specifically to a given nucleic acid
20 sequence. The following EST clones coding for the YY1 transcription factor are tested: IMAGE IDs, 3987868, 3156776, 2655378, and 3859359 (Incyte Genomics). For a control, the luciferase plasmid included in the TnT kit from Promega is used. DNA is prepared from these clones using the Qiagen miniprep kit (Qiagen, Los Angeles, CA).

The oligo specific for YY1 is made synthetically (IGEN International, Inc.,
25 Gaithersburg, MD) using the following sequences 5'ORI-tag-labeled-
ACGTACGTACCGCTCCGCGGCCATCTTGCGGCTGGT [SEQ ID No. 15] and its complement 5'*ACCAGCCGCCAAGATGGCCGCGGAGCGGTACGTACGT* [SEQ ID

5 No. 16]. These two oligonucleotides are annealed by mixing together equimolar amounts in 10mM Tris-HCL pH 7.9, 1mM EDTA, 50mM KCl. This double stranded oligonucleotide (ECL-oligo) is then used in the following DNA binding assay.

The YY1 protein and the control luciferase are produced in a coupled TnT reaction, as described in the Materials and Methods. Then 5 µl of the reaction product is
10 mixed with, 50 µl of binding buffer and 28-14ng/ml 5'ORI-tag-labeled double stranded oligonucleotide produced above, in a streptavidin-coated NPT IPR plate (see examples above). The plate is left on a tabletop shaker for 1 hour to allow for biotinylated proteins to bind to the surface of the plate and for the ECL-oligo to bind to the biotinylated proteins. Thereafter the plate is washed three times with PBS followed by the addition of
15 100 µl of ORIGEN assay buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals are measured. The ECL signals are measured using an imaging plate reader (IPR). In a typical assay the presence of YY1 encoding plasmid is expected to produce a greater than 2 fold higher ECL signal compared to the luciferase control vector demonstrating the specific binding of the DNA sequence to the YY1 protein.

20

EXAMPLE 16. Assay For DNA Binding Proteins, Using A Multi-Spot™ Approach (Prophetic).

Assay for DNA proteins produced by an in vitro translation system to DNA targets arrayed on multiple spots in a single well.

25 Four DNA oligos and their binding proteins (Table 21) are selected for an assay of multiple DNA-protein interaction in 4-spot multi-array IPR plates. The EST clones for c-jun IMAGE ID # 3606344, 4053956, 4446852, 3912000, 4182406, 3493248, 3968444,

- 5 4018781; the Glucocorticoid Receptor IMAGE ID #4036433, 3584269; the p53 protein IMAGE ID # 4508539, 4384628, 4524419, 3599812, 3966816, 4503010; and the CCAAT displacement protein (CDP) IMAGE ID # 4516029, 4420011, 4385939 are ordered from Incyte genomics (Palo Alto, CA).

10 **Table 21** List of DNA and their binding proteins

DNA oligo	Binding protein	Sequence
AP-1	c-jun	5' SH-X-ACTGACTGACcgcttgatgactcagccggaa [SEQ ID No. 17]
Gluc	Glucocorticoid Receptor	5' SH-X-ACTGACTGACgaccctagaggatctgtacaggatgttctagat [SEQ ID No. 18]
P53	p53	5' SH-X-ACTGACTGACtacagaacatgtctaagcatgctggggact [SEQ ID No. 19]
CDP	CDP	5' SH-X-ACTGACTGACacccaatgattattagccaatttctga [SEQ ID No. 23]

The DNA sequences listed in Table 21 are synthesized as well as the complementary sequences without 5' modifications. These oligos are rendered double stranded using the method described above by mixing the complementary pairs together.

- 15 The SH-X- group at the 5' end of the oligonucleotide sequence is introduced during synthesis using a cycle of Spacer Phosphoramidite 18 (Catalog Number: 10-1918-xx Glenn Research, Herndon, VA) followed by a cycle of Thiol-Modifier C6 S-S (Catalog Number: 10-1936-xx Glenn Research, Herndon, VA) during synthesis. This results in a 5' free SH group attached to a hexaethyleneglycol spacer ready for coupling.
- 20 The SH-X- moiety at the 5' terminus is added to the sequence to allow for covalent coupling of the DNA to a carrier protein. A maleimide pre-activated BSA (Pierce, Pittsburgh PA) is used as the protein carrier. The protein contains about 17 active maleimide groups on the protein surface and is supplied as lyophilized preparation.

- 5 The coupling reaction is carried out with 2 mg BSA (30 nmol) and different molar amount of the DNA in 400 μ l PBS. The molar ratio of DNA relative to the BSA is between 4:1 to 17:1. The reaction is terminated with 2 mM L-cystine after incubation at room temperature for 30 minutes. The DNA:BSA conjugate is then purified by gel filtration to remove uncoupled DNA and analyzed with SDS PAGE to monitor the
- 10 coupling reaction. After coupling and purification, the column fractions containing the DNA:BSA conjugates are pooled and the protein concentration of the pooled samples is determined by BCA assay (Pierce, Pittsburgh PA). NaN₃, (0.02%) is added to the final peptide;BSA conjugate sample for long term storage at 4 °C.

- To prepare the multi spot IPR plates, approximately 2.4 pmol to 1.2 pmole DNA-
- 15 BSA conjugates in 2.5 μ l are deposited on carbon surface in a single well of a 96-well plate using a Bio-Dot dispenser. At this stage, the plates are dried then used or stored under desiccated condition. A few hours prior to usage, the plates are rehydrated and blocked with 3% BSA, in PBS.

- DNA for the EST clones encoding c-jun, glucocorticoid receptor, p53 and CDP
- 20 are isolated using QIA-prep column (QIAGEN, Los Angeles, CA). These DNA molecules are used to produce the proteins in a Quick coupled SP6 *in vitro* transcription and translation (TnT) reaction (Promega, Milwaukee, WI) as described in Materials and Methods. The proteins are transferred to a well of the 4 spot DNA:BSA coated and BSA blocked IPR plates. To these wells 50 to 100 ng/well of Sulfo-TAG labeled Streptavidin
- 25 (see example 2) is added as the detection agent. The binding reaction can be carried out in cold room for over two hours or at room temperature for 1 hour without significant difference. After binding, the IPR plates are washed twice with PBS and 100 μ l of

- 5 ORIGIN Assay Buffer (Cat. # 110006, IGEN International, Inc., Gaithersburg, MD) is added to each well before reading the ECL signal. The ECL signals are measured using an imaging plate reader (IPR).

The results demonstrate the potential of the multiple binding domains (4 spots) in a single well to increase both the speed and specificity of screens for binding interactions.

- 10 This method also provides for significant savings of reagents in a screen with 4 differing binding species.

EXAMPLE 17. ECL Based Assays For DNA And Protein Interaction (Prophetic).

Assay using multiple DNA oligos for protein interactions in a single well.

- 15 DNA synthesis. The following oligonucleotide and their complement (with out 5' modifications) are chemically synthesized (Midland certified reagent company, Midland TX). Table 22 lists the oligonucleotides and their expected protein binding partners.

- 20 AP1, 5' SH-X-ACTGACTGACcgcttgatgactcagccggaa [SEQ ID No. 17]
 Gluc, 5' SH-X-ACTGACTGACgaccctagaggatctgtacaggatgttctagat [SEQ ID No. 18]
 P53, 5' SH-X-ACTGACTGACtacagaacatgtctaaagcatgtggggact [SEQ ID No. 19]
 YY1, 5' SH-X- ACGTACGTACcgCTCCGCGGCCATCTTGGCGGCTGGT [SEQ ID No. 20]
 C/EBP, 5' SH-X-ACTGACTGACtgcagattgcgaatctgca [SEQ ID No. 21]
 HNF, 5' SH-X-ACTGACTGACatctagggtcaaaggtcatact [SEQ ID No. 22]
- 25

Table 22.

DNA	SEQ ID NOs	Binding Partner
Ap1	[SEQ ID No. 17]	c-jun
Gluc	[SEQ ID No. 18]	Glucocorticoid receptor
p53	[SEQ ID No. 19]	p53
YY1	[SEQ ID No. 20]	YY1 transcription factor
C/EBP	[SEQ ID No. 21]	CCAAT enhancer binding protein gamma
HNF	[SEQ ID No. 22]	HNF-4

5 The SH residues at the terminus are added to the sequence to allow for covalent coupling of the DNA to a carrier protein as described in Example 16.

 To prepare the multi spot IPR plates, in this example we make use of pools of the DNA:BSA conjugates to coat each of 4 spots per well in a 96 well plate. To achieve this we make the following pools.

10 Pool A; Ap1, Gluc and P53
 Pool B; Ap1, YY1 and C/EBP
 Pool C; P53, YY1 and HNF
 Pool D; Gluc, HNF and C/EBP

15 In an alternative method the conjugation reaction to BSA is carried out with a pool of the oligos to give rise to a mixed conjugate that achieves the same effect of combining the various oligos into a pool.

 This combination of the various DNA:BSA conjugates results in a single DNA conjugate being present in two pools and any pair of pools contains only one DNA conjugate in
20 common. This allows the determination of the specific DNA binding partner based on the two spots that produce signal. Each of these four pools is then spotted on to a unique spot in a 4 spot array such that each pool. In this way any single specific binding protein would bind to two spots which allows the determination of the specific DNA oligo involved by determination of the specific pools a given protein bound to. The pair of
25 pools that a given protein binds to defines a code that determines which specific oligonucleotide was responsible for mediating the binding. The coding resulting from the pools described above is shown in Table 23

Table 23.

DNA:BSA conjugate	SEQ ID NOs	Pool Code
-------------------	------------	-----------

C/EBP	[SEQ ID No. 21]	B, D
HNF	[SEQ ID No. 22]	C, D
Ap1	[SEQ ID No. 20]	A, B
P53	[SEQ ID No. 19]	A, C
Gluc	[SEQ ID No. 18]	A, D
YY1	[SEQ ID No. 17]	B, C

5

Approximately 120 fmole of DNA:BSA conjugate in 0.25 μ l is deposited on each spot of a 4-spot multi-array IPR plates using BioDot (Irvine CA). At this stage, the plates are dried then used or stored under desiccated condition. A few hours prior to usage, the plates are rehydrated and blocked with 3% BSA, in PBS.

- 10 To test the system the following EST clones for c-jun IMAGE ID # 4446852, 3912000, 4182406, 3493248, 3968444, 4018781; the Glucocorticoid Receptor IMAGE ID #4036433, 3584269; the p53 protein IMAGE ID # 4508539, 4384628, 4524419, 3599812, 3966816, 4503010; the C/EBP gamma protein IMAGE ID # 3445301, 4368690, 3898882, 3709074, 4010465; and the HNF-4 protein IMAGE ID # 4238842,
- 15 are purchased from Incyte genomics (Palo Alto, CA). Plasmid DNAs from these various clones are prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs are used to produce the proteins as described in the Materials and Methods and the each protein is transferred to a separate well of the 4 spot DNA:BSA coated and BSA blocked ECL plates. To these wells 50 to 100 ng/well of Sulfo-TAG labeled Streptavidin
- 20 (see example 2) is added as the detection agent. The binding reaction can be carried out in cold room for over two hours or at room temperature for 1 hour without significant difference. After binding, the ECL plates are washed twice with PBS and 100 μ l of ORIGIN Assay Buffer (Cat. # 110006, IGEN International, Inc., Gaithersburg, MD) is

5 added to each well before reading the ECL signal. The ECL signals are measured using an imaging plate reader (IPR).

Most of the of the clones produce the expected coded binding response as predicted below:

c-jun IMAGE ID # 4446852, 3912000, 4182406, 3493248, 3968444, 4018781; give

10 binding code A,B;

Glucocorticoid Receptor IMAGE ID #4036433, 3584269; give binding code A,D;

p53 protein IMAGE ID # 4508539, 4384628, 4524419, 3599812, 3966816, 4503010;

give binding code A,C;

C/EBP gamma protein IMAGE ID # 3445301, 4368690, 3898882, 3709074, 4010465;

15 give binding code B,D;

HNF-4 protein IMAGE ID # 4238842 give binding code C, D.

These results demonstrate the potential of this method of pooling DNA in combination with multiple spots to improve the screening of large numbers of binding species immobilized on to a solid phase.

20

EXAMPLE 18. Assay For Peptide Binding Proteins Produced In A Tnt Reaction, Using A Labeled Peptide (Prophetic).

Assay for the binding activity of β TRCP to a peptide derived from IkBa.

25 The peptide from IkBa, H2N-LKKERLLDDRHDS(p)GLDS(p)MKDEEYEC [SEQ ID No. 1] is synthesized chemically. The ECL label is coupled post synthesis using ORI-TAG-Maleimide (IGEN International, Inc., Gaithersburg MD) to produce the

5 following peptide H2N-LKKERLLDDRHDS(p)GLDS(p)MKDEEYEC-ORI-TAG. The following clones for testing are obtained from Incyte (CA) β TRCP1 IMAGE ID #3491843; β TRCP2 IMAGE ID #4237375; Grb2 IMAGE ID #4398016; PLC γ IMAGE ID #4419252. These clones are grown up and DNA prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs are used to produce the proteins in the
10 transcription and translation reaction as described in the Materials and Methods.

The reaction products are added to separate wells of an IPR plate coated with streptavidin and combined with 10-100 ng/ml of ORI-TAG labeled peptide . The plate is left on a tabletop shaker for 1 hour to allow for biotinylated proteins to bind to the surface of the plate and for the ORI-TAG labeled peptide to bind to biotinylated proteins.
15 Thereafter the plate is washed three times with PBS followed by addition of 100 μ l of ORIGIN Assay Buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals are measured in IPR Analyzer. The results demonstrate specific signal, above that of the control clones, for the clones able to direct the transcription and translation of the β TRCP binding proteins (3491843 and 4237375).

20

EXAMPLE 19. Assay For The Detection Of Proteins Binding To Non-Peptide Small Molecule Binding Partners.

Assay for detecting the binding of Glucocorticoid receptor and Progesterone
25 receptor to labeled steroids cortisol and progesterone respectively.

The following ECL labeled steroids are purchased from IGEN International, Inc. . (Gaithersburg, MD, these are part of Roche Diagnostic Kits): Estradiol (2.75ng/ml),

- 5 Progesterone (10ng/ml), Testosterone (3ng/ml), Cortisol (25ng/ml). These steroids are labeled via a peptide linker attached to the steroid. The following clones for testing are obtained from Incyte (CA) Glucocorticoid receptor IMAGE ID # 4036433, 3584269; progesterone binding proteins IMAGE ID # 4449225, 4365385; and the control clones bTRCP1 IMAGE ID #3491843; bTRCP2 IMAGE ID #4237375;. These clones are grown
- 10 up and DNA prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs are used to produce the proteins as described in Example 7 and mixed with 1-10 ng/ml ORI-TAG-labeled steroid in IPR plate coated with streptavidin. The plate is left on a tabletop shaker for 1 hour to allow for biotinylated proteins to bind to the surface of the plate and for the ORI-TAG-labeled peptide to bind to biotinylated proteins.
- 15 Thereafter the plate is washed three times with PBS followed by addition of 100 μ l of ORIGIN Assay Buffer (IGEN International, Inc., Gaithersburg MD) into each well, and ECL signals are measured. The ECL signals are measured using an imaging plate reader (IPR). The results demonstrate specific signal above that of the control clones for the clones able to direct the transcription and translation of the steroid receptors. In addition,
- 20 no specific signal is associated with related ECL labeled steroids that were not bound by the specific steroid receptors.

EXAMPLE 20. Protein:Protein Binding Assay (Prophetic).

Assay for detecting the binding of fos and jun.

- 25 The Sulfo-TAG labeled anti-BODIPY®FL antibody (Molecular Probes, CA) was produced and purified as described in Materials and Methods. The antibody is stored in 25mM TRIS-HCl pH 7.5, 0.05% sodium azide. The following clones for testing are

- 5 obtained from Incyte (CA) mouse fos IMAGE ID #,3583544, 4457761, 3586465; human fos IMAGE ID # 3688670; mouse jun IMAGE ID # 3493248, 3968444, 4018781; human Jun IMAGE ID # 3606344, 4053956, 4446852, 3912000, 4182406; and the control clones bTRCP1 IMAGE ID #3491843; bTRCP2 IMAGE ID #4237375;. These clones are grown up and DNA prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA).
- 10 These DNAs are used to produce the proteins encoded by the various cloned DNAs in the following transcription and translation reaction. These clones are transcribed and translated in two reactions one with biotin-lys-tRNA and one with FluoroTect™Green(BODIPY®FL)-Lys-tRNA to generate a copy of each protein encoded by these clones labeled with biotin and a copy labeled with BODIPY®FL.
- 15 Transcription-translation reaction mixtures described in Materials and Methods were used to produce protein. Following these TnT reactions a sample from each clone from the biotin tRNA reaction is mixed with a sample from each clone from the FluoroTect™Green-Lys-tRNA reaction as follows: Then 4-8 µl of the biotin-lys-tRNA TnT reaction and 4-8ul of the FluoroTect™Green-Lys-tRNA TnT reaction is mixed with
- 20 50 µl of binding buffer (PBS, pH7.4, 0.1%BSA, 0.1% bovine IgG, 0.2% tween-20, and protease inhibitor tablets without EDTA (Roche)), and 50 ng Sulfo-TAG labeled anti-BODIPY®FL antibody in a IPR plate coated with streptavidin. This combination of the clones results in a set of incubations where each clone is allowed to bind to each of the other clones and also to its self from a complementary reaction with an alternatively
- 25 modified tRNA. Following this set up the plate is left on a tabletop shaker for 1 hour to allow for biotinylated proteins to bind to the surface of the plate and for the Sulfo-TAG labeled antibody to bind to the BODIPY®FL labeled proteins. Thereafter the plate is

- 5 washed three times with PBS followed by addition of 100 μ l of ORIGEN Assay Buffer (IGEN International, Inc., Gaithersburg MD) into each well, and ECL signals are measured. The ECL signals are measured using an imaging plate reader (IPR). The results demonstrate specific signal above that of the control clones for the clones able to direct the transcription and translation of the proteins known to bind to each other.

10

EXAMPLE 21. Protein:Protein Binding Assay (Prophetic).

Assay for detecting the binding of Myc and Max and p53 and T antigen.

- The following clones for testing are obtained pGBKT7-53, pGADT7-T, pGBKT7-c-Myc, pGADT7-Max and the control clones, pGBKT7, pGADT7 pGBKT7-
15 lam (Clontech, Palo Alto CA). These clones were grown up and DNA prepared using the Qiagen miniprep kit (Qiagen, Los Angeles, CA). These DNAs are used to produce the proteins encoded by the various cloned DNAs in the following transcription and translation reaction. Each of these clones are transcribed and translated, as described in Materials and Methods, in two reactions: one supplemented with biotin-lys-tRNA and
20 one under normal conditions to generate a copy of each protein encoded by these clones labeled with biotin or unlabeled.

- Following the TnT reactions a sample from each clone from the biotin tRNA reaction is mixed with a sample from each clone from the standard TnT reaction as follows: 4-8 μ l of the biotin-lys-tRNA TnT reaction and 4-8 μ l of the standard TnT
25 reaction is mixed with 50 μ l of binding buffer (PBS, pH7.4, 0.1%BSA, 0.1% bovine IgG, 0.2% tween-20, and protease inhibitor tablets without EDTA (Roche)), and 50 to 100 ng/well of Sulfo-TAG labeled Streptavidin (see Materials and Methods) in NPT IPR plate

- 5 coated with anti HA epitope antibody F-7 (Santa Cruz, CA). In a duplicate experiment the same set of sample mixes are added to an NPT IPR plate coated with anti Myc epitope antibody 9E10 (Sigma). This combination of the clones results in a set of incubations where each clone is allowed to bind to each of the other clones in a pair wise fashion and also to its self from a complementary reaction without a modified tRNA.
- 10 Following this set up the plate is left on a tabletop shaker for 1 hour to allow the proteins to bind specifically to the antibody coated surface of the plate and for the biotinylated proteins to bind to Sulfo-TAG labeled streptavidin. Thereafter the plate is washed three times with PBS followed by addition of 100 µl of ORIGEN Assay Buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals are measured in
- 15 the IPR Analyzer to determine which proteins are binding resulting in ECL signals over that seen with the control clones pGBKT7, pGADT7 pGBKT7-lam.

The results demonstrate specific signal for the binding of p53 (pGBKT7-53) to T antigen (pGADT7-T). This p53 –T antigen binding is demonstrated with a specific signal on the anti-myc coated IPR plate with the mix from these TnT reactions; pGBKT7-53

20 normal TnT with pGADT7-T biotin-lys-tRNA TnT. With the anti-HA coated IPR plate the specific signal is seen with the mix from these TnT reactions; pGADT7-T in a normal TnT with pGBKT7-53 in a biotin-lys-tRNA TnT.

The results also show the binding of Myc (pGBKT7-c-Myc) to Max (pGADT7-Max). This Myc to Max binding is demonstrated with a specific signal on the anti-myc

25 coated IPR plate with the mix from these TnT reactions; pGBKT7-c-Myc normal TnT with pGADT7-Max biotin-lys-tRNA TnT. With the anti-HA coated IPR plate the

- 5 specific signal is seen with the mix from these TnT reactions; pGADT7-Max in a normal TnT with pGBKT7-c-Myc in a biotin-lys-tRNA TnT.

EXAMPLE 22. Assay To Detect And Identify Antigens Recognized By Antibodies.

- 10 In order to demonstrate the detection and identification of antigens produced by an in vitro translation system using antibodies we use the antibodies from the serum of patients with the auto-immune disease, Sjogren syndrome.

- The following patient serum samples are obtained: samples 1-5 from patients diagnosed with Sjogren syndrome, samples 6-10 from control normal patients (patients without Sjogren syndrome). Rabbit anti human antibodies (Rockland) are labeled with Sulfo-
15 TAG-NHS and purified as described in Materials and Methods. The following clones are purchased IMAGE ID #, 4395342, 3922229, 3904700, 3459939, 3047963, 3857068, 4342257, 3454454, 3910607, 4237375 and 3491843 (Incyte, Palo Alto, CA). These clones are grown in 2 ml LB with 50 µg/ml Amp, and DNA is isolated using QIAprep Spin Miniprep Kit (Qiagen). DNA yield is 5-20 µg.

- 20 The clones are as follows;
Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro), 4395342;
Sjogren syndrome antigen A1 (52kD, ribonucleoprotein autoantigen SS-A/Ro), 3922229, 3904700;
Sjogren's syndrome nuclear autoantigen 1, 3459939, 3047963;
25 Sjogren's syndrome/scleroderma autoantigen 1, 3857068, 4342257;
Sjogren syndrome antigen B (autoantigen La), 3454454, 3910607;
βTRCP1, 3491843;

5 β TRCP2, 4237375.

The DNA from these clones is translated in a transcription and translation system as described in Materials and Methods. Then 5 μ l of the reaction product is mixed with 50 μ l of binding buffer in a well of a 96 well NPT IPR plate coated with streptavidin . In this way 2, 96 well plates are generated with 5 rows A, B, C, D, E containing the 11
10 clones in each of these rows, one clone in each well with the 12th well in each row as a control well (no protein) in combination with the two β TRCP clones, as control proteins. The plate is left on a tabletop shaker for 1 hour to allow for the biotinylated proteins from the transcription translation reaction to bind to the surface of the plate. Thereafter the plate is washed three times with PBS.

15 Then patient samples 1-10 are diluted into PBS, pH7.4, 0.3%BSA, 0.2% tween-20 to generate dilutions from 1/200 to 1/2,000 these diluted patient samples are then added 50 μ l per well in such a way that each patient sample is added to a row on the 96 well plate with the 11 clones coated on to the surface. These plates are then left on a tabletop shaker for 1 hour to allow for the patient antibodies to bind to the proteins coated on the
20 plate. Thereafter the plate is washed three times with PBS. To these washed plates 50 μ l of PBS, pH7.4, 0.3%BSA, 0.2% tween-20, 60 mg/ml Sulfo-TAG labeled anti-human antibody is added followed by incubation with shaking for 1h. Thereafter the plate is washed three times with PBS followed by addition of 100 μ l of ORIGEN Assay Buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals are
25 measured. The ECL signals were measured using an imaging plate reader (IPR).

The results demonstrate that the patient samples 1-5 contain antibodies to the Sjogren syndrome antigens produced and coated on to 96 well plates, where as the

- 5 normal patients 6-10 who did not have Sjogren syndrome did not. This demonstrates the value of this method for the discovery and identification of antigens recognized by antibodies especially from complex mixtures of antibodies such as autoantibodies in patient samples.

10 **EXAMPLE 23. Demonstration Of A Multiwell Screening Method For Multiple Clones; Screen Of 90 EST Clones In 96-Well Format.**

The example demonstrates a screen to identify (i) substrates of ubiquitylation in reticulocyte lysates; (ii) proteins binding to specific phosphopeptides; and (iii) proteins possessing tyrosine-kinase activities.

15 **A, Preparation of plasmid DNA**

90 Bacterial clones containing different EST cDNAs were grown in 1.3 ml LB with 100 µg/ml Amp, and DNA was isolated using QIAprep 96 turbo Miniprep Kit (Qiagen) in 96-well format. DNA yield was, typically, 5-50 µg. Seven of these clones produced less than 5 µg DNA. Mean DNA concentration was 470 µg/ml. The clone

- 20 IMAGE ID # were as follows; 3870426, 3893964, 3919253, 3491843, 4237375, 4398016, 4419252, 3907115, 2899921, 2900118, 2900273, 2900421, 2900551, 2900956, 2901296, 3048141, 3048356, 3048606, 3445488, 3446518, 3446546, 3449836, 3449955, 3450936, 3451168, 3452024, 3452494, 3452714, 3453890, 3454025, 3454207, 3454505, 3454625, 3455258, 3455871
- 25 3458308, 3458973, 3459189, 3459274, 3460054, 3460621, 3461825, 3462090, 3462906, 3463478, 3463640, 3464547, 4181547, 3845821, 3847788, 3853408, 3857590, 3857760,

5 3859672, 3862264, 3866131, 3868632, 3868989, 3872315, 3877854, 3886015, 3886018, 3886999, 3894925, 3897353, 3898275, 3901471, 3901641, 3902385, 3906095, 3906517 3907984, 3908004, 3908182, 3908412, 3910505, 3912185, 3912628, 3914731, 3915089, 3919253, 3920860, 3921259, 3923156, 4343428, 3911953, 3909654, 3913291, 3914467, 3909921, 4191647 (Incyte Genomics, Palo Alto CA).

10 In addition, four clones were purified separately using Qiagen Midiprep kit and introduced into the 96-well plate at 470 µg/ml in addition to the rest of the clones to serve as positive controls in the assays. Two of these control clones (IMAGE IDs 3920860, 3912628) contained full-length RGS4 cDNA, a known substrate of ubiquitylation (Examples 1, 2, 3, 4, 5, 6) and the remaining two clones (IMAGE ID 3491843 and 15 4237375) encode for βTRCP1 and βTRCP2 respectively, proteins known to bind to a phosphorylated peptide derived from IκBa (Examples 10, 11, 12). These 4 clones were introduced into the wells of the 96 well plate in row H, positions H9, H10, H11, H12. The DNA samples were arranged on the 96 well plate as shown in Tables 24 and 25.

20 Table 24

	1	2	3	4	5	6
A	3870426	3893964	3919253	3491843	4237375	4398016
B	2900421	2900551	2900956	2901296	3048141	3048356
C	3450936	3451168	3452024	3452494	3452714	3453890
D	3458308	3458973	3459189	3459274	3460054	3460621
E	4181547	3845821	3847788	3853408	3857590	3857760
F	3877854	3886015	3886018	3886999	3894925	3897353
G	3907984	3908004	3908182	3908412	3910505	3912185
H	3923156	4343428	3911953	3909654	3913291	3914467

Table 25

	7	8	9	10	11	12
--	---	---	---	----	----	----

A	4419252	3907115	No Clone	2899921	2900118	2900273
B	3048606	3445488	3446518	3446546	3449836	3449955
C	3454025	3454207	3454505	3454625	3455258	3455871
D	3461825	3462090	3462906	3463478	3463640	3464547
E	3859672	3862264	3866131	3868632	3868989	3872315
F	3898275	3901471	3901641	3902385	3906095	3908517
G	3912628	3914731	3915089	3919253	3920860	3921259
H	3909921	4191647	3920860	3912628	3491843	4237375

5

B. Transcription-translation reactions

Transcription-translation reactions were assembled in a 96-well plate as described in Materials and Method in a total volume of 19 μ l. The amounts of DNA in each reaction varied depending on DNA yields at purification stage, while the four positive control wells contained reactions with 20 μ g/ml plasmid DNA. The reactions were incubated at 30°C for 40min.

10

C. Ubiquitylation assay

After incubation, 1 μ l of the TNT reaction was mixed with 50 μ l of BB1 in an IPR plate coated with FK2 antibody (750 ng antibody per well) (see Materials and Methods). The plate was left on a tabletop shaker for 1 hour to allow for ubiquitylated proteins to bind to the surface of the plate and for the Sulfo-TAG labeled streptavidin to bind to biotinylated proteins. Thereafter the plate was washed three times with PBS followed by addition of 100 μ l of ORIGIN Assay Buffer (IGEN International, Inc., Gaithersburg, MD) into each well, and ECL signals were measured.

15

20

Figure 2 shows that three RGS4-encoding IMAGE clones (3912628, 3914731, and 3920860) produced strong specific signal in this assay (\diamond) comparable to the signal produced by the two control RGS4 clones (\square). The rest of the 88 EST clones analyzed in

- 5 this experiment produced much weaker signals (◆). The assay was able to identify RGS4 as an efficient substrate of ubiquitylation in reticulocyte lysates, as previously reported (Davydov and Varshavsky, 2000, *J. Biol. Chem.*, 275:22931-22941).

D. Screen for phosphopeptide binding proteins

- 10 A screen was conducted using 7-spot IPR plates. The 7 spot NPT IPR plates are described in more detail in copending Provisional Application No. 60/301,932 (entitled "Assay Plates, Reader Systems and Methods for Luminescence Test Measurements", filed on June 29, 2001, hereby incorporated by reference) and particularly in the description of Plate Type D in Example 6.1 (NPT IPR plate) and U.S. Application Serial
- 15 Nos. 10/185,274 and 10/185,363, filed June 28, 2002, each hereby incorporated by reference. These plates consist of a 96 wells with 7 zones (spots) for the immobilization of proteins or other reagents. Each spot was coated with BSA conjugated to either a single phosphopeptide or multiple phosphopeptides. The peptides used in the study are shown in Table 26

20

Table 26

Peptide name	Binding protein	Sequence
PY992	PLC γ	DADE(p)YLIPQQGFFSSPSTSC [SEQ ID No. 5]
PY1068	Grb2, PLC γ	LPVPE(p)YINQSVPKRPAGSVC [SEQ ID No. 7]
PY1148	Shc	KGSHQISLDNPD(p)YQQDFFPKEAKPNC [SEQ ID No. 9]
I κ B	β TRCP	LKKERLLDDRHD(p)SGLD(p)SMKDEEYC [SEQ ID No. 1]
Myc	Unknown	CPSEDIWKKFELLP(p)TPPL(p)SPSRRSGL [SEQ ID No. 4]

Smad3C	Unknown	CGPLQWLDKVLTKMGSPHNPIS(p)SV(p)S [SEQ ID No. 11]
--------	---------	--

5

The plates were prepared essentially as described in example 12. The seven spots supported, respectively, the following BSA conjugates IkB, pY992, pY1068, pY1148, Myc, "A", and "6-P". "A" refers to a conjugate of BSA with multiple peptides: IkB, pY1148, Myc which were then coupled to BSA. "6-P" refers to a conjugate of BSA with the following multiple peptides: IkB, pY1148, pY992, pY1068, Smad3C.

For the assay, 4 μ l from TnT reaction product described above were added to the coated plate containing 50 μ l of binding buffer supplemented with 50 ng/well Ru-Streptavidin. The binding reaction was allowed to proceed at room temperature for 1 hour with constant shaking. At the end of incubation, the plate was washed twice with PBS and 100 μ l of Origen Assay Buffer (IGEN International, Inc., Gaithersburg MD) was added for reading the ECL. The ECL signals were measured using an imaging plate reader (IPR). The raw data from the IPR reader was then normalized using two steps of normalization. The first round was based on the 50 lowest values for a given specific spot. These 50 lowest values were averaged and divided into each signal for that spot to generate a signal value which could be compared readily between the peptide-conjugate spots. This was then followed by a second round of normalization using the lowest normalized value for a spot within a well to divide the signals from the other spots. This method provides a means to reduce the signals from proteins which bound non specifically to all the spots within a well. Following this the data was sorted for the highest signals for each of the spots to determine the rank order of the hits from each of the 7 peptide spots produced in the 96 well plate.

5 The results below demonstrate the expected correlation between the specific peptide and its binding partner demonstrating the value of this approach for the screening of libraries of clones for specific binding partners using a multi well plate with multiple binding domains (spots). The results from the multiple peptide spots ("A" and "6-P") agreed with the single peptide spots demonstrating the value of pooling peptides to increase the number of peptides per screen.

The Myc peptide showed binding to the F-Box protein β TRCP indicating that it might be modulated via ubiquitination as I κ Ba is on its phosphorylation.

The results from the screen were as expected. The results for the top 9 clones for each of the single peptide spots are shown below. The data from the multiple peptide spots also agreed with this data. This approach with multiple spots readily allowed us to normalize the background within a well which prove valuable with some clones that had high background binding to all the peptide spots in the well.

In the case of the I κ B peptide [SEQ ID No. 1], the data is shown in Table 27, the controls of β TRCP (4237375, 3491843) gave the highest signals followed by the two clones which were grown up in the 96 well format (3491843, 4237375) which are the two β TRCP clones. The clone 3445488 was not considered a hit as it produced high background on a number of the peptide spots which was not fully corrected with this normalization protocol.

25 Table 27

		I κ Ba
β TRCP [c]	4237375	38
β TRCP [c]	3491843	23
β TRCP	3491843	12

	3445488	7
βTRCP	4237375	3
	3886018	2
	3452714	2
	3915089	2
	3463640	2

5

The results in the case of the pY1148 [SEQ ID No. 9] (Table 28) were as expected with the four Shc clones and PLCγ giving the highest signals. The top 9 clones are listed below.

10 Table 28

	pY1148	
Shc	3909921	5
PLCγ	4419252	4
Shc	3911953	3
Shc	3909654	3
Shc	3914467	3
	3445488	2
	4237375	1
	3491843	1
	3491843	1

The results with the pY992 peptide [SEQ ID No. 5] (Table 29) were also as expected with the PLCγ clone showing the highest signal.

15 Table 29

	pY992	
PLCγ	4419252	10
	3909921	1
	3911953	1
	3909654	1
	3914467	1
	3445488	1
	4237375	1
	3491843	1

3491843	1
---------	---

5

The results with the pY1068 peptide [SEQ ID No. 7] (Table 30) also reflected the expected result with the highest signals from clones of Grb2 and PLC γ .

Table 30

	pY1068
Grb2	4398016 119
PLC γ	4419252 55
	3919253 3
	3445488 2
	3886018 2
	3909921 1
	3911953 1
	3909654 1
	3914467 1

10

The results from the Myc peptide [SEQ ID No. 4] (Table 31) were as expected as no protein binding partner has been identified as yet. The weak binding to the β TRCP clone products was not unexpected due to the homologous nature of the Myc peptide to that of the I κ B peptide.

15

Table 31

	Myc
β TRCP	4237375 10
β TRCP	3491843 8
	3445488 6
	3886018 5
	3915089 5
	3908004 5
	3491843 4
	3452714 4
	3463640 4

5 Tyrosine Kinase assay.

After incubating the 96-well plate with transcription-translation reactions for 50 min at 30°C, 5 µl of the reaction was mixed with 50 µl of binding buffer, and immobilized onto SA coated NPT-IPR plates by shaking at room temperature for 45 min. The unbound components of the reaction containing endogenous kinases were removed by washing
10 eight times with wash buffer [25 mM Tris containing 5 mM MgCl₂ and 0.004% Triton]. Immobilized protein was then used to phosphorylate substrate protein, poly Glu-Tyr (Sigma, pEY) in a 50 µl reaction containing 5 nM pEY, 25 mM Tris buffer pH 7.4, 5 mM MgCl₂, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT, EDTA-free protease inhibitor (Roche Molecular Biochemicals) and 100 mM ATP, by shaking at room
15 temperature for 60 minutes. About 45 µl of multi-phosphorylated pEY was transferred to a separate SA coated IPR plate containing a 30 µl mixture of 2.5 nM biotinylated anti-phosphotyrosine and 50 ng Sulfo-TAG labeled anti-phosphotyrosine in buffer containing 25 mM Tris buffer pH 7.4, 5 mM MgCl₂, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT and 0.05% IgG. The available phosphotyrosine residues were reacted at room
20 temperature for 60 min. The unbound reagents were removed by washing three times with water, and the TAG label ECL was detected in presence of 100 µl IPR assay buffer (IGEN International, Inc., Gaithersburg MD). The ECL signals were measured using an imaging plate reader (IPR).

Figure 3 shows that two Tyrosine Kinase encoding clones (IMAGE ID # 3870426
25 and 3893964) produced strong specific signals in this assay (□) when compared to the remaining EST clones which produced much weaker signals (◆). Thus in a multiwell

- 5 based assay system, the assay was able to identify specific tyrosine kinase activity toward substrate pEY from the immobilized proteins.

EXAMPLE 24. Direct Coating Of Proteins Onto Magnetic Beads.

EST clones were obtained from Incyte (Palo Alto, CA). Plasmid DNA was
10 prepared from these EST clones using QIAprep96 Turbo Miniprep (cat#27191, QIAgen, Los Angeles, CA), according to manufacturer's instructions. cDNA was eluted using 150 µl buffer EB (QIAgen).

The DNA from these clones was translated in a transcription and translation system as described in Materials and Methods. For binding of the proteins from the TnT reaction to
15 the magnetic beads we used the following protocol. The transcription-translation reaction (1 µl) was added to 40 µg of uncoated magnetic beads (SPHERO(TM) Carboxyl Magnetic Particles- Smooth Surface, 1% w/v, 3.2 µm Cat# CMS-30-5, Spherotech,) in 50ul PBS pH 7.4, with EDTA and protease inhibitors (Roche Biochemicals) in a 96 well plate. The beads were incubated for 2 hours followed by the addition of 35-40ng Sulfo-
20 TAG labeled streptavidin to each well in a 50 µl volume using assay buffer (25mM Tris pH7.4, 0.005% Triton, 1% BSA, protease inhibitors) and the plate was incubated for 1h at room temperature with shaking. After incubation, 100 µl of assay buffer was added and the plate was analyzed by ECL detection on an M8 Analyzer (IGEN International, Inc., Gaithersburg, MD). The results demonstrate the binding of proteins directly to a
25 magnetic bead from the TnT reactions. Typically signals are in the range of 5-160 fold over the signal seen with vector controls not producing proteins from cloned DNA. This data correlated well with a radioactive assay where the products of the transcription and

- 5 translation were analyzed by gel electrophoresis followed by detection and quantitation of the incorporated C14 labeled lysine.

EXAMPLE 25. Screening for EGFR Binding Proteins.

- The example describes an ORIGEN based HTS assay for EGFR binding to reticulocyte
10 lysate-expressed Grb2 and PLC γ . The assay uses Sulfo-TAG labeled anti-EGFR/anti-phosphotyrosine for detection.

- Upon EGF activation of cells, several adapter proteins bind specific sites in EGFR and transduce signals inside the cells. Seven tyrosine moieties of EGFR are under the regulation of autophosphorylation dependant signaling. The goals of this assay are to
15 identify the members of proteome that interact to the phosphopeptide motifs of EGFR. The interactions of Grb2 to pY1068 site and PLC γ to pY992 and pY1173 sites of EGFR are well established. We have developed screening methods to detect specific EGFR binding to *in vitro* expressed cDNAs. The assay format developed for this purpose utilizes following steps:

- 20 Proteins were produced in an *in vitro* transcription and translation reaction using 40-100 ng of plasmid DNA. Mock (Luciferase, Promega), Grb2 or PLC γ (IMAGE IDs# 4398016 or 4419252, Incyte Genomics, CA) were produced and immobilized on SA coated NPT-IPR plates as described in the Materials and Methods. The unbound components of the reaction containing endogenous kinases were removed by three
25 washes with TT- buffer [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton], two five minutes washings with high-salt wash buffer [25 mM Tris-HCl buffer pH 7.4, 0.004% Triton, 1M NaCl and 5 mM DTT] and 3 more washes with TT-buffer. To these

- 5 immobilized and purified proteins 1.5 nM phosphorylated EGFR (Sigma Chemical Co, MO, self-phosphorylated for 30 min in presence of 25 mM Tris-HCl buffer pH 7.4, 0.05 mM Na_3VO_4 , 0.004% TritonX-100, 2 mM DTT, 5 mM MgCl_2 , 5 mM MnCl_2 , 100 μM ATP) was added in buffer containing 1X Phosphate buffered saline (Quality Biological, MD), 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche
- 10 Molecular Biochemicals, IN)], and allowed to bind for 45 minutes. The unbound EGFR was washed by 4 times washing with TT- buffer [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton]. The amount of EGFR bound to the reticulocyte lysate expressed protein was determined by detecting the kinase activity of EGFR. A tyrosine kinase substrate, 5 nM pEY (poly Glu-Tyr, Sigma, MO) was added in a 50 μl reaction containing 5 mM
- 15 MgCl_2 , 5 mM MnCl_2 , 100 μM ATP, 25 mM Tris-HCl buffer pH 7.4, 0.05 mM Na_3VO_4 , 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche Molecular Biochemicals). This mixture was incubated with shaking at room temperature for 1 or 12 hours to allow phosphorylation of the pEY substrate by the EGFR. Following this incubation 45 μl of this mixture was transferred to a SA - NPT IPR plate coated with
- 20 biotinylated anti-phosphotyrosine antibody (PY20, Zymed labs, CA) followed by incubation for 30 minutes at room temperature to allow the binding of the phosphorylated pEY substrate to the PY20 coated NPT plate. Following this binding step 50 ng Sulfo-TAG labeled anti-phosphotyrosine in buffer containing 25 mM Tris-HCl buffer pH 7.4, 5 mM MgCl_2 , 0.05 mM Na_3VO_4 , 0.004% TritonX-100, 2 mM DTT and 0.05% IgG was
- 25 added followed by incubation at room temperature for 30 min.

Alternatively, the bound EGFR was directly detected in the original plate by incubating with 20 nM TAG labeled anti-EGFR (Clone 225, Neo Markers, CA) in 50 μl

- 5 buffer containing 25 mM Tris-HCl buffer pH 7.4, 5 mM MgCl₂, 0.05 mM Na₃VO₄,
0.004% TritonX-100, 2 mM DTT and 0.05% IgG at room temperature for 60 min.

The unbound reagents were removed by one time washing with TT- buffer [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton], and the TAG label was detected in presence of 150 µl IPR assay buffer (0.4 mM Gly-Gly buffer, pH 7.8, 1 mM EDTA, 0.1

- 10 M TPA). The ECL signals were measured using an imaging plate reader.

We have demonstrated that Grb2 and PLCγ specifically bind to EGFR; these are suggested to interact through phosphorylated sites of EGFR. The control protein Luciferase (Mock) did not show any significant level of binding to EGFR. The binding of EGFR to Grb2 or PLCγ was detected either by identifying tyrosine kinase activity of
15 EGFR towards pEY (see Table 32) or directly by using TAG-labeled anti-EGFR (Table-33). The detection of bound EGFR was substantially increased by its prolonged (12 hr) phosphorylation of tyrosine kinase substrate pEY (see Table 32).

Table 32

Reticulocyte lysate	Reaction time	-	+	+	+	+
Plasmid		none	Grb2	PLCγ	Mock	none
no EGFR	-	957	1,497	1,695	1,462	1,426
+ EGFR	1 hr	2,241	25,214	17,966	2,683	2,598
+ EGFR	12 hr	2,429	62,912	39,767	3,303	3,088

20

Table 33

Reticulocyte lysate	-	+	+	+
Plasmid	none	Grb2	PLCγ	Mock
no EGFR	2,181	2,356	2,271	2,534
+ EGFR	5,447	48,027	30,389	8,742

5 The interaction of Grb2 towards EGFR known to be mediated through phospho-tyrosine site 1068 was further confirmed in this assay as the EGFR binding to this proteins was significantly reduced in presence of phosphorylated (pY1068) form of the peptide (Phosphopeptide, amino acids 1063-1081 [SEQ ID No. 7]), but not in the presence of its un-phosphorylated form (Peptide [SEQ ID No. 8]) (see Table 34).

10

Table 34

Plasmid			
Mock	+ EGFR		2,683
Grb2	+ EGFR		25,214
Grb2	+ EGFR	+ Phosphopeptide	7,348
Grb2	+ EGFR	+ Peptide	34,055
none	+ EGFR		2,598

EXAMPLE 26. ORIGIN Based HTS Assay For Protein Tyrosine Phosphatase

15 Activity Of PTP-N2 (Protein Tyrosine Phosphatase, Non-Receptor Type 2)

Expressed In Reticulocyte Lysate.

The example demonstrates an assay to screen for protein tyrosine phosphatase activity.

Protein Tyrosine phosphatases (PTPs) are a family of enzymes found ubiquitously in cells, and are not only are involved in growth factor mediated signaling process, but
 20 also are implicated in modulating other cellular processes such as the maintaining integrity of the cytoskeleton and cell-cell interactions. T-cell protein tyrosine phosphatase (PTP-N2) is one such phosphatase that exits the nucleus upon EGF receptor activation and recognizes the EGFR and p52^{Shc} as a cellular substrates (Tiganis et. Al Mol. Cell. Biol. 18, 1680, 1998). Using *in vitro* expression screening strategy, we have

5 measured the phosphatase activity from full-length clone PTP-N2 (protein tyrosine phosphatase, non-receptor type 2). The assay format developed for this purpose utilizes following steps:

Several proteins were produced in an *in vitro* transcription and translation reaction using 1-150 ng of plasmid DNA including: Mock Luciferase (Promega); protein tyrosine
10 phosphatase; non-receptor type 2 (PTP-N2, IMAGE ID# 3872164, Incyte Genomics, CA); and fer (fms/fps related) protein kinase, testis specific 2 clone (Fert2, IMAGE ID# 4485050, Incyte Genomics, CA). The proteins were produced and immobilized on SA coated NPT-IPR plates, as described in Example 7. The unbound components of the translation reaction (including endogenous kinases) were removed by 3 washes with TT-
15 buffer [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton], two five minutes washes with high-salt wash buffer [25 mM Tris-HCl buffer pH 7.4, 0.004% Triton, 1M NaCl and 5 mM DTT} and 3 washes with TT-buffer.

A tyrosine phosphate substrate was prepared by enzymatically phosphorylating poly(Glu,Tyr). To the immobilized and purified Fert2 kinase, a tyrosine kinase substrate
20 (2.5 μ M of poly(Glu,Tyr)) was added in a 50 μ l reaction containing 5 mM $MgCl_2$, 5 mM $MnCl_2$, 100 μ M ATP, 25 mM Tris-HCl buffer pH 7.4, 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche Molecular Biochemicals). This mixture was incubated with shaking at room temperature for 45 min to allow phosphorylation of the pEY substrate by the immobilized Fert2. The phosphorylation in the product was
25 determined by transferring serially diluted reaction mixture to a streptavidin-coated NPT IPR plate and assaying for phosphorylated-poly(Glu,Tyr) as described in previous examples (see, e.g., Example 7).

- 5 The phosphorylated poly(Glu,Tyr) was used as a substrate to measure the phosphatase activity of the purified and immobilized PTP-N2. To wells containing immobilized PTP-N2 was added 50 uL of a reaction mixture containing 5 nM phospho-pEY (described above), 5 mM MgCl₂, 25 mM Tris-HCl buffer pH 7.4, 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor (Roche Molecular Biochemicals).
- 10 This mixture was incubated with shaking at room temperature 45 min to allow de-phosphorylation of the phospho-pEY substrate by the immobilized phosphatase. Following this incubation 45 µl of this mixture was transferred to a streptavidin-coated NPT IPR plate and the solution analyzed for phospho-poly(Glu,Tyr) content as described above.
- 15 Using our novel phosphatase substrate (phospho-pEY), a significant decrease in the signal was observed due to phosphatase activity from PTP-N2, when compared to Mock (Luciferase) (see Table 35).

Table 35

	ECL signal
No TnT reactants	487,082
Mock	408,302
PTP-N2	70,574

20

EXAMPLE 27. In Vitro Assay For A Set Of Kinases.

This example illustrates the use of methods of the invention to express a library of potential kinases and screen this library for kinase activity. In this example, the kinases

- 5 were assayed for their ability to auto-phosphorylate as well as their ability to phosphorylate a non-autologous substrate.

Proteins were produced in an *in vitro* transcription and translation reaction as described in the Materials and Methods. This process resulted in the transcription and translation of the various proteins with biotin groups randomly incorporated at some lysine residues. The reaction was stopped by mixing with BB2 buffer. Biotinylated proteins from 50 μ l of the mixture (representing 0.5 μ l to 5 μ l of TnT reaction) were immobilized onto streptavidin or avidin coated NPT-IPR plates by shaking at room temperature for 45 min. The activity of the immobilized protein towards pEY or autophosphorylation was further assayed by the methods described in examples 7 and 8.

- 15 When 5 μ l of expressed protein was tested for its activity towards pEY, clones having sequence or structural homology to known tyrosine kinase catalytic domains, phosphotransferases, or the tyrosine-specific kinase subfamily showed significantly higher signal than non-kinases or proteins serving as substrates to tyrosine kinases (Scap2) (see Table 12 below).

20

Table 36

IMAGE ID	Locus		HTS signal
2644960	Kit	kit oncogene	9,164
2654352	Fgfr2	fibroblast growth factor receptor 2	296,481
3156400	Src	Rous sarcoma oncogene	145,950
3156953	Wee1	wee 1 homolog (S. pombe)	981
3482498	Tek	endothelial-specific receptor tyrosine kinase	10,287
3601246	FRK	B-cell src-homology tyrosine kinase	15,235
3673003	Ephb3	Eph receptor B3	1,174
3866791	JAK1	Janus kinase 1 (a protein tyrosine kinase)	729
3870426	SYK	spleen tyrosine kinase	650,826
3873932	MATK	megakaryocyte-associated tyrosine kinase	47,477

3896359	FGFR1	fibroblast growth factor receptor 1 (fms-related : TK2)	2,339
3919253	BMX	BMX non-receptor tyrosine kinase	523,662
3921724	FGR	FYN oncogene related to SRC	93,081
3978518	Hck	hemopoietic cell kinase	184,534
3982920	Clk4	CDC like kinase 4	2,244
3989782	Yes	Yamaguchi sarcoma viral (v-yes) oncogene homolog	2,208
3991628	EPHA7	Eph receptor A7	24,930
3995512	CLK2	CDC-like kinase 2	634
4013934	Ephb4	Eph receptor B4	7,357
4036253	CLK3	CDC-like kinase 3	704
4037899	FGFR1	fibroblast growth factor receptor 1	450,413
4181574	NTRK3	neurotrophic tyrosine kinase	36,515
4190326	Lyn	Yamag sarcoma viral (vyes1) oncogene homolog	427,178
4191610	LCK	lymphocyte protein tyrosine kinase	3,110
4238984	Kdr	kinase insert domain protein receptor	107,459
4239139	Fgfr4	fibroblast growth factor receptor 4	7,343
4343428	PTK2B	protein tyrosine kinase 2 beta	57,486
4363897	FGR	FYN oncogene related to SRC	402,243
4384416	BTK	Bruton agammaglobulinemia tyrosine kinase	793,874
4387232	CLK1	CDC-like kinase 1	5,109
4398416	Csk	c-src tyrosine kinase	683,039
4419031	BLK	B lymphoid tyrosine kinase	37,907
4419700	LCK	lymphocyte-specific protein tyrosine kinase	898
4419973	FGR	GR feline sarcoma viral (v-fgr) oncogene homolog	104,946
4471986	ALK	anaplastic lymphoma kinase (Ki-1)	905
4485050	Fert2	fer (fms/fps related) protein kinase	952,661
4498209	EPHB1	EphB1	853
4515877	Frk	fyn-related kinase	271,855
4537393	TTK	TTK protein kinase	1,711
4778819	Hck	hemopoietic cell kinase	958,415
Negative Controls			
		Mock	520
		Average signal of ten Non-Tyrosine Kinase clones	564
3599914	Scap2	Tyrosine Kinase substrate	587

5

Similarly, the autophosphorylation activity from the expressed protein of these clones was robustly detected, as the signal from kinases was significantly different from the signal from non-kinases (Table 37).

5 Table 37

IMAGE ID	Locus		ECL signal
2644960	Kit	kit oncogene	88,966
2654352	Fgfr2	fibroblast growth factor receptor 2	180,059
3156400	Src	Rous sarcoma oncogene	76,933
3156953	Wee1	wee 1 homolog (S. pombe)	27,452
3482498	Tek	endothelial-specific receptor tyrosine kinase	84,706
3601246	FRK	B-cell src-homology tyrosine kinase	28,243
3673003	Ephb3	Eph receptor B3	10,540
3870426	SYK	spleen tyrosine kinase	228,700
3873932	MATK	megakaryocyte-associated tyrosine kinase	27,372
3896359	FGFR1	fibroblast growth factor receptor 1 (fms-related TK2)	7,696
3919253	BMX	BMX non-receptor tyrosine kinase	443,933
3921724	FGR	FYN oncogene related to SRC	241,697
3978518	Hck	hemopoietic cell kinase	301,418
3982920	Clk4	CDC like kinase 4	192,787
3989782	Yes	Yamaguchi sarcoma viral (v-yes) oncogene homolog	4,542
3991628	EPHA7	Eph receptor A7	115,662
3995512	CLK2	CDC-like kinase 2	20,748
4013934	Ephb4	Eph receptor B4	28,275
4036253	CLK3	CDC-like kinase 3	42,712
4037899	FGFR1	fibroblast growth factor receptor 1	240,550
4181574	NTRK3	neurotrophic tyrosine kinase	55,017
4190326	Lyn	Yamaguchi sarcoma viral (vyes1) oncogene homolog	599,680
4191610	LCK	lymphocyte protein tyrosine kinase	24,183
4238984	Kdr	kinase insert domain protein receptor	61,364
4239139	Fgfr4	fibroblast growth factor receptor 4	12,588
4343428	PTK2B	protein tyrosine kinase 2 beta	274,742
4363897	FGR	FYN oncogene related to SRC	44,220
4384416	BTK	Bruton agammaglobulinemia tyrosine kinase	1,503,772
4387232	CLK1	CDC-like kinase 1	423,938
4398416	Csk	c-src tyrosine kinase	349,847
4419031	BLK	B lymphoid tyrosine kinase	146,775
4419700	LCK	lymphocyte-specific protein tyrosine kinase	7,230
4419973	FGR	Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog	117,395
4471986	ALK	anaplastic lymphoma kinase (Ki-1)	4,069
4485050	Fert2	fer (fms/fps related) protein kinase	1,350,546
4498209	EPHB1	EphB1	3,138
4515877	Frk	fyn-related kinase	148,139
4537393	TTK	TTK protein kinase	50,479
4778819	Hck	hemopoietic cell kinase	1,198,625
Negative Controls			

		Mock	2,251
		Non-Tyrosine Kinase clones (n=10)	2,169
3599914	Scap2	TK substrate, Scap2	2,912

5

EXAMPLE 28. ORIGEN Based HTS Assay For Kinase Activity Of Tyrosine Kinase Array In Presence Of Kinase Inhibitors.

This example shows the profiling of a panel of kinase inhibitors against a panel of

10 tyrosine kinases. The example demonstrates the use of proteins expressed in *in vitro* transcription/translation systems in inhibition assays and/or drug screening assays. The example shows specificity data for proteins generated from a library of eighteen full-length clones. The assay format developed for this purpose utilizes following steps:

Proteins were produced using 100 ng of plasmid DNA Mock (Luciferase, Promega) or

15 tyrosine kinases (Fert2 IMAGE ID # 4485050, FGFR1 IMAGE ID # 4037899, Fgfr2 IMAGE ID # 2654352, Src IMAGE ID # 3156400, BMX IMAGE ID # 3919253, LCK IMAGE ID # 4191610, EphA7 IMAGE ID # 3991628, Ephb4 IMAGE ID # 4013934, Tek IMAGE ID # 3482498, HCK IMAGE ID # 4778819, BTK IMAGE ID # 4478463, CSK IMAGE ID # 4398416, SYK IMAGE ID # 3870426, FGR IMAGE ID # 4419973,

20 PTK2B IMAGE ID # 4339456, FRK IMAGE ID # 4515877, Kit IMAGE ID # 2644960, Fgfr-4 IMAGE ID # 4239139, NTRK3 IMAGE ID # 4181574, Kdr IMAGE ID # 4238984, Incyte Genomics, CA) and immobilized on SA or avidin coated NPT-IPR plates as described in previous examples. The unbound components of the translation reaction (including any endogenous kinases) were removed by 3 washes with TT- buffer

25 [25 mM Tris-HCl buffer pH 7.4 and 0.004% Triton], two five minutes washes with high-salt wash buffer [25 mM Tris-HCl buffer pH 7.4, 0.004% Triton, 1M NaCl and 5 mM

5 DTT] and 3 washes with TT-buffer. To these immobilized and purified proteins a tyrosine kinase substrate, 10 nM pEY (poly Glu-Tyr, Sigma, MO) was added in 25 μ L of buffer A (5 mM MgCl₂, 5 mM MnCl₂, 25 mM Tris-HCl buffer pH 7.4, 0.05 mM Na₃VO₄, 0.004% TritonX-100, 2 mM DTT and EDTA-free protease inhibitor) containing 1 μ L of one of a DMSO solution of one of the potential inhibitors (Damnacanthol, PP2, 10 AG 490, WHIP 131, LFMA 13, AG 597, Lavendustin A, Compound 56, Genistein, AG1478, AG 1296, AG 17, AG 1024, AG 538, AG 879, SU 1498, Oxindole 1, VEGFR2 inhibitor1, VEGFR inhibitor were from CalBiochem, Pasadena, CA; and PP1, Erbstatin Analogue and AG1433 were from AG Scientific, San Diego, CA). The mixture was incubated at room temperature for 10 min before starting the kinase reaction by adding 25 15 μ L of 200 μ M ATP in buffer A. This mixture was incubated with intermittent shaking at room temperature for 2 hours to overnight to allow (a) phosphorylation of the pEY substrate and (b) autophosphorylation of the immobilized kinases. Autophosphorylation and phosphorylation of the pEY was measured as described in Examples 7 and 8.

We used tyrosine kinase inhibitors at 1X and 10X the reported IC₅₀ 20 concentrations for inhibition of the tyrosine kinases reported to be the target of each inhibitor (1X concentrations were 620 nM Damnacanthol, 600 nM PP1, 4 nM PP2, 100 nM AG-490, 7.8 μ M WHI-P131, 17.2 μ M LFM-A13, 750 nM AG-957, 780 nM Erbstatin, 11 nM Lavendustin A, 6 μ M Compound-56, 2.6 μ M Genistein, 3 nM AG- 1478, 5 μ M AG-1433, 1 μ M AG-1296, 500 nM AG-17, 18 μ M AG-1024, 60 nM AG- 25 538, 10 μ M AG879, 700 nM SU-1498, 390 nM Oxindole 1, 2 μ M VEGFR inhibitor and 70 nM VEGFR2 inhibitor) and tested their specificity against an "Array of Kinases", eighteen tyrosine kinases representing diverse family of non-membrane and membrane

- 5 bound kinases. The ECL signal in control wells produced by tyrosine kinases was compared to the wells containing inhibitor compounds. The signal produced from Mock was negligible. Thus, a profile of inhibition specificity for each compound for high inhibition ("H" = less than 25% of the activity remaining), medium inhibition ("M" = between 25 to 50% of the activity remaining), and low inhibition ("L" = between 50-75% of the activity remaining) was developed towards pEY substrate phosphorylation (Table 38) and autophosphorylation (Table 39).

Table 38.

	Inhibition specificity towards pEY phosphorylation at 10X IC50															
	Fer2	FGFR1	FGFR2	Src	BMX	LCK	Epha7	EphA4	Tek	HCK	BTk	CSK	SYK	PTK2B	FRK	Kit
Damnacanthal	L	H	H	H	H	H	H	H	M	H	H	H	H	H	H	H
PP1		L			L	M		L			M				M	M
PP2															L	
AG-490											L					
WHI-P131		L	L	L	L	H	L	M	L	L	M			L	H	L
LFM-A13											M				M	M
AG-957		L	L		L			L	L			M			L	
Erbstatin analog								L							L	
Lavendustin A															L	
Compound-56																
Genistein								L							M	
AG-1478																
AG-1433		H	H	H	H		L	H	M	M	H	M	M	L	H	H
AG-1296								L							M	
AG-17															L	
AG-1024		L	L					L	L		H		L		L	M
AG-538																
AG879											L					
SU-1498																
Oxindole 1										L	M	M	L	M	L	H
VEGFR inhibitor			L			H		M			M				L	L

VEGFR2 inhibitor	H	H	H	H	L			L	L							M		M
------------------	---	---	---	---	---	--	--	---	---	--	--	--	--	--	--	---	--	---

5

Table 39.

	Inhibition specificity towards Autophosphorylation at 10X IC50																	
	Fer2	FGFR1	FGFR2	Src	BMX	LCK	Epha7	Ephb4	Tek	HCK	BTk	CSK	SYK	PTK2B	FRK	Kit	Fgfr-4	Kdr
Damnacanthal	L	M	M	H	H	H	H	H	H	M	H	M	M	M	H	H	H	H
PP1				L														L
PP2															L			
AG-490																		
WHI-P131						M										L		M
LFM-A13											L							
AG-957		L	L	L	L			L	M	L	L	L	L	L	L	L	L	L
Erbstatin analog	L		L	L	L	L		L	L	L	L		L	L		L		L
Lavendustin A																		
Compound-56																		
Genistein																		
AG-1478																		
AG-1433	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
AG-1296																		
AG-17																		
AG-1024			L						M		L						L	
AG-538								L										
AG879																		
SU-1498																		
Oxindole 1											L		L	L		M	L	M
VEGFR inhibitor						L		L			L							M
VEGFR2 inhibitor	H	H	H	H					L									L

10

8. INCORPORATION OF REFERENCES

5 The present invention is not to be limited in scope by the specific embodiments
described herein. Indeed, various modifications of the invention in addition to those
described herein will become apparent to those skilled in the art from the foregoing
description and accompanying figures. Such modifications are intended to fall within the
scope of the claims. Various publications are cited herein, the disclosures of which are
10 incorporated by reference in their entireties.

5 **CLAIMS:**

1. A multi-well plate with 20 or more wells containing the *in vitro* transcription and translation products of unique nucleic acid constructs.
2. The multi-well plate of claim 1, wherein said wells contain magnetic beads coated with said products.
- 10 3. The multi-well plate of claim 1, wherein said products are immobilized on said wells.
4. The multi-well plate of claim 1, wherein said wells are coated with a binding species.
5. The multi-well plate of claim 4, wherein said binding species is a biological
- 15 molecule, or is structurally or functionally homologous to a biological molecule.
6. A multi-well plate with 20 or more wells coated with a binding species and containing the *in vitro* transcription and translation products of unique nucleic acid constructs, said products being immobilized in said wells via binding interactions with said binding species.
- 20 7. A multi-well plate with 20 or more wells containing the *in vitro* transcription and translation products of unique nucleic acid constructs, said products being immobilized in said wells via non-specific adsorption.
8. The multi-well plate as in any one of claims 1 or 3-7, wherein said wells of said multi-well plates comprise electrodes.
- 25 9. The multi-well plate as in any one of claims 3 or 6-8, wherein said products are immobilized on the surface of electrodes in said wells.

- 5 10. The multi-well plate according to claim 8 or 9, wherein said electrodes are carbon
or carbon composite electrodes.
11. The multi-well plate of claim 8, 9 or 10 wherein said electrodes are suitable for
inducing electrochemiluminescence.
12. The multi-well plate as in any one of claims 1 or 3-11, wherein said wells of said
10 multi-well plate comprise 2 or more specific binding zones.
13. The multi-well plate as in any one of claims 1-12, wherein said wells further
comprise a tRNA precharged with a modified amino acid.
14. A multi-well plate with at least 20 wells containing *in vitro* transcription and
translation products of unique nucleic acid constructs, each of said wells produced
15 by the method comprising:
- a) obtaining a nucleic acid construct,
- b) transcribing said nucleic acid to generate RNA,
- c) translating said RNA in a cell-free translation system containing a tRNA
precharged with a modified amino acid, to produce an amino acid
20 sequence containing said modified amino acid, and
- d) contacting said amino acid sequence with a surface of a solid phase
present in said well so as to immobilize said amino acid sequence on said
surface.
15. The multi-well plate of claim 14, wherein said multi-well plate comprises
25 electrodes.
16. The multi-well plate of claim 15, wherein said amino acid sequence is
immobilized on one of said electrodes.

- 5 17. The multi-well plate of claim 14, wherein said multi-well plate comprises a carbon or carbon composite surface.
18. The multi-well plate of claim 17, wherein said amino acid sequence is immobilized on said carbon or carbon composite surface.
- 10 19. A multi-well plate for screening for an activity of interest, said plate having 20 or more wells containing the *in vitro* transcription and translation products of unique nucleic acid constructs and said wells having immobilized therein assay domains comprising an assay reagent selected from the group consisting of i) a substrate of said activity, ii) a binding reagent specific for a substrate of said activity and iii) a binding reagent specific for a product of said activity.
- 15 20. The multi-well plate of claim 19, wherein said wells comprise electrodes and said assay reagent is immobilized on said electrodes.
21. The multi-well plate of claim 19, wherein said wells comprise a carbon surface or a carbon composite surface and said assay reagent is immobilized on said surface.
22. The multi-well plate of claim 19, wherein said *in vitro* transcription and translation products are immobilized in said wells.
- 20 23. A method of producing a multi-well plate with at least 20 wells containing unique *in vitro* transcription and translation products, said method comprising, for each of said wells:
- a) obtaining a nucleic acid construct,
- 25 b) transcribing said nucleic acid construct to generate RNA,

- 5 c) translating said RNA in a cell-free translation system containing a tRNA
 precharged with a modified amino acid, to produce an amino acid
 sequence containing said modified amino acid, and
- d) contacting said amino acid sequence with a surface of a solid phase
 present in said well so as to immobilize said amino acid sequence on said
10 surface.
24. The method of claim 23, wherein said solid phase support is an electrode.
25. The method of claim 23, wherein said solid phase support is carbon or a carbon
 composite.
26. The method of claim 23, wherein said immobilization of said amino acid
15 sequence is via a specific binding interaction with a binding species coated on
 said surface.
27. The method of claim 23, wherein steps b-d are conducted in said well.
28. The method of claim 23, wherein step (c) further comprises modifying said amino
 acid sequence with a post-translational modification.
- 20 29. The method of claim 23, further comprising
- e) contacting said amino acid sequence with a first enzyme that introduces or
 removes post-translational modifications.
30. The method of claim 29, wherein step (e) precedes step (d).
31. The method of claim 29, wherein step (d) precedes step (e).
- 25 32. The method of claim 29, further comprising
- f) contacting said amino acid sequence with a second enzyme that introduces
 a post-translational modification

- 5 wherein, said first enzyme removes post-translational modifications and
step (f) is carried out after step (e).
33. A method for screening nucleic acid constructs for those encoding amino acid
sequences subject to a post-translational modification activity comprising the
following steps:
- 10 a) obtaining a nucleic acid construct,
 b) transcribing said nucleic acid to generate RNA,
 c) translating said RNA in a cell-free system containing a tRNA precharged
 with a modified amino acid, to produce an amino acid sequence containing
 said modified amino acid, and
- 15 d) detecting said post-translational modification of said amino acid sequence
 by a solid phase binding assay for the binding of said amino acid sequence
 to a binding species specific for said post-translational modification.
34. The method of claim 33, wherein said binding species is immobilized on a solid
phase and said solid phase binding assay comprises:
- 20 i) binding said amino acid sequence to said binding species so as to
 capture said amino acid sequence on said solid phase, and
 ii) detecting said captured amino acid sequences on said solid phase
 using a binding reagent specific for said modified amino acid.
35. The method of claim 33, wherein said solid phase binding assay comprises:
- 25 i) capturing said amino acid sequence on a surface of a solid phase
 via an immobilized binding reagent specific for said modified
 amino acid, and

- 5 ii) detecting said captured amino acid sequences on said surface using
 a binding species specific for said post-translational modification.
36. The method of claim 35, wherein said solid phase comprises an array of
 additional binding species specific for different post-translational modifications.
37. The method of claim 33, 34, 35 or 36, wherein said cell-free system further
10 comprises a substrate that can be linked to a protein to form a post-translational
 modification.
38. The method of claim 33, 34, 35, 36 or 37, wherein said post-translational
 modification is a covalent post-translational modification.
39. The method of claim 38, wherein said post-translational modification is selected
15 from the group consisting of signal peptide cleavage, phosphorylation,
 acetylation, adenylation, proteolysis, amino peptidase clipping, arginylation,
 disulphide bond formation and cleavage, amidation, glycosylation, isoprenylation,
 myristoylation, ubiquitination, SUMOlation, Agp12 ligation, Nedd8 ligation and
 covalent addition of proteins.
- 20 40. A method for screening nucleic acid constructs for those encoding amino acid
 sequences subject to a post-translational modification activity comprising the
 following steps:
- (a) obtaining a nucleic acid construct,
- (b) transcribing said nucleic acid to generate RNA,
- 25 (c) translating said RNA in a cell-free system containing a tRNA precharged
 with a modified amino acid and a substrate that can be linked to a protein
 to form a post-translational modification, said substrate being modified

- 5 with a detectable species, to produce an amino acid sequence containing
 said modified amino acid and said post-translational modification, and
- (d) detecting said post-translational modification of said amino acid sequence
 by a solid phase binding assay for the binding of said amino acid sequence
 to a binding species specific for said post-translational modification or the
10 binding of said amino acid sequence to a binding reagent specific for said
 modified amino acid.
41. The method of claim 40, wherein said binding reagent is immobilized on a solid
 phase and said solid phase binding assay comprises:
- i) capturing said amino acid sequence on said solid phase by a
15 binding interaction with said binding reagent; and
- ii) detecting said captured amino acid sequences on said solid phase
 using said detectable species on said post-translational
 modification.
42. The method of claim 40, wherein said binding species is immobilized on said
20 solid phase and said solid phase binding assay comprises:
- i) capturing said amino acid sequence on said solid phase by a
 binding interaction with said binding species; and
- ii) detecting said captured amino acid sequences on said solid phase
 using said modified amino acid.
- 25 43. The method of claim 42, wherein said solid phase comprises an array of
 additional binding species specific for different post-translational modifications.

- 5 44. The method of claim 40, 41, 42 or 43, wherein said post-translational
modification is a covalent post-translational modification.
45. The method of claim 44, wherein said post-translational modification is selected
from the group consisting of signal peptide cleavage, phosphorylation,
acetylation, adenylation, proteolysis, amino peptidase clipping, arginylation,
10 disulphide bond formation and cleavage, amidation, glycosylation, isoprenylation,
myristoylation, ubiquitination, SUMOlation, Agp12 ligation, Nedd8 ligation and
covalent addition of proteins.
46. The method as in claim 44, where said post-translational modification is
ubiquitination, said substrate is ubiquitin and said binding species is an antibody
15 to ubiquitin.
47. A method for screening nucleic acid constructs for those encoding amino acid
sequences with enzymatic activity comprising the following steps:
- 20 a) obtaining a nucleic acid construct,
b) transcribing said nucleic acid to generate RNA,
c) translating said RNA in a cell-free system containing a tRNA precharged
with a modified amino acid, to produce an amino acid sequence containing
said modified amino acid, and
d) detecting enzymatic activity of said amino acid sequence using a method
comprising the following steps:
- 25 i) capturing said amino acid sequence onto a solid phase via an
immobilized binding reagent specific for said modified amino acid,
ii) adding enzyme reaction buffer, and

- 5 iii) detecting the product of the enzyme activity.
48. The method of claim 47, wherein said enzymatic activity is selected from the
group consisting of kinases, hydrolases, protease, polymerases, glycosidases, and
phosphatases.
49. The method of claim 47, wherein said enzymatic activity is a post-translational
10 modification activity.
50. The method of claim 47, wherein said enzymatic activity is a joining or cleaving
activity.
51. A method for screening nucleic acid constructs for those encoding amino acid
sequences that are substrates of enzymatic activity comprising the following
15 steps:
- a) obtaining a nucleic acid constructs,
- b) transcribing said nucleic acid to generate RNA,
- c) translating said RNA in a cell-free system containing a tRNA precharged
with a modified amino acid, to produce an amino acid sequence containing
20 said modified amino acid, and
- d) detecting said amino acid sequences which are substrates of an enzyme
activity using a method comprising the following steps:
- i) capturing said amino acid sequence onto a solid phase via an
immobilized binding reagent specific for said modified amino
25 acid;
- ii) adding an enzyme; and

- 5 iii) detecting the product of the enzyme activity on said amino acid sequence.
52. The method of claim 51, further comprising the step of treating said captured amino acid sequence with one or more reagents that remove a post-translational modification that occurred during said translating step.
- 10 53. The method of claim 52, wherein said post-translational modification interferes with said detecting of said product.
54. The method of claim 53, further comprising treating said captured amino acid sequence with a post-translational modification activity prior to adding said enzyme.
- 15 55. The method of claim 51, 52, 53 or 54, wherein said enzymatic activity is selected from the group consisting of kinases, hydrolases, protease, polymerases, glycosidases, and phosphatases.
56. The method of claim 51, 52, 53 or 54, wherein said enzymatic activity is a post-translational modification activity.
- 20 57. The method of claim 51, 52, 53 or 54, wherein said enzymatic activity is a joining or cleaving activity.
58. A method for screening nucleic acid constructs for those encoding amino acid sequences with binding activity comprising the following steps:
- 25 a) obtaining a nucleic acid construct,
- b) transcribing said nucleic acid to generate RNA,

- 5 c) translating said RNA in a cell-free system containing a tRNA precharged
 with a modified amino acid, to produce an amino acid sequence containing
 said modified amino acid, and
- d) detecting binding activity of said amino acid sequence for a binding
 partner via a solid phase binding assay.
- 10 59. The method of claim 58, wherein said solid phase assay comprises:
- i) capturing said amino acid sequence on a solid phase using an
 immobilized binding reagent specific for said modified amino acid,
 and
- ii) detecting said captured binding activity using said binding partner.
- 15 60. The method of claim 59, wherein said solid phase assay further comprises mixing
 said amino acid sequence and binding partner in solution prior to capturing said
 amino acid sequence.
61. The method of claim 58, wherein said binding partner is immobilized on a solid
 phase and said solid phase binding assay comprises the steps of:
- 20 i) capturing said amino acid sequence on solid phase via said binding
 activity to said binding partner immobilized on said solid phase,
 and
- ii) detecting said captured amino acid sequence on said solid phase
 using said modified amino acid.
- 25 62. The method of claim 61, wherein said capturing step further comprises mixing
 said binding partner and said amino acid sequence in solution then immobilizing
 said binding partner on said solid phase.

- 5 63. The method of claim 61, wherein said solid phase comprises an array of additional different binding partners for screening for a plurality of binding activities.
64. The method of claim 58, 59, 60, 61, 62 or 63, wherein said binding partner is a phosphopeptide.
- 10 65. A method for screening nucleic acid constructs for those encoding amino acid sequences with binding activity comprising the following steps:
- a) obtaining a first nucleic acid construct and second nucleic acid construct,
 - b) transcribing said first nucleic acid construct to generate a first RNA and transcribing said second nucleic acid constructs to generate a second
15 RNA,
 - c) translating said first RNA in a cell-free system containing a tRNA precharged with an amino acid containing a binding species, to produce a first amino acid sequence containing said binding species,
 - d) translating said second RNA in a cell-free system containing a tRNA
20 precharged with an amino acid containing a detectable species, to produce a second amino acid sequence containing said detectable species, and
 - e) detecting binding activity of said first amino acid sequence to said second amino acid sequence using a method comprising the following steps:
 - i) contacting a sample of said first amino acid sequence with said
25 second amino acid sequence, and
 - ii) capturing said binding species on a surface of a well of a multi-well plate via a second binding species

- 5 iii) detecting said detectable species bound to said surface.
66. A method for screening nucleic acid constructs for those encoding amino acid sequences with nascent binding activity comprising the following steps:
- a) obtaining a nucleic acid construct,
- b) transcribing said nucleic acid to generate RNA,
- 10 c) translating said RNA in a cell-free system containing a tRNA precharged with a modified amino acid, to produce an amino acid sequence containing said modified amino acid,
- d) capturing said amino acid sequence on a surface of a well of a multi-well plate via a binding reagent specific for said modified amino acid to form a coated surface,
- 15 e) contacting said amino acid sequence with a modifying activity to covalently modify said amino acid sequence,
- f) contacting said modified amino acid sequence with a second binding species labeled with a detectable species, and
- 20 g) detecting the complex of said second binding species and said immobilized amino acid sequence.
67. The method of claim 64, where in said second binding species labeled with a detectable label is made using a method comprising the following steps:
- h) obtaining a second nucleic acid construct,
- 25 i) transcribing said second nucleic acid to generate a second RNA, and
- j) translating said second RNA in a cell-free system containing a tRNA precharged with a second modified amino acid, to produce an amino acid

- 5 sequence containing said second modified amino acid where said second
 modified amino acid comprising said detectable species.
68. The method of claim 66 or 67, wherein said modifying activity is an enzymatic
 activity.
69. The method of claim 68, wherein said enzymatic activity is selected from the
10 group consisting of kinases, hydrolases, protease, polymerases, glycosidases, and
 phosphatases.
70. The method of claim 68, wherein said enzymatic activity is a post-translational
 modification activity.
71. The method of claim 68, wherein said enzymatic activity is a joining or cleaving
15 activity.
72. A method for screening for antigens with binding activity for antibodies
 comprising the following steps:
- (a) obtaining a nucleic acid construct,
- (b) transcribing said nucleic acid in vitro to generate RNA,
- 20 (c) translating said RNA in a cell-free system, to produce an amino acid
 sequence, and
- (d) conducting a solid phase binding assay to detect the binding of said amino
 acid sequence with an antibody.
73. The method of claim 72, wherein said solid phase assay comprises:
- 25 i) immobilizing said amino acid sequence on a solid phase,
- ii) mixing said amino acid sequence with said antibody, and

iii) detecting the formation of a binding complex between said antibody and said amino acid sequence.

74. The method of claim 72, wherein said solid phase assay comprises:

10 i) forming a composition comprising said amino acid sequence and said antibody, wherein said antibody is immobilized on a solid phase and

ii) detecting the formation of a binding complex between said antibody and said amino acid sequence.

75. The method of claim 74, wherein said solid phase comprises an array of additional different antibodies.

15 76. The method of claim 72, 73, 74 or 75, wherein the cell-free system contains a
tRNA precharged with a modified amino acid so that said amino acid sequence
comprises said modified amino acid.

77. The method of claim 72, 73, 74, 75 or 76, wherein the antibody is from a blood sample.

20 78. The method of claim 77, wherein the blood sample is from an animal with cancer or an autoimmune disease.

79. The method of claim 78, wherein said animal is a mammal.

80. The method of any one of claims 33-79 or 104, wherein said solid phase is a bead in a well of a multi-well plate.

25 81. The method of claim 80, wherein said bead is a magnetic bead.

82. The method of any one of claims 33-79, 104 or 105, wherein said solid phase is a surface of a well of a multi-well plate.

- 5 83. The method of claim 82, wherein said surface is an electrode surface.
84. The method of claim 82 or 83, wherein said surface comprises elemental carbon or a composite comprising elemental carbon.
85. The method of any one of claims 80-84, wherein a plurality of different amino acid sequences generated from different nucleic acid constructs are tested in
10 parallel in different wells of said multi-well plate.
86. The methods of any one of claims 80-85, wherein said nucleic acid is translated in the same well used for said detection step.
87. The method of any one of claims 33-86, wherein said detection step employs electrochemiluminescence detection.
- 15 88. The method of any one of claims 33-87, wherein activity is measured in the presence of test material so as to determine the effect of said test material on said activity.
89. The method of claim 88, wherein said method is a screen for modulators of said activity.
- 20 90. The method of any one of claims 33-71 or 76, wherein said modified amino acid comprises biotin.
91. The method of any one of claims 33-71, 76 or 90, wherein said tRNA is tRNA_{lys}.
92. The method of any one of claims 58-63, wherein said binding partner is selected from the group consisting of proteins, nucleic acids, oligosaccharides, lipids and
25 combinations thereof.

- 5 93. The method of any one of claims 58-63, wherein said binding partner is selected from the group consisting of enzymes, receptors, receptor ligands, hormones and second messengers.
94. The method of any one of claims 37 or 40-46, wherein said substrate is selected from the group consisting of proteins, nucleic acids, oligosaccharides, lipids and combinations thereof.
- 10 95. The method of any one of claims 48-50, wherein said solid phase further comprises an assay domain comprising a reagent that binds a substrate of said enzymatic activity or a product of said enzymatic activity.
96. A method for screening nucleic acid constructs for those encoding amino acid sequences subject to a post-translational modification activity comprising the following steps:
- 15 a) obtaining a nucleic acid construct coding for an amino acid sequence and an affinity tag,
- b) transcribing said nucleic acid to generate RNA,
- 20 c) translating said RNA in a cell-free system to produce an amino acid sequence linked to said affinity tag, and
- d) detecting said post-translational modification of said amino acid sequence by a solid phase binding assay for the binding of said amino acid sequence to a binding species specific for said post-translational modification.
- 25 97. A method for screening nucleic acid constructs for those encoding amino acid sequences subject to a post-translational modification activity comprising the following steps:

- 5 (a) obtaining a nucleic acid construct coding for an amino acid sequence and an affinity tag,
- (b) transcribing said nucleic acid to generate RNA,
- (c) translating said RNA in a cell-free system containing a substrate that can be linked to a protein to form a post-translational modification, said
- 10 substrate being modified with a detectable species, to produce an amino acid sequence containing said affinity tag and said post-translational modification, and
- (d) detecting said post-translational modification of said amino acid sequence by a solid phase binding assay for the binding of said amino acid sequence
- 15 to a binding species specific for said post-translational modification or the binding of said amino acid sequence to a binding reagent specific for said affinity tag.
98. A method for screening nucleic acid constructs for those encoding amino acid sequences with enzymatic activity comprising the following steps:
- 20 (a) obtaining a nucleic acid construct coding for an amino acid sequence and an affinity tag,
- (b) transcribing said nucleic acid to generate RNA,
- (c) translating said RNA in a cell-free system to produce an amino acid sequence linked to said affinity tag, and
- 25 (d) detecting enzymatic activity of said amino acid sequence using a method comprising the following steps:

- 5 i) capturing said amino acid sequence onto a solid phase via an
 immobilized binding reagent specific for said affinity tag,
 ii) adding enzyme reaction buffer, and
 ii) detecting the product of the enzyme activity.
99. A method for screening nucleic acid constructs for those encoding amino acid
10 sequences that are substrates of enzymatic activity comprising the following
 steps:
 (a) obtaining a nucleic acid construct coding for an amino acid sequence and
 an affinity tag,
 (b) transcribing said nucleic acid to generate RNA,
15 (c) translating said RNA in a cell-free system to produce an amino acid
 sequence containing said modified amino acid, and
 (d) detecting said amino acid sequences which are substrates of an enzyme
 activity using a method comprising the following steps:
 i) capturing said amino acid sequence onto a solid phase via an
20 immobilized binding reagent specific for said affinity tag,
 ii) adding an enzyme; and
 iii) detecting the product of the enzyme activity on said amino acid
 sequence.
100. A method for screening nucleic acid constructs for those encoding amino acid
25 sequences with binding activity comprising the following steps:
 (a) obtaining a nucleic acid construct coding for an amino acid sequence and
 an affinity tag,

- 5 (b) transcribing said nucleic acid to generate RNA,
- (c) translating said RNA in a cell-free system to produce an amino acid
 sequence containing said modified amino acid, and
- (d) detecting binding activity of said amino acid sequence for a binding
 partner via a solid phase binding assay.
- 10 101. A method for screening nucleic acid constructs for those encoding amino acid
 sequences with binding activity comprising the following steps:
- (a) obtaining a first nucleic acid construct and a second nucleic acid construct,
 said nucleic acid constructs coding for first and second amino acid
 sequences linked to first and second affinity tags,
- 15 (b) transcribing said first nucleic acid construct to generate a first RNA and
 transcribing said second nucleic acid constructs to generate a second
 RNA,
- (c) translating said first RNA in a cell-free system to produce a first amino
 acid sequence linked to said first affinity tag,
- 20 (d) translating said second RNA in a cell-free system to produce a second
 amino acid sequence linked to said second affinity tag, and
- (e) detecting binding activity of said first amino acid sequence to said second
 amino acid sequence using a method comprising the following steps:
- i) contacting a sample of said first amino acid sequence with said
25 second amino acid sequence,
- ii) capturing said first affinity tag on a surface of a well of a multi-
 well plate via a first binding species, and

- 5 iii) detecting said second affinity tag bound to said surface.
102. A method for screening nucleic acid constructs for those encoding amino acid sequences with nascent binding activity comprising the following steps:
- (a) obtaining a nucleic acid construct coding for an amino acid sequence linked to an affinity tag,
- 10 (b) transcribing said nucleic acid to generate RNA,
- (c) translating said RNA in a cell-free system to produce an amino acid sequence linked to said affinity tag,
- (d) capturing said amino acid sequence on a surface of a well of a multi-well plate via a binding reagent specific for said affinity tag to form a coated surface,
- 15 (e) contacting said amino acid sequence with a modifying activity to covalently modify said amino acid sequence,
- (f) contacting said modified amino acid sequence with a second binding species labeled with a detectable species, and
- 20 (g) detecting the complex of said second binding species and said immobilized amino acid sequence.
103. The method of claim 72, wherein said amino acid sequence is linked to an affinity tag and the method further comprises using said affinity tag to capture or detect said amino acid sequence.
- 25 104. A method for screening nucleic acid constructs for those encoding amino acid sequences with enzymatic activity comprising the following steps:
- (a) obtaining a nucleic acid construct,

- 5 (b) transcribing said nucleic acid to generate RNA, :
 (c) translating said RNA in a cell-free system to produce an amino acid
 sequence, and
 (d) detecting enzymatic activity of said amino acid sequence using a method
 comprising the following steps:
- 10 i) contacting said amino acid sequence with an enzyme substrate
 immobilized on a solid phase, and
 ii) measuring conversion of the substrate to product.
105. The method of claim 104, wherein said solid phase comprises an array of
 additional different immobilized substrates.
- 15 106. A method for measuring the kinase activity of amino acid sequences coded by
 nucleic acid constructs comprising the following steps:
- (a) obtaining a nucleic acid construct,
 (b) transcribing said nucleic acid to generate RNA,
 (c) translating said RNA in a cell-free system containing a tRNA precharged
20 with a modified amino acid, to produce an amino acid sequence containing
 said modified amino acid, and
 (d) detecting enzymatic activity of said amino acid sequence using a method
 comprising the following steps:
- i) capturing said amino acid sequence on a solid phase via an
25 immobilized binding reagent specific for said modified amino acid,
 ii) incubating said protein under conditions suitable for kinase activity
 and optionally, comprising a soluble kinase substrate, and


- 5 iii) measuring the tyrosine kinase activity of said amino acid sequence.
107. The method of claim 106, wherein said measuring step further comprises
detecting autophosphorylation of said amino acid sequence.
108. The method of claim 107, wherein said detection of autophosphorylation
comprises contacting said amino acid sequence with an antibody specific for
10 phospho-peptides and detecting the binding of the antibody to the amino acid
sequence.
109. The method of claim 106, 107 or 108, wherein said conditions include the
presence of a soluble kinase substrate and said measuring step further comprises
detecting the phosphorylation of said substrate.
- 15 110. The method of any one of claims 106-109, wherein said solid phase is a surface of
a well of a multi-well plate.
111. The method of claim 110, wherein said surface is the surface of a carbon
composite electrode within said well.
112. The method of claim 110 or 111, wherein said method further comprises parallel
20 testing of a plurality of additional different amino acid sequences in different
wells of said multi-well plate.
113. The method of any one of claims 106-112, wherein said incubation is conducted
in the presence of a modulator or potential modulator of said kinase activity so as
to measure the effect of said modulator or potential modulator on said activity.
- 25 114. The method of claim 113, wherein a panel of amino acid sequences having kinase
activity are screened against a panel of said modulators or potential modulators so
as to determine the specificity profiles of said panel of said modulators.

- 5 115. The method of any one of claims 106-114, wherein said soluble kinase substrate is poly(glu, tyr).
116. The method of any one of claims 106-115, wherein said kinase activity is tyrosine kinase activity.
117. The method of any one of claims 106-116, wherein said kinase activity is detected
10 with an anti-phosphotyrosine antibody.
118. The method of any one of claims 106-117, where in said amino acid sequence comprises a sequence that is homologous to a protein, or a kinase domains derived therefrom, the protein selected from the list comprising: kit oncogene, fibroblast growth factor receptor 2, endothelial-specific receptor tyrosine kinase,
15 B-cell src-homology tyrosine kinase, Eph receptor B3, Janus kinase 1 (a protein tyrosine kinase), fibroblast growth factor receptor 1 (fms-related TK2), FYN oncogene related to SRC, hemopoietic cell kinase, CDC like kinase 4, Yamaguchi sarcoma viral (v-yes) oncogene homolog, CDC-like kinase 2, Eph receptor B4, CDC-like kinase 3, fibroblast growth factor receptor 1, kinase insert domain
20 protein receptor, fibroblast growth factor receptor 4, protein tyrosine kinase 2 beta, Bruton agammaglobulinemia tyrosine kinase, CDC-like kinase 1, lymphocyte-specific protein tyrosine kinase, GR feline sarcoma viral (v-fgr) oncogene homolog, anaplastic lymphoma kinase (Ki-1), fer (fms/fps related) protein kinase, EphB1, fyn-related kinase, TTK protein kinase, Eph receptor B3,
25 Eph receptor B4, fibroblast growth factor receptor 4.
119. An *in vitro* kinase assay for a kinase selected from the list comprising: kit oncogene, fibroblast growth factor receptor 2, endothelial-specific receptor


- 5 tyrosine kinase, B-cell src-homology tyrosine kinase, Eph receptor B3, Janus
kinase 1 (a protein tyrosine kinase), fibroblast growth factor receptor 1 (fms-
related TK2), FYN oncogene related to SRC, hemopoietic cell kinase, CDC like
kinase 4, Yamaguchi sarcoma viral (v-yes) oncogene homolog, CDC-like kinase
2, Eph receptor B4, CDC-like kinase 3, fibroblast growth factor receptor 1, kinase
10 insert domain protein receptor, fibroblast growth factor receptor 4, protein
tyrosine kinase 2 beta, Bruton agammaglobulinemia tyrosine kinase, CDC-like
kinase 1, lymphocyte-specific protein tyrosine kinase, GR feline sarcoma viral (v-
fgr) oncogene homolog, anaplastic lymphoma kinase (Ki-1), fer (fms/fps related)
protein kinase, EphB1, fyn-related kinase, TTK protein kinase, Eph receptor B3,
15 Eph receptor B4, fibroblast growth factor receptor 4.
120. The *in vitro* kinase assay of claim 119, wherein said assay is a solid phase binding
assay for the a product formed by the phosphorylation of a substrate by said
kinase.
121. The *in vitro* kinase assay of claim 119, wherein said assay is a solid phase binding
20 assay for autophosphorylation.
122. The *in vitro* kinase assay of claim 119, wherein said assay includes both a solid
phase binding assay for phosphorylation of a substrate by said kinase and a solid
phase binding assay for autophosphorylation.
123. The method of any one of claims 106-112, wherein said kinase assay is used to
25 screen for modulators of a kinase activity.
124. The method of any one of claims 23-105, wherein said transcription and
translation are coupled.

- 5 125. The method of any one of claims 23-105 or 124, wherein said translation is
conducted using a bacterial lysate, plant germ extract or reticulocyte lysate.
126. The method of any one of claims 23-105, 124 or 125, wherein said translation is
conducted in the presence of a membrane preparation.
127. The method of claim 126, wherein said membrane preparation comprises
10 microsomal membranes.
128. The methods of claim 47, 48, 49 or 50, wherein said captured amino acid
sequence is purified prior to conducting a measurement of enzymatic activity.
129. The method of claim 128, wherein said purification comprises a high-stringency
wash.
- 15 130. The method of claim 128, further comprising repeating said method with no wash
or a low stringency wash to identify amino acid sequences that recruit enzymes
with said enzymatic activity.
131. The method of claim 130 further comprising identifying recruited enzymes.
132. The method of claim 47, 48, 49 or 50, wherein said captured amino acid sequence
20 is contacted with a modifying activity to expose a nascent enzymatic activity.


Figure 1



SUBSTITUTE SHEET (RULE 26)

**Figure 2**

SUBSTITUTE SHEET (RULE 26)

**Figure 3**

SEQUENCE LISTING

<110> Meso Scale Technologies, LLC
 Kenten, John H
 Biebuyck, Hans
 Davydov, Ilia
 Pampori, Nisar
 Cheng, Steven Yan
 Nelson, Stefanie

<120> METHODS, REAGENTS, KITS AND APPARATUS FOR PROTEIN FUNCTION

<130> 100405-6461 16383W00

<140> 00/000,000
 <141> 2002-09-10

<150> 60/318,289
 <151> 2001-09-10

<150> 60/318,293
 <151> 2001-09-10

<150> 60/318,284
 <151> 2001-09-10

<150> 60/363,498
 <151> 2002-03-11

<150> 00/000,000
 <151> 2002-09-09

<160> 23

<170> PatentIn version 3.1

<210> 1
 <211> 24
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Fragment of IkBa-p

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> PHOSPHORYLATION

<220>
 <221> MOD_RES
 <222> (17)..(17)
 <223> PHOSPHORYLATION

<400> 1

Leu Lys Lys Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gly Leu Asp
 1 5 10 15

Ser Met Lys Asp Glu Glu Tyr Cys

20

<210> 2
 <211> 24
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Fragment of IkBa

<400> 2

Leu Lys Lys Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gly Leu Asp
 1 5 10 15

Ser Met Lys Asp Glu Glu Tyr Cys
 20

<210> 3
 <211> 26
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Fragment of c-Myc

<400> 3

Cys Pro Ser Glu Asp Ile Trp Lys Lys Phe Glu Leu Leu Pro Thr Pro
 1 5 10 15

Pro Leu Ser Pro Ser Arg Arg Ser Gly Leu
 20 25

<210> 4
 <211> 26
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Fragment of c-Myc-p

<220>
 <221> MOD_RES
 <222> (15)..(15)
 <223> Phosphorylated

<220>
 <221> MOD_RES
 <222> (15)..(15)
 <223> PHOSPHORYLATION

<220>
 <221> MOD_RES
 <222> (19)..(19)
 <223> Phosphorylated

<400> 4

Cys Pro Ser Glu Asp Ile Trp Lys Lys Phe Glu Leu Leu Pro Thr Pro
 1 5 10 15

Pro Leu Ser Pro Ser Arg Arg Ser Gly Leu
 20 25

<210> 5

<211> 20

<212> PRT

<213> Artificial

<220>

<223> Synthetic Fragment of EGFR-pY992

<220>

<221> MOD_RES

<222> (5)..(5)

<223> Phosphorylated

<220>

<221> MOD_RES

<222> (5)..(5)

<223> PHOSPHORYLATION

<400> 5

Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly Phe Phe Ser Ser Pro
 1 5 10 15

Ser Thr Ser Cys
 20

<210> 6

<211> 20

<212> PRT

<213> Artificial

<220>

<223> Synthetic Fragment of EGFR-Y992

<400> 6

Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly Phe Phe Ser Ser Pro
 1 5 10 15

Ser Thr Ser Cys
 20

<210> 7

<211> 20

<212> PRT

<213> Artificial

<220>

<223> Synthetic Fragment of EGFR-pY1068

<220>

<221> MOD_RES

<222> (6)..(6)

<223> Phosphorylation

<220>

<221> MOD_RES

<222> (6)..(6)

<223> PHOSPHORYLATION

<400> 7

Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val Pro Lys Arg Pro Ala
1 5 10 15

Gly Ser Val Cys
20

<210> 8

<211> 20

<212> PRT

<213> Artificial

<220>

<223> Synthetic Fragment of EGFR-Y1068

<400> 8

Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val Pro Lys Arg Pro Ala
1 5 10 15

Gly Ser Val Cys
20

<210> 9

<211> 26

<212> PRT

<213> Artificial

<220>

<223> Synthetic Fragment of EGFR-pY1148

<220>

<221> MOD_RES

<222> (13)..(13)

<223> PHOSPHORYLATION

<400> 9

Lys Gly Ser His Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln Gln Asp
1 5 10 15

Phe Phe Pro Lys Glu Ala Lys Pro Asn Cys
20 25

<210> 10
<211> 26
<212> PRT
<213> Artificial

<220>
<223> Synthetic Fragment of EGFR-Y1148

<400> 10

Lys Gly Ser His Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln Gln Asp
1 5 10 15

Phe Phe Pro Lys Glu Ala Lys Pro Asn Cys
20 25

<210> 11
<211> 25
<212> PRT
<213> Artificial

<220>
<223> Synthetic Fragment of Smad3C-p

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Phosphorylated

<220>
<221> MOD_RES
<222> (25)..(25)
<223> Phosphorylated

<400> 11

Cys Gly Pro Leu Gln Trp Leu Asp Lys Val Leu Thr Gln Met Gly Ser
1 5 10 15

Pro His Asn Pro Ile Ser Ser Val Ser
20 25

<210> 12
<211> 25
<212> PRT
<213> Artificial

<220>
<223> Synthetic Fragment of Smad3C

<400> 12

Cys Gly Pro Leu Gln Trp Leu Asp Lys Val Leu Thr Gln Met Gly Ser
 1 5 10 15

Pro His Asn Pro Ile Ser Ser Val Ser
 20 25

<210> 13

<211> 57

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide primer 1 for flag-bTRCP

<400> 13

tatgtcgaca tggattataa ggatgacgat gacaaagacc cggcagaggc ggtgctg 57

<210> 14

<211> 32

<212> DNA

<213> Artificial

<220>

<223> Synthetic Oligonucleotide primer 2 for flag-bTRCP

<400> 14

tatgcggccg cttatctgga gatgtaggtg ta 32

<210> 15

<211> 37

<212> DNA

<213> Artificial

<220>

<223> 5'ORI-tag-labeled synthetic oligonucleotide for YY1

<400> 15

acgtacgtac cgctccgcgg ccatcttggc ggctggt 37

<210> 16

<211> 37

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide complement for YY1

<400> 16

accagccgcc aagatggccg cggagcggtta cgtacgt 37

<210> 17

<211> 31

<212> DNA

<213> Artificial

<220>

<223> 5' SH-X- Synthetic oligo AP1
 <400> 17
 actgactgac cgcttgatga ctcagccgga a 31

<210> 18
 <211> 43
 <212> DNA
 <213> Artificial

<220>
 <223> 5' SH-X- Synthetic oligo Gluc
 <400> 18
 actgactgac gaccctagag gatctgtaca ggatgttcta gat 43

<210> 19
 <211> 40
 <212> DNA
 <213> Artificial

<220>
 <223> 5' SH-X- Synthetic oligo P53
 <400> 19
 actgactgac tacagaacat gtctaagcat gctggggact 40

<210> 20
 <211> 37
 <212> DNA
 <213> Artificial

<220>
 <223> 5' SH-X- Synthetic oligo YY1
 <400> 20
 acgtacgtac cgctccgcgg ccattcttggc ggctggt 37

<210> 21
 <211> 30
 <212> DNA
 <213> Artificial

<220>
 <223> 5' SH-X- Synthetic oligo C/EBP
 <400> 21
 actgactgac tgcagattgc gcaatctgca 30

<210> 22
 <211> 31
 <212> DNA
 <213> Artificial

<220>
 <223> 5' SH-X- Synthetic oligo HNF
 <400> 22

actgactgac atctagggtca aagggtcatat t

31

<210> 23

<211> 37

<212> DNA

<213> Artificial

<220>

<223> SH-X- Synthetic oligo CDP

<400> 23

actgactgac acccaatgat tattagccaa tttctga

37